



9603249-5
IPO's
copy


THIS SHEET HAS BEEN
REPLACED

62428J.61

Asymmetrically substituted xanthines with
adenosine-antagonistic properties

The present invention relates to new xanthine derivatives, processes for preparing them and their use as pharmaceutical compositions and their use as intermediates.

The new compounds correspond to the general formula






wherein R_1 cannot simultaneously represent R_2 , and are defined as follows:

R_1 represents hydrogen, C_1 - C_6 -alkyl, preferably methyl, ethyl, n-butyl or allyl, most preferably n-propyl, C_3 - C_6 -alkenyl, C_3 - C_6 -alkynyl;

R_2 denotes hydrogen, a C_1 - C_8 -alkyl-, C_2 - C_8 -alkenyl- or C_2 - C_8 -alkynyl- group which is substituted by -CN, $-CH_2NR_6R_7$, OH (multiple

substitution also being possible), $-\text{OR}_8$, $-\text{NR}_6\text{R}_7$,
 $-\text{NHCOR}_8$, $-\text{NHCONR}_6\text{R}_7$, halogen, $-\text{OCOR}_8$,
 $-\text{OCH}_2\text{COOH}$, $-\text{OCH}_2\text{COOR}_8$, $-\text{SO}_2\text{R}_5$, $-\text{S-R}_5$, $-\text{NHCONH}$ phenyl,
 $-\text{OCH}_2-\text{CONR}_6\text{R}_7$, $-\text{OCH}_2\text{CH}_2\text{OH}$, $-\text{SO}_2-\text{CH}_2-\text{CH}_2-\text{O}-\text{COR}_8$,
 $-\text{OCH}_2-\text{CH}_2-\text{NR}_6\text{R}_7$, $-\text{SO}_2-\text{CH}_2-\text{CH}_2-\text{OH}$, $-\text{CONHSO}_2\text{R}_8$,
 $-\text{CH}_2\text{CONHSO}_2\text{R}_8$, $-\text{OCH}_2\text{CH}_2\text{OR}_8$, $-\text{COOH}$, $-\text{COOR}_8$,
 $-\text{CONR}_6\text{R}_7$, $-\text{CHO}$, $-\text{SR}_8$, $-\text{SOR}_8$, $-\text{SO}_2\text{R}_8$,
 $-\text{SO}_3\text{H}$, $-\text{SO}_2\text{NR}_6\text{R}_7$, $-\text{OCH}_2-\text{CH}_2\text{OCOR}_8$,
 $-\text{CH}=\text{NOH}$, $-\text{CH}=\text{NOR}_8$, $-\text{COR}_9$, $-\text{CH}(\text{OH})\text{R}_9$,
 $-\text{CH}(\text{OR}_8)_2$, $-\text{CH}=\text{CH}-\text{R}_{10}$, OCONR_6R_7 ,



or by 1,3-dioxolane or 1,3-dioxane which is optionally mono- or polysubstituted, preferably mono- substituted, by methyl;

R_2 denotes phenyl- C_1 - C_6 -alkylene, preferably phenyl- C_1 - C_4 -alkylene, phenyl- C_2 - C_6 -alkenylene or phenyl- C_2 - C_6 -alkynylene, in which the phenyl ring is optionally substituted, either directly or via a C_{1-4} -alkylene group, with one or more, preferably one, of the following groups,




$-\text{C}_1$ - C_3 -alkyl, $-\text{CN}$, $-\text{CH}_2\text{NR}_6\text{R}_7$, $-\text{NO}_2$,
 $-\text{OH}$, $-\text{OR}_8$, $-\text{CH}_2-\text{NH}-\text{SO}_2-\text{R}_8$, $-\text{NHCOR}_8$,
 $-\text{NHCONR}_6\text{R}_7$, halogen, $-\text{OCOR}_8$, $-\text{OCH}_2\text{COOH}$,
 $-\text{OCH}_2\text{COOR}_8$, $-\text{CH}_2\text{OCOR}_8$, $-\text{SO}_2\text{R}_5$,
 $-\text{OCH}_2-\text{CONR}_6\text{R}_7$, $-\text{OCH}_2\text{CH}_2\text{OH}$,
 $-\text{OCH}_2-\text{CH}_2-\text{NR}_6\text{R}_7$, $-\text{CONHSO}_2\text{R}_8$,
 $-\text{OCH}_2\text{CH}_2\text{OR}_8$, $-\text{COOH}$, $-\text{COOR}_8$, $-\text{CF}_3$,
cyclopropyl, $-\text{CONR}_6\text{R}_7$, $-\text{CH}_2\text{OH}$,



This Sheet Has Been Replaced




-CH₂OR₈, -CHO, -SR₈, -SOR₈, -SO₂R₈,
-SO₃H, -SO₂NR₆R₇, -OCH₂-CH₂OCOR₈,
-CH=NOH, -CH=NOR₈, -COR₉, -CH(OH)R₉,
-CH(OR₈)₂, -NHCOOR₈, -CH₂CONHSO₂R₈,
-CH=CH-R₁₀, -OCONR₆R₇,
-CH₂-O-CONR₆R₇,
-CH₂-CH₂-O-CONR₆R₇,






or by 1,3-dioxolane or 1,3-dioxane which is optionally mono- or polysubstituted, preferably monosubstituted, by methyl;

R₂ denotes C₃-C₇-cycloalkyl-C₁-C₆-alkylene-,
C₃-C₇-cycloalkyl-C₂-C₆-alkenylene-,
C₃-C₇-cycloalkyl-C₂-C₆-alkynylene-, in which the
cycloalkyl group may optionally be substituted,
either directly or via a C₁₋₄-alkylene group, by
-CN, -CH₂NR₆R₇, =O, -OH, -OR₈, -NR₆R₇,
-NHCOR₈, -NHCONR₆R₇, halogen, -OCOR₈,
-OCH₂COOH, -OCH₂COOR₈, -CH₂OCOR₈,
-SO₂R₅, -OCH₂-CONR₆R₇,
-OCH₂CH₂OH, -OCH₂-CH₂-NR₆R₇,
-OCH₂CH₂OR₈, -COOH, -COOR₈,
-CONR₆R₇, -CH₂OH, -CH₂OR₈, -CHO,
-SR₈, -SOR₈, -SO₂R₈, -SO₃H,
-SO₂NR₆R₇, -OCH₂-CH₂OCOR₈, -CH=NOH,
-CH=NOR₈, -COR₉, -CH(OH)R₉,
-CONHSO₂R₈, -CH(OR₈)₂, -NHCOOR₈,




This Sheet Has Been Replaced



or by 1,3-dioxolane or 1,3-dioxane which is optionally mono- or polysubstituted, preferably monosubstituted, by methyl;

R_2 denotes a group of the formula

$\text{A}-\text{C}_1-\text{C}_6$ -alkylene-, $\text{A}-\text{CONH}-\text{C}_1-\text{C}_6$ -alkylene-, $\text{A}-\text{CONH}-\text{C}_2-\text{C}_6$ -alkenylene-, $\text{A}-\text{CONH}-\text{C}_2-\text{C}_6$ -alkynylene-, $\text{A}-\text{NH}-\text{CO}-\text{C}_1-\text{C}_6$ -alkylene-, $\text{A}-\text{NH}-\text{CO}-\text{C}_2-\text{C}_6$ -alkenylene-, $\text{A}-\text{NH}-\text{CO}-\text{C}_2-\text{C}_6$ -alkynylene-, $\text{A}-\text{C}_2-\text{C}_6$ -alkenylene- or $\text{A}-\text{C}_2-\text{C}_6$ -alkynylene-, wherein A is a C- or N-linked 5- or 6-membered heterocyclic ring which contains nitrogen, oxygen or sulphur as heteroatoms and may optionally be mono- or polysubstituted, preferably monosubstituted, by C_1-C_4 -alkyl, halogen, $-\text{OR}_8$, $-\text{CN}$, $-\text{NO}_2$, $-\text{NH}_2$, $-\text{CH}_2\text{NR}_6\text{R}_7$, $-\text{OH}$, $=\text{O}$, a ketal, $-\text{COOH}$, $-\text{SO}_3\text{H}$, $-\text{COOR}_8$, $-\text{CONR}_6\text{R}_7$, $-\text{COR}_9$, $-\text{SO}_2-\text{R}_8$, $-\text{CONR}_6\text{R}_7$ or



R_3 denotes C_3-C_7 -cycloalkyl, preferably cyclopentyl, optionally substituted by $=\text{O}$, $-\text{OH}$, $-\text{OR}_8$, OCOR_8 , or

- 5 -

R_3 denotes phenyl, which is optionally substituted by $-OH$, halogen, $-OR_8$, C_1-C_4 -alkyl, preferably $-CH_3$ -, $-NH_2$, $-COOH$, $-SO_3H$, $-COOR_8$, $-OCH_2COOR_8$, $-CN$, or $-OCH_2CONR_6R_7$, or




R_3 denotes a norbornane-, norbornene-, a C_3-C_6 -dicycloalkylmethyl, preferably dicyclopropylmethyl, adamantane- or noradamantane- group;

R_3 denotes $-CH=CH$ -phenyl, wherein the phenyl ring is mono- or polysubstituted by methoxy, hydroxy or halogen;

R_3 denotes a [3.3.0]-bicyclooctane, preferably a [3.3.0]-bicyclooctan-2-yl;

R_3 denotes a C-linked piperidine or furan;

R_4 denotes hydrogen, methyl or benzyl, in which the benzyl group may be substituted by 1-3 methoxy groups;



privaloyloxymethyl or



R_5 denotes C_1-C_4 -alkyl, optionally substituted by OH , $OCOR_8$, NH_2 , NR_6R_7 or $NHCOR_8$, and R_5 preferably represents $-CH_2-CH_2-OH$, $-CH_2CH_2OCOR_8$, $-CH_2-CH_2-CH_2-OH$; $-CH_2-CH_2CH_2OCOR_8$;



R_6 denotes hydrogen, an optionally substituted C_{3-6} -cycloalkyl group, a branched or unbranched alkyl-, alkenyl- or alkynyl group having up to 10 carbon atoms, preferably a C_{1-4} -alkyl group, which may optionally be substituted by hydroxy, phenyl, substituted phenyl, amino, substituted amino, C_1 to C_8 , preferably C_1 to C_4 -alkoxy, or it denotes $-(CH_2)_m-NHCOOR_8$ wherein $m = 1, 2, 3$ or 4 ;

R_7 denotes hydrogen, an optionally substituted C_{3-6} -cycloalkyl group, a branched or unbranched alkyl-, alkenyl- or alkynyl group having up to 10, preferably 1 - 4, carbon atoms, which may optionally be substituted by hydroxy, phenyl, substituted phenyl, amino, substituted amino, C_1 to C_8 , preferably C_1 to C_4 -alkoxy, or it denotes $-(CH_2)_m-NHCOOR_8$ wherein $m = 1, 2, 3$ or 4 ;

or

R_6 and R_7 together with the nitrogen atom form a saturated or unsaturated 5- or 6-membered ring which may contain as heteroatoms nitrogen, oxygen or sulphur, whilst the heterocyclic ring may be substituted by a branched or unbranched C_{1-4} -alkyl group, preferably methyl, or may carry one of the following groups:

$-(CH_2)_n-NH_2$, $=O$, a ketal - preferably $-O-CH_2-CH_2-O-$,
 $-(CH_2)_nNH-C_1-C_4$ -alkyl,
 $-(CH_2)_n-N(C_1-C_8$ -alkyl) $_2$,
 $-(CH_2)_n-NHCOOR_8$, ($n = 2, 3, 4$), halogen,
 $-OR_8$, $-CN$, $-NO_2$, $-NH_2$, $-CH_2NR_6R_7$,
 $-OH$, $-COOH$, $-SO_3H$, $-COOR_8$, $-CONR_6R_7$, $-SO_2-R_8$,

R_8 denotes hydrogen, C_1-C_4 -alkyl, C_2-C_4 -alkenyl, C_2-C_4 -alkynyl, a benzyl- or phenyl-group, which is optionally mono- or polysubstituted by OCH_3 ;



R_9 denotes C_1 - C_4 -alkyl, C_2 - C_4 -alkenyl, C_2 - C_4 -alkynyl, optionally substituted phenyl, optionally substituted benzyl, C_3 - C_6 -cycloalkyl,

R_{10} denotes $-COOR_8$, $-CH_2OR_8$, $-CONR_6R_7$, hydrogen, C_1 - C_3 -alkyl, optionally substituted phenyl, $-CH_2NR_6R_7$;

R_{11} denotes hydrogen, phenyl, substituted phenyl, $-CH_3$;

optionally in the form of the racemates, the enantiomers, the diastereomers and the mixtures thereof and optionally in the form of the pharmacologically acceptable salts thereof.

The compounds which are preferred as pharmaceutical compositions are the compounds of general formula I wherein R_1 does not denote hydrogen but R_4 is hydrogen, since compounds of general formula I wherein R_1 = hydrogen have a lowering A_1 -receptor-affinity; however, these compounds are of particular importance as intermediates.

Preferred compounds of general formula I are those wherein




R_1 = methyl, ethyl, n-butyl, allyl and preferably n-propyl;

R_2 denotes a C_2 -alkyl or an unbranched C_3 -alkyl group which is substituted by

$-CN$, $-CH_2NR_6R_7$, $-OH$, $-OR_8$, $-NR_6R_7$,
 $-NHCOR_8$, $-NHCONR_6H$, halogen, $-OCOR_8$,
 $-OCH_2COOH$, $-OCH_2COOR_8$, $-SR_5$, $-SO_2R_5$,
 $-OCH_2-CONR_6R_7$, $-OCH_2CH_2OH$,
 $OCH_2-CH_2-NR_6R_7$, $CONHSO_2R_8$,
 $-CH_2CONHSO_2R_8$,
 $-OCH_2CH_2OR_8$, $-COOH$, $-COOR_8$,



-CONR₆R₇, -CHO, -SR₈, -SO₂R₈,
-SO₃H, -SO₂NR₆R₇, -OCH₂-CH₂OCOR₈,
=NOH, =NOR₈, -COR₉, -CH(OH)R₉,
-CH=CH-R₁₀, OCONR₆H






or by 1,3-dioxolane or 1,3-dioxane optionally mono-
or polysubstituted, preferably monosubstituted, by
methyl;

R₂ denotes a benzyl- or phenethyl- or phenylpropyl
group which is substituted by one of the following
groups


-C₁-C₃-alkyl, -CN, -CH₂NR₆R₇,
-NO₂, -OH, -OR₈, -NHCOR₈,
-NHCONR₆R₇, halogen, -OCOR₈, -OCH₂COOH,
-OCH₂COOR₈, -CH₂OCOR₈, -SO₂R₅,
-OCH₂-CONR₆R₇, -OCH₂CH₂OH,
-CH₂CONHSO₂R₈, -OCH₂-CH₂-NR₆R₇,
-CONHSO₂R₈, -OCH₂CH₂OR₈, -COOH,
-COOR₈, -CF₃,
cyclopropyl, -CONR₆R₇, -CH₂OH,
-CH₂OR₈, -CHO, -SR₈, -SOR₈, -SO₂R₈,
-SO₃H, -SO₂NR₆R₇, -OCH₂-CH₂OCOR₈,
-CH=NOH, CH=NOR₈, -COR₉, -CH(OH)R₉,
-CH(OR₈)₂, -NHCOOR₈,
-CH=CH-R₁₀, -OCONR₆R₇,
-CH₂-O-CONR₆R₇,
-CH₂-CH₂-O-CONR₆R₇,








or by 1,3-dioxolane or 1,3-dioxane optionally mono- or polysubstituted, preferably monosubstituted, by methyl, and if R_2 represents OR_8 , particularly OCH_3 , the phenyl group may be trisubstituted;





R_2 denotes a C_3 -, C_4 -, C_5 - or C_6 -cycloalkyl- C_2 - C_3 -alkylene group, wherein the cycloalkyl group is optionally monosubstituted by $-\text{CN}$, $-\text{CH}_2\text{NR}_6\text{R}_7$, $=\text{O}$, $-\text{OH}$, $-\text{OR}_8$, $-\text{NR}_6\text{R}_7$, $-\text{NHCOR}_8$, $-\text{NHCONR}_6\text{R}_7$, halogen, $-\text{OCOR}_8$, $-\text{OCH}_2\text{COOH}$, $-\text{OCH}_2\text{COOR}_8$, $-\text{CH}_2\text{OCOR}_8$, $-\text{SO}_2\text{R}_5$, $-\text{OCH}_2-\text{CONR}_6\text{R}_7$, $-\text{OCH}_2\text{CH}_2\text{OH}$, $-\text{OCH}_2-\text{CH}_2-\text{NR}_6\text{R}_7$, $-\text{OCH}_2\text{CH}_2\text{OR}_8$, $-\text{COOH}$, $-\text{COOR}_8$, $-\text{CONR}_6\text{R}_7$, $-\text{CH}_2\text{OH}$, $-\text{CH}_2\text{OR}_8$, $-\text{CHO}$, $-\text{SR}_8$, $-\text{SOR}_8$, $-\text{SO}_2\text{R}_8$, $-\text{SO}_3\text{H}$, $-\text{SO}_2\text{NR}_6\text{R}_7$, $-\text{OCH}_2-\text{CH}_2\text{OCOR}_8$, $-\text{CH}=\text{NOH}$, $-\text{CH}=\text{NOR}_8$, $-\text{COR}_9$, $-\text{CH}(\text{OH})\text{R}_9$, $-\text{CH}(\text{OR}_8)_2$, $-\text{NHCOOR}_8$, $-\text{CONHSO}_2\text{R}_8$, $-\text{CH}=\text{CH}-\text{R}_{10}$, $-\text{OCONR}_6\text{R}_7$, $-\text{CH}_2-\text{O}-\text{CONR}_6\text{R}_7$, $-\text{CH}_2-\text{CH}_2-\text{O}-\text{CONR}_6\text{R}_7$,





or by 1,3-dioxolane or 1,3-dioxane optionally mono- or polysubstituted, preferably monosubstituted by methyl;

R_2 denotes a group of the formula




wherein A is a C- or N-linked 5- or 6-membered heterocyclic ring which contains nitrogen, oxygen or sulphur as heteroatoms and which may optionally be mono- or polysubstituted by C_{1-4} -alkyl, =O, OH, COR_9 , SO_2-R_8 , NH_2 , COOR_8 , CONR_6R_7 , or OR_8 ;

and R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} and R_{11} are as hereinbefore defined, optionally in the form of the racemates, the enantiomers, the diastereomers and the mixtures thereof and optionally the pharmacologically acceptable salts thereof.

Particularly preferred R_3 groups are cyclopentyl, wherein

- 11 -

the cyclopentyl group may be substituted by =O, or mono- or disubstituted by -OH, -OR₈, particularly -OCH₃, or -OCOR₈, particularly OCOCH₃, and these groups are particularly preferred in conjunction with R₁ = n-propyl and R₄ = hydrogen of general formula Ia



Ia

wherein R₂ is defined as hereinbefore.

Compounds of general formula I or Ia wherein

R₂ = an unbranched C₂₋₅-alkyl group substituted by -CN, -OH, SO₂-R₅, -O-C₁-C₄-alkyl, -COOH, -COOR₈, particularly COOCH₃ or -COOC₂H₅, -OCOCH₃, -OCOC₂H₅, -CONR₆R₇, =NOH, -NR₆R₇ or a C-linked 5- or 6-membered heterocyclic group containing nitrogen, are preferred inter alia.

Particularly preferred groups R₂ of general formulae I and Ia are:

~~-CH₂CH₂CH₂CN~~
 -CH₂CH₂CH₂CH₂CH₂CN
 -CH₂CH₂OCH₃
 -CH₂CH₂CH₂OCH₃
 -CH₂CH₂OH





This Sheet Has Been Replaced













THIS SHEET HAS BEEN
REPLACED

- CH₂CH₂CH₂OH
- CH₂CH₂OCOCH₃
- CH₂CH₂CH₂OCOCH₃
- CH₂CH₂COOH
- CH₂CH₂COOCH₃
- CH₂CH₂CONH₂
- CH₂CH₂CONHCH₃


This Sheet Has Been Replaced



- CH₂CH₂NHCOCH₃
- CH₂CH(OH)CH₂OH
- CH₂CH₂CH(OH)CH₃
- CH₂CH₂COCH₃
- CH₂CH=NOH
- CH₂CH₂CH₂CH₂NH₂




THIS SHEET HAS BEEN
REPLACED



optionally in the form of the racemates, the enantiomers, the diastereomers and the mixtures thereof and optionally the pharmacologically harmless salts thereof.











Compounds of general formula I or Ia which are particularly readily water-soluble are those wherein R_2 denotes




This Sheet Has Been Replaced



THIS SHEET HAS BEEN
REPLACED

















$\text{CH}_2\text{CH}_2\text{SO}_2\text{CH}_2\text{CH}_2\text{OH}$, $\text{CH}_2\text{CH}(\text{OH})\text{CH}_2\text{OH}$, $-\text{CH}_2-\text{CH}_2-\text{CHOH}-\text{CH}_3$
or










Although less readily water-soluble, compounds of general formula Ia wherein R_2 has the following groups are preferred on account of their pharmacological properties:





This Sheet Has Been Replaced






The following groups are particularly preferred:






and








Also preferred are compounds of general formula Ia



wherein

R_3 denotes a radical from the group



cyclopentyl being preferred,


and

R_2 denotes CH_2CH_2OH ,
 $CH_2CH_2OCOCH_3$,
 $(CH_2)_3OCOCH_3$,
 $(CH_2)_3OCH_3$,
 $CH_2CH_2COCH_3$,
 $CH_2CH_2CH(OH)CH_3$,
 $CH_2CH_2COOCH_3$,
 $CH_2CH_2CONH_2$,
 $(CH_2)_3CONH_2$,
 $CH_2CH=NOH$,
 $(CH_2)_3CN$,
 $CH_2CH_2SCH_2CH_3$,
 $CH_2CH_2SCH_2CH_2OH$,
 $CH_2CH_2SO_2CH_2CH_2OH$,
 $CH_2CH_2SO_2CH_2CH_2OCOCH_3$,

R_2 denotes $A-(CH_2)_2-$ or
 $A-(CH_2)_3-$





wherein A is a C- or N-linked 5- or 6-membered heterocyclic ring containing nitrogen, oxygen or sulphur as heteroatoms, especially pyridine, morpholine, thiomorpholine, piperidine, tetrazol,

the following groups R_2 being particularly preferred:



$CH_2CH_2SCH_2CH_2OH$,
 $CH_2CH_2SO_2CH_2CH_2OH$,
 CH_2CH_2OH ,
 $CH_2CH_2CH_2OCH_3$,





The following xanthine derivatives are of particular interest:

1-propyl-3-(2-(pyridin-4-yl)ethyl)-8-cyclopentyl-7H-purine-2,6-dione

1-propyl-3-(2-(2-hydroxyethyl)-thioethyl)-8-cyclopentyl-7H-purine-2,6-dione

1-propyl-3-(2-(2-hydroxyethyl)-sulfonyl-ethyl)-8-cyclopentyl-7H-purine-2,6-dione

1-propyl-3-(2-hydroxyethyl)-8-cyclopentyl-7H-purine-2,6-dione

1-propyl-3-(3-methoxypropyl)-8-cyclopentyl-7H-purine-2,6-dione

1-propyl-3-(3-morpholin-1-yl-propyl)-8-cyclopentyl-7H-purine-2,6-dione

1-propyl-3-(3-tetrazol-5-yl-propyl)-8-cyclopentyl-7H-



purine-2,6-dione

1-propyl-3-(3-(aminocarbonyl)propyl)-8-cyclopentyl-7H-
purine-2,6-dione

1-propyl-3-(hydroxyiminoethyl)-8-cyclopentyl-7H-purine-
2,6-dione

1-propyl-3-(3-pyridin-3-yl-propyl)-8-cyclopentyl-7H-
purine-2,6-dione

The term "alkyl groups" (even when they are components of other groups) refers to branched and unbranched C_{1-10} , preferably C_{1-4} -alkyl groups, for example: methyl, ethyl, n-propyl, iso-propyl, butyl, iso-butyl, sec.butyl, tert.-butyl, pentyl, iso-pentyl, hexyl, heptyl and octyl.

The term "alkenyl groups" denotes branched and unbranched C_{2-10} , preferably C_{2-3} -alkenyl groups, provided that they have at least one double bond, e.g. including the alkyl groups mentioned above provided that they have at least one double bond, such as vinyl (provided that no unstable enamines or enolethers are formed), propenyl, isopropenyl, butenyl, pentenyl and hexenyl.

Examples of alkynyl groups are C_{2-10} -alkynyl groups provided that they have at least one triple bond, such as ethynyl, propargyl, butynyl, pentynyl and hexynyl.

The term C_{3-6} -cycloalkyl groups denotes, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, which may also be substituted by branched or unbranched C_{1-4} -alkyl, hydroxy and/or halogen or which may be substituted as hereinbefore defined. The word halogen generally refers to fluorine, chlorine, bromine or iodine.



Examples of cyclic groups of general formula NR_6R_7 include: pyrrole, pyrroline, pyrrolidine, 2-methylpyrrolidine, 3-methylpyrrolidine, piperidine, piperazine, N-methylpiperazine, N-ethylpiperazine, N-(n-propyl)-piperazine, N-benzylpiperazine, morpholine, thiomorpholine, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine - the above-mentioned heterocycles may be substituted by C_{1-4} -alkyl, preferably methyl, or carry one of the following groups:

- $(\text{CH}_2)_n\text{-NH}_2$, a ketal,
- $(\text{CH}_2)_n\text{NH-C}_1\text{-C}_4\text{-alkyl}$,
- $(\text{CH}_2)_n\text{-N(C}_1\text{-C}_8\text{-alkyl)}_2$, =O,
- $(\text{CH}_2)_n\text{-NHCOOR}_8$, ($n = 2, 3, 4$), halogen,
- OR₈, -CN, -NO₂, -NH₂, -CH₂NR₆R₇,
- OH, -COOH, -SO₃H, -COOR₈, -CONR₆R₇,
- CONR₆R₇.

Examples of C-linked 5- or 6-membered heterocyclic rings which may contain nitrogen, oxygen or sulphur as heteroatoms, include tetrahydrofuran, 2-methyltetrahydrofuran, 2-hydroxymethylfuran, tetrahydrofuranone, γ -butyrolactone, α -pyran, γ -pyran, tetrahydropyran, pyrrole, pyrroline, pyrrolidine, piperazine, morpholine, thiomorpholine, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, triazole, tetrazole, oxazole, oxadiazole, pyrazolidine, whilst the heterocycle may be substituted as specified in the definitions.

"=O" denotes an oxygen atom linked via a double bond.

Xanthine derivatives with a high adenosine-A₁-affinity promote neurotransmission in the brain and can be regarded for example as functional cholinomimetics.

Substances of this kind of great interest for the

symptomatic treatment of degenerative disorders of the central nervous system such as senile dementia and Alzheimer's disease.

The high receptor affinity should make it possible to treat patients with low doses, so that virtually no side effects can be expected which cannot be traced back to the blockade of adenosine receptors. In addition to their use as gerontopsychopharmaceuticals and nootropics, the adenosine antagonists described could be useful in the treatment of cardiac and circulatory disorders and in the treatment of respiratory disorders, particularly bronchial asthma. Furthermore, xanthines of general formula I exhibit diuretic properties and are thus of interest in the treatment of kidney disease and, because of their diuretic properties, for treating high blood pressure.

Other possible indications are degenerative illnesses such as organic brain syndrome, Parkinson's disease, depression, traumatic CNS-damage, post stroke neurological deficit, respiratory depression (intoxication, post op) neonatal brain trauma, dyslexia and hyperactivity. Compounds of general formula I, wherein R_3 has an optionally substituted phenylvinylene group are proposed for the treatment of Parkinson's disease.

Cystic fibrosis - also known as mucoviscidosis - is a hereditary disorder caused by a genetic defect on a certain chromosome. Only homozygotic carriers of the feature succumb to the disease. The genetic defects leads to the dysfunction of exocrine glands. As a result of increased production and greater viscosity of the secretions of the mucous glands in the bronchi, severe complications may arise in the respiratory tract. Preliminary investigations have shown that A_1 -antagonists



increase the efflux of chloride ions, e.g. in CF PAC cells. The cells come from a pancreas adenocarcinoma cell line which was isolated from patients suffering from cystic fibrosis (CF). The activity was successfully blocked by agonists such as 2-chloroadenosine. Interestingly, an increase in the efflux was observed only in those cells which came from patients suffering the disease or having the corresponding genetic defect.

Starting from these findings it is to be expected that, in patients suffering from cystic fibrosis (mucoviscidosis), the compounds according to the invention will regulate the disrupted electrolyte management of the cells and will alleviate the symptoms of the disease.

Adenosine antagonists can be used to treat lung diseases, particularly asthma, allergic lung diseases and chronically obstructive lung diseases. It is to be expected that the compounds according to the invention will also be suitable for the treatment of lung diseases by inhalation, because of their high potency.

Of particular interest is also a combination of compounds of general formula I according to the invention, in particular the compounds mentioned by name, with cholinomimetic active substances, for example 3-(2-propynyloxy)-1-azabicyclo[2.2.2]octane (Wal 801), for the treatment of degenerative diseases of ageing.

The receptor binding values were determined analogously to ~~Loewinger~~ ~~et al.~~ in "Cloning and functional characterisation of human A₁ adenosine receptor - Biochemical and Biophysical Communications, Vol 187, No. 2, 919-926, 1992".



Effect on the inhibition of locomotor activity in the mouse achieved by adenosine antagonists: adenosine-antagonism:

Subcutaneous administration of an adenosine-agonist was able to induce inhibition of locomotor activity in mice in the hour following administration. The test is to determine how a test substance will influence this hypomotility.

The measurements for this test are concerned with the number of times a light beam is broken in motility chambers. The figures are recorded by computer immediately after the substance has been administered. Only the first hour after administration is evaluated, since the activity of adenosine agonist occurs during this period.

In addition to the mice which are given both the adenosine agonist and the test substance, one group is given placebo (tylose and NaCl solution), one is given the adenosine agonist and tylose solution and one group is given the maximum dose of the test substance and NaCl solution. The individual animals of all the treatment groups are tested in separate measuring chambers over the same period of time.







Table Ia

Examples according to Table I	Ki[nMol/l] A ₁	Locom. (mg/kg)
01	7.5	3.0
04	8.0	0.6
05	46.7	0.6
06	66.8	0.6
07	2.7	
08	3.5	10.0
10	3.1	10.0
11	4.0	0.6
14	36.4	2.5
15	6.4	0.6
17	3.8	0.6
19	11.5	0.6
24	1.7	
28	29.3	
31	9.1	10.0
47	2.1	2.5
52	5.0	0.6
59	2.0	0.6
60	3.8	0.6
68	32.6	2.5
70	6.2	0.6

The compounds according to the invention can be prepared by analogous methods known per se as illustrated, for example, in synthesis plans I, II and III. The person skilled in the art is familiar enough with the synthesis of xanthines, but the following experimental section will explain it in detail once more with reference to ~~some~~ important key compounds.



$$\begin{array}{c}
 R_2' - NH_2 + KOCN \longrightarrow R_2' - NH - CO - NH_2 \\
 \downarrow NC - CH_2 - COOH \\
 R_2' - NH - CO - NH - CO - CH_2 - CN \\
 \swarrow \quad \searrow \\
 \text{Structure 1: } \text{A pyrimidine ring with } R_2' \text{ at N1, } NH \text{ at N3, } NO_2 \text{ at C2, and } NH_2 \text{ at C4.} \\
 \text{Structure 2: } \text{A pyrimidine ring with } R_2' \text{ at N1, } NH \text{ at N3, and } NH_2 \text{ at C4.}
 \end{array}$$


A characteristic feature of the synthesis illustrated in plan I is that R_2' is introduced at the diaminouracil stage (III). R_2' is a functional group, selected from the group of definitions of R_2 with the proviso that R_2' must not interfere with the synthesis of the xanthine and can be converted into the desired R_2 of general formula I before or after the cleavage of the protecting group R_4 (preferably benzyl) (formula VIII). A preferred definition of R_2' is a methoxybenzyl group, for example. R_3 is inserted by aminoacylation and subsequent cyclisation to form the xanthine. In order to be able to carry out alkylation deliberately in 1-position, it is necessary to protect the 7-position, e.g. using a benzyl group. The alkylations are carried out by reacting with R_4 -Z, wherein R_4 = benzyl or methyl and Z is a readily cleavable group such as halogen, mesyl or tosyl. In case R_4 denotes a methyl group in the final compound of general formula I, the xanthine V is already irreversibly methylated at this stage.

R_1 is then inserted into the protected xanthine VI by N-alkylation. The conversion of R_4 into hydrogen can then be carried out by cleaving the protecting group in the 7-position. If R_2' has not yet assumed the desired definition R_2 of the end compound I, R_2' can now be converted into R_2 (formula VIIa) and, if this has not yet happened, the protecting group is then split off. Examples of this are described in the general operation instructions under points 12 and 14 to 23. The compounds of general formula II and III are important intermediates and are claimed as such. It has been found, surprisingly, that a p-methoxybenzyl group or a ~~di- or trimethoxybenzyl~~ group in the 3-position of the xanthine of formula IX can be selectively cleaved in order to obtain the benzyl protecting group in the 7-position. This opens up a new method of obtaining xanthine derivatives of general formula I. By




- 27 -

alkylating xanthenes of general formula X with $R_2'-X$ ($X =$ halogen, OH, mesyl or tosyl), cleaving the benzyl protecting group and optionally converting R_2' into R_2 , compounds of general formula I can be obtained in a simple manner.

This Sheet Has Been Replaced




The invention also relates to a simple and generally applicable method of preparation for synthesising xanthine derivatives substituted in the 1- and 3-positions, wherein R_1 and R_2 may represent any desired groups, provided that they can be inserted by an electrophilic reaction.

Synthesis plan II

Compounds of general formula X (R_4 -benzyl) can easily be obtained by acid hydrolysis (e.g. with formula IX wherein R_4 = benzyl and R_2 = p-methoxybenzyl).

Synthesis plan III



The following are general operative instructions in order to prepare the compounds according to the invention.



1. Monosubstituted ureas:

0.69 mol of amine are dissolved in a solution of 18.3 ml (0.34 mol) of conc. H_2SO_4 and 1000 ml of distilled water. The mixture is heated to 85°C , 55.8 g (0.69 mol) of KOCN are added and the resulting mixture is stirred at this temperature until the reaction is complete (30 - 90 min.). The reaction mixture is diluted with ethanol, cooled to ambient temperature and filtered. The filtrate is evaporated down and the solid residue is dried in a drying cupboard.

The following monosubstituted ureas, inter alia, were prepared in this way:

a)

p-methoxybenzylurea, 85.5 % of theory, mp. = $156 - 158^\circ\text{C}$

b)

2-(p-methoxyphenyl)-ethylurea, 91.4 % of theory, mp. = 127°C

c)

3-(p-methoxyphenyl)-propylurea, 91.8 % of theory, mp. = $170 - 173^\circ\text{C}$

d)

2-methoxyethylurea, 97.3 % of theory, mp. = 72°C

e)

3-methoxypropylurea, 92.2 % of theory, mp. = $79 - 81^\circ\text{C}$

f)

2-(p-chlorophenyl)-ethylurea, 73.2% of theory, mp. = $150 - 151^\circ\text{C}$

g)

2-(p-bromophenyl)-ethylurea, 92.3% of theory, mp. = $183 - 184^\circ\text{C}$

h)

3-(p-chlorophenyl)-propylurea, 82.4 % of theory, mp. = $146 - 150^\circ\text{C}$



2. Substituted cyanoacetylureas:

220 ml of acetanhydride are mixed with 57.6 g (0.68 mol) of cyanoacetic acid and 0.62 Mol of monosubstituted urea [see 1.]. The mixture is heated to 75 - 80°C and stirred at this temperature until the reaction is complete (30 - 90 min.). It is then cooled, diluted with ether and suction filtered and the crystalline product is washed with ether. The following cyanoacetylureas, inter alia, were prepared in this way:

a)

N-(p-methoxybenzyl)-N'-cyanoacetylurea, 81.3 % of theory, mp. = 185°C

b)

N-(2-(p-methoxyphenyl)-ethyl)-N'-cyanoacetylurea, 69 % of theory, mp. = 142 - 151°C

c)

N-(3-(p-methoxyphenyl)-propyl)-N'-cyanoacetylurea, 83.7 % of theory, mp. = 162 - 164°C

d)

N-2-methoxyethyl-N'-cyanoacetylurea, 78.9 % of theory, mp. = 129 - 132°C

e)

N-3-methoxypropyl-N'-cyanoacetylurea, 74.4 % of theory, mp. = 138 - 140°C

f)

N-(2-(p-chlorophenyl)-ethyl)-N'-cyanoacetylurea, 59.5 % of theory, mp. = 192 - 193°C

g)

N-(2-(p-bromophenyl)-ethyl)-N'-cyanoacetylurea, 80.2 % of theory, mp. = 192 - 193°C

3. 1-Substituted 6-aminouracils:

0.5 mol of substituted cyanoacetylurea [see 2.] is placed in 1250 ml of absolute ethanol and heated to 50 -



80°C. A solution of 3.8 g (0.17 mol) of sodium in 190 ml of absolute ethanol is added dropwise and the resulting suspension is stirred for 30 minutes at reflux temperature. The mixture is diluted with distilled water, cooled, optionally neutralised with HCl and the crystalline product is suction filtered.

The following 1-substituted 6-aminouracils were prepared, inter alia, using this method:

- a)
6-amino-1-(p-methoxybenzyl)-uracil, 63.3 % of theory,
mp. = 276 - 278°C
- b)
6-amino-1-(2-(p-methoxyphenyl)-ethyl)-uracil, 69 % of
theory, mp. = 233 - 236°C
- c)
6-amino-1-(3-(p-methoxyphenyl)-propyl)uracil, 69.3 % of
theory
- d)
6-amino-1-(2-methoxyethyl)-uracil, 41.6 % of theory, mp.
= 229 - 230°C
- e)
6-amino-1-(3-methoxypropyl)-uracil, 68.1 % of theory,
mp. = 208 - 210°C
- f)
6-amino-1-(2-(p-chlorophenyl)-ethyl)-uracil, 78.1 % of
theory, mp. = 282 - 283°C
- g)
6-amino-1-(2-(p-bromophenyl)-ethyl)-uracil, 56.1 % of
theory, mp. = 291 - 292°C

4.4-Substituted 6-amino-5-nitrosouracils:

0.005 mol of 1-substituted 6-aminouracil [see 3.] is suspended in 12.5 ml of distilled water; in the case of starting compounds which are particularly difficult to



- 33 -

dissolve, ethanol is also added. The mixture is heated to 80°C and combined with a solution of 0.36 g (5.3 mMol) of sodium nitrite in 3 ml of distilled water. Then 0.7 ml of glacial acetic acid are added and the mixture is stirred at 80°C until the reaction has ended. The reaction mixture is cooled, the reddish-violet residue is suction filtered and washed with distilled water.

The following 1-substituted 6-amino-5-nitrosouracils were prepared, inter alia, using this method:

a)

6-amino-5-nitroso-1-(p-methoxybenzyl)-uracil, 90.6 % of theory, mp. = 233°C

b)

6-amino-5-nitroso-1-(2-(p-methoxyphenyl)-ethyl)-uracil, 75.8 % of theory, mp. = 227°C

c)

6-amino-5-nitroso-1-(3-(p-methoxyphenyl)-propyl)-uracil, 49.1 % of theory,

d)

6-amino-5-nitroso-1-(2-methoxyethyl)-uracil, 80 % of theory, mp. = 222°C

e)

6-amino-5-nitroso-1-(3-methoxypropyl)-uracil, 58.5 % of theory, mp. = 227 - 228°C

f)

6-amino-5-nitroso-1-(2-(p-chlorophenyl)-ethyl)-uracil, 88.5 % of theory, mp. = 235 - 236°C

g)

6-amino-5-nitroso-1-(2-(p-bromophenyl)-ethyl)-uracil, 76.6 % of theory, mp. = 248°C

This Sheet Has Been Replaced



5. 1-Substituted 5,6-diaminouracils

4.5 mMol of 1-substituted 6-amino-5-nitrosouracil [see 4.] are dissolved in 50 ml of conc. ammonia; for starting compounds which are particularly difficult to dissolve, ethanol is added. At 30°C a solution of 2.35 g (13.5 mMol) of sodium dithionite in 24 ml of distilled water is added dropwise. The mixture is stirred at ambient temperature until the reaction has ended, then the crystalline product is suction filtered and washed with distilled water.

The following 1-substituted 5,6-diaminouracils, inter alia, were prepared using this method:

- a)
5,6-diamino-1-(p-methoxybenzyl)-uracil, 93.2 % of theory, mp. = 252°C
- b)
5,6-diamino-1-(2-(p-methoxyphenyl)-ethyl)-uracil, 88.5 % of theory, mp. = 249 - 250°C
- c)
5,6-diamino-1-(3-(p-methoxyphenyl)-propyl)-uracil, 80.5 % of theory, mp. = 252 - 253°C
- d)
5,6-diamino-1-(2-methoxyethyl)-uracil, 84.4 % of theory, mp. = 246°C
- e)
5,6-diamino-1-(3-methoxypropyl)-uracil, 58.5 % of theory, mp. = 248°C (decomposition)
- f)
1-(2-(p-chlorophenyl)-ethyl)-5,6-diaminouracil, 66.3 % of theory, mp. = 279 - 280°C
- g)
1-(2-(p-bromophenyl)-ethyl)-5,6-diaminouracil, 79.7 % of theory, mp. = 273°C (decomposition)



6. 1-Substituted 6-amino-5-acylaminouracils and
1-substituted 5-amino-6-acylaminouracils

The acylating position (5- or 6-position) is not important for the following reaction and has not been determined. In the interests of simplicity, the name of the product acylated in the 5-position is given hereinafter!

0.46 ml of 1-substituted 5,6-diaminouracil [see 5.] are suspended together with 78.2 g (0.64 mol) of 4-dimethylaminopyridine (DMAP) in 2400 ml of absolute dimethylformamide (DMF). At 0 - 5°C a solution consisting of 0.55 mol of the corresponding acid chloride in 200 ml of absolute DMF is added dropwise thereto, the mixture is stirred, whilst cooling with ice, until the reaction has ended and is then allowed to come up to ambient temperature. The reaction mixture is evaporated to dryness, the residue is triturated with distilled water. The crystalline product is suction filtered and washed with distilled water and diethylether.

The following title compounds were prepared, inter alia, using this method:

a)

6-amino-5-cyclopentylcarbonylamino-1-(p-methoxybenzyl)-uracil, 88.3 % of theory, mp. = 261 - 262°C


b)

6-amino-5-cyclopentylcarbonylamino-1-(2-(p-methoxyphenyl)-ethyl)-uracil, 80.6 % of theory, mp. = 217 - 222°C

c)

6-amino-5-cyclopentylcarbonylamino-1-(3-(p-methoxyphenyl)-propyl)-uracil, 84.8 % of theory, mp. = 126 - 128°C

d)



- 36 -

6-amino-5-cyclopentylcarbonylamino-1-(2-methoxyethyl)-
uracil 84.4 % of theory, mp. = 209 - 213°C

e)

6-amino-5-cyclopentylcarbonylamino-1-(3-methoxypropyl)-
uracil, 84 % of theory,

f)

6-amino-5-cyclopentylcarbonylamino-1-(2-(p-
chlorophenyl)-ethyl)-uracil, 66.3 % of theory, mp. =
258 - 259°C

g)

6-amino-5-cyclopentylcarbonylamino-1-(2-(p-bromophenyl)-
ethyl)-uracil, 68.5 % of theory, mp. = 245 - 246°C

7. Xanthines substituted in the 3- and 8-positions

0.01 mol of 1-substituted 6-amino-5-acylamino-uracil (or
1-substituted 5-amino-6-acylamino-uracil) [see 6.] are
suspended in 10 ml of tetrahydrofuran and combined with
a solution of 2.38 g (0.056 mol) of lithium hydroxide-
hydrate in 70 ml of distilled water. The reaction
mixture is stirred at 70 - 80°C until the reaction has
ended, then made acidic with HCl and left to cool. The
crystalline product is suction filtered and washed with
distilled water. If necessary, it is recrystallised
from ethanol in order to purify it.

The following xanthines substituted in the 3- and 8-
positions were prepared, inter alia, by this method:

a)

8-cyclopentyl-3-(p-methoxybenzyl)-xanthine, 77.8 % of
theory, mp. = 311°C

b)

8-cyclopentyl-3-(2-(p-methoxyphenyl)-ethyl)-xanthine,
42.3 % of theory, mp. = 256 - 258°C

c)

8-cyclopentyl-3-(3-(p-methoxyphenyl)-propyl)-xanthine,



- 37 -

90.5 % of theory, mp. = 292 - 293°C

d)

8-cyclopentyl-3-(2-methoxyethyl)-xanthine, 68.3 % of theory, mp. = 293 - 294°C

e)

8-cyclopentyl-3-(3-methoxypropyl)-xanthine, 90.9 % of theory, mp. = 240 - 247°C

f)

8-cyclopentyl-3-(2-(p-chlorophenyl)-ethyl)-xanthine, 81.3 % of theory, mp. = 298 - 299°C

g)

8-cyclopentyl-3-(2-(p-bromophenyl)-ethyl)-xanthine, 60.1 % of theory, mp. = 306 - 307°C

8. 7-Benzylxanthines substituted in 3- and 8-positions

0.02 Mol of xanthine substituted in the 3- and 8-positions [see 7.] and 3.0 g (0.022 mol) of potassium carbonate are suspended in 140 ml of absolute DMF. The mixture is stirred for one hour at ambient temperature and then 2.62 ml (0.022 mol) of benzylbromide are added dropwise. The mixture continues to be stirred at ambient temperature. If the reaction stops before all the starting compounds have been reacted, up to 35 mol % of potassium carbonate and benzylbromide may be added. After the reaction has ended the mixture is evaporated to dryness, the residue is taken up in methylene chloride and extracted with water. The organic phase is dried with sodium sulphate and evaporated to dryness. The residue is purified by crystallisation or by chromatography.

This Sheet Has Been Replaced



- 38 -

Using this method, the following 7-benzylxanthines substituted in the 3- and 8-positions, inter alia, were prepared:

a)

7-benzyl-8-cyclopentyl-3-(p-methoxybenzyl)-xanthine,
66.2 % of theory, mp. = 165°C

b)

7-benzyl-8-cyclopentyl-3-(2-(p-methoxyphenyl)-ethyl)-
xanthine, 77 % of theory, mp. = 152°C

c)

7-benzyl-8-cyclopentyl-3-(3-(p-methoxyphenyl)-propyl)-
xanthine, 64 % of theory, mp. = 146 - 148°C

d)

7-benzyl-8-cyclopentyl-3-(2-methoxyethyl)-xanthine,
69.1 % of theory, mp. = 140°C

e)

7-benzyl-8-cyclopentyl-3-(3-methoxypropyl)-xanthine,
77.7 % of theory, mp. = 130 - 132°C

f)

7-benzyl-8-cyclopentyl-3-(2-(p-chlorophenyl)-ethyl)-
xanthine, 39.8 % of theory, mp. = 179 - 180°C

9. 7-Benzylxanthine substituted in the 1-, 3- and 8-positions

6.5 mMol of 7-benzylxanthine substituted in the 3- and 8-positions [see 8.], 1.0 g (7.15 mMol) of potassium carbonate and 7.15 mMol of alkyl-, alkenyl- or alkynylhalide are stirred in 56 ml of absolute DMF until the starting substance has reacted completely (if necessary, some more potassium carbonate and alkylhalide may be added). The reaction mixture is neutralised, evaporated down, the residue is taken up in methylene chloride and extracted with distilled water. The organic phase is dried with sodium sulphate and



evaporated to dryness and the residue is purified, if necessary, by crystallisation or by chromatography.

Using this method, the following 7-benzylxanthines substituted in the 1-, 3- and 8-positions were prepared, inter alia:

a)

7-benzyl-8-cyclopentyl-3-(p-methoxybenzyl)-1-propylxanthine, 99 % of theory, mp. = 110 - 111°C

b)

7-benzyl-8-cyclopentyl-3-(2-(p-methoxyphenyl)-ethyl)-1-propylxanthine, 77 % of theory, mp. = 151°C

c)

7-benzyl-8-cyclopentyl-3-(3-(p-methoxyphenyl)-propyl)-1-propylxanthine, 95.3 % of theory, mp. = 99 - 101°C

d)

7-benzyl-8-cyclopentyl-3-(2-methoxyethyl)-1-propylxanthine, 97.7 % of theory, mp. = 80 - 81°C

e)

7-benzyl-8-cyclopentyl-3-(3-methoxypropyl)-1-propylxanthine, 61.8 % of theory, mp. = 76 - 80°C

f)

7-benzyl-8-cyclopentyl-3-(2-(p-chlorophenyl)-ethyl)-1-propyl-xanthine, 67.9 % of theory, colourless oil

g)

1-allyl-7-benzyl-8-cyclopentyl-3-(3-methoxypropyl)-xanthine, 86.5 %, colourless oil

Numerous other xanthine derivatives described by the general formula were prepared from the xanthines thus obtained by varying the substituents in the 3-position. Only those methods which are familiar to those skilled in the art were used.



10. 7-Benzylxanthines substituted in the 1- and 8-positions

6.3 mMol of 7-benzyl-3-p-methoxybenzylxanthine substituted in the 1- and 8-positions [see 9.] were mixed with 30 ml of trifluoroacetic acid and stirred for 4 days at 60°C under a protective gas atmosphere. The mixture was diluted with distilled water, extracted with ethyl acetate, and the combined organic phases were dried with sodium sulphate and evaporated to dryness. The residue was purified by crystallisation or by chromatography.

Using this method, the following title compound was prepared, inter alia:

a) from

7-benzyl-8-cyclopentyl-3-(2-p-methoxybenzyl)-1-propylxanthine:

7-benzyl-8-cyclopentyl-1-propylxanthine, 90 % of theory,
mp. = 214°C

11. Introduction of substituents into the 3-position of 7-benzylxanthines substituted in the 1- and 8-positions

Method A:

0.5 mMol of 7-benzylxanthine substituted in the 1- and 8-positions [see 10.], 75 mg (0.55 mMol) of potassium carbonate and 0.55 mMol (optionally substituted, as described under R₂) of alkyl-, alkenyl- or alkynyl halide are stirred in 3.5 ml of absolute DMF until the reaction has ended, optionally with heating. The mixture is neutralised, evaporated to dryness and the residue is distributed between methylene chloride and distilled water. The organic phase is dried over sodium sulphate and evaporated down and the residue is purified, if necessary, by crystallisation or by chromatography.



Using this method, the following title compound was prepared, inter alia:

a) from

7-benzyl-8-cyclopentyl-1-propylxanthine:

7-benzyl-8-cyclopentyl-3-(Z-(p-methoxycarbonylphenyl)-ethyl)-1-propylxanthine, 67 % of theory, viscous oil

Method B:

To a solution of 0.56 g (2.1 mMol) of triphenylphosphine in 3.5 ml of absolute tetrahydrofuran (THF) are added, successively, 0.37 g (2.1 mMol) of diethylazodicarboxylate (DEAD) and 1.4 mMol of 7-benzylxanthine substituted in the 1- and 8-positions [see 10] and the mixture is cooled to 5°C. At this temperature, 1.4 mMol of (optionally substituted, as described in R₂) alkyl-, alkenyl- or alkynylalcohol are added dropwise and the mixture is stirred at ambient temperature until all the starting substance has reacted. The mixture is evaporated to dryness and the residue is purified by crystallisation or by chromatography.

Using this method, the following title compounds were prepared, inter alia:

from 7-benzyl-8-cyclopentyl-1-propylxanthine:

a)

7-benzyl-8-cyclopentyl-1-propyl-3-(2-(2-pyridyl)-ethyl)-xanthine, 87 % of theory, colourless oil

b)

7-benzyl-8-cyclopentyl-1-propyl-3-(3-(3-pyridyl)-propyl)-xanthine

c)

7-benzyl-3-(2-(p-cyanophenyl)-ethyl)-8-cyclopentyl-1-



propyl-xanthine, 29.7 % of theory, colourless oil

Using the methods 11. A) and 11. B), many of the substituents R_2 described in the general formula were introduced directly or in the form of suitable precursors which were converted into the desired group R_2 by conventional methods.

12. Hydrolysis of methylethers

Method A:

0.5 mMol of methylether-derivative are dissolved in 5 ml of absolute acetonitrile. 300 mg (40 mMol) of sodium iodide are added followed by 0.39 ml (3.0 mMol) of chlorotrimethylsilane and the suspension is stirred at ambient temperature or at reflux temperature until the reaction has ended. The mixture is cooled to ambient temperature, mixed with distilled water and extracted with methylene chloride. The combined organic phases are washed with sodiumthiosulphate solution, dried over sodium sulphate and evaporated to dryness. The product is purified by crystallisation or chromatography, if required. Using this method the following title compounds were prepared, inter alia:

a)

7-benzyl-8-cyclopentyl-3-(3-hydroxypropyl)-1-propylxanthine, 78.4 % of theory, yellowish oil

b)

7-benzyl-8-cyclopentyl-3-(2-hydroxyethyl)-1-propylxanthine, 90 % of theory, mp. = 208 - 209°C

Method B:

4.8 mMol of methylether-derivative are dissolved in 60 ml of absolute methylene chloride. At $-20 \pm 5^\circ\text{C}$ a solution of 0.65 ml (6.5 mMol) of boron tribromide in 7 ml of absolute methylene chloride is added dropwise



and the resulting mixture is stirred at ambient temperature until the reaction has ended. The reaction mixture is washed with distilled water, the organic phase is dried over sodium sulphate and evaporated to dryness. The residue is purified by crystallisation or by chromatography.

Using this method, the following title compounds were prepared, inter alia:

- a)
8-cyclopentyl-3-(2-hydroxyethyl)-1-propylxanthine,
80.7 % of theory, mp. = 216°C
- b)
8-cyclopentyl-3-(2-(p-hydroxyphenyl)-ethyl)-1-propylxanthine, 83.5 % of theory, mp. = 270 - 272°C
- c)
7-benzyl-8-cyclopentyl-3-(3-(p-hydroxyphenyl)-propyl)-1-propylxanthine, 97.3 % of theory, mp. = 130 - 132°C
- d)
7-benzyl-8-cyclopentyl-3-(3-hydroxypropyl)-1-propylxanthine, 83.6 % of theory, mp. = 116 - 117°C


13. Hydrogenolysis of N-benzyl substituents

Method A:

0.01 mol of N-benzyl compound are hydrogenated together with 0.5 g of palladium on activated charcoal or Pearlman catalyst in methanol, tetrahydrofuran or in glacial acetic acid under pressure and optionally with heating until all the starting compound has reacted.

The catalyst is filtered off, the filtrate is evaporated to dryness and the residue is purified by crystallisation or chromatography.

Using this method, numerous hydrogenolyses are carried out, to obtain, inter alia:



a) from

7-benzyl-8-cyclopentyl-3-(2-(p-methoxyphenyl)-ethyl)-1-propylxanthine:

8-cyclopentyl-3-(2-(p-methoxyphenyl)-ethyl)-1-propylxanthine, 70.6 % of theory, mp. = 208°C

b) from

1-allyl-7-benzyl-8-cyclopentyl-3-(3-methoxypropyl)-xanthine:

8-cyclopentyl-3-(3-methoxypropyl)-1-propylxanthine, 71.4 % of theory, mp. = 174 - 175°C

c) from

7-benzyl-8-cyclopentyl-3-(3-(hydroxypropyl)-1-propylxanthine:

8-cyclopentyl-3-(3-(hydroxypropyl)-1-propylxanthine, 26.6 % of theory, mp. = 213 - 215°C

d) from

7-benzyl-8-cyclopentyl-3-(3-(p-methoxyphenyl)-propyl)-1-propylxanthine:

8-cyclopentyl-3-(3-(p-methoxyphenyl)-propyl)-1-propylxanthine, 80.6 % of theory, mp. = 153 - 154°C

e) with palladium on activated charcoal in methanol/HCl from

7-benzyl-3-(2-carboxyethyl)-8-cyclopentyl-1-propylxanthine:

8-cyclopentyl-3-(2-methoxycarbonyl-ethyl)-1-propylxanthine, 16.3 % of theory, mp. = 201 - 203°C

f) from

7-benzyl-8-cyclopentyl-3-(3-(p-hydroxyphenyl)-propyl)-1-propylxanthine:


8-cyclopentyl-3-(3-(p-hydroxyphenyl)-propyl)-1-propylxanthine, 26.8 % of theory, mp. = 239 - 241°C

g) from

7-benzyl-8-cyclopentyl-3-(2-(methylaminocarbonyl)-ethyl)-1-propylxanthine:

8-cyclopentyl-3-(2-(methylaminocarbonyl)-ethyl)-1-propylxanthine, 67.7 % of theory, mp. = 297 - 298°C

h) from



7-benzyl-8-cyclopentyl-3-(2-(3,4,5-trimethoxybenzylaminocarbonyl)-ethyl)-1-propylxanthine:
8-cyclopentyl-3-(2-(3,4,5-trimethoxybenzylamino-carbonyl)-ethyl)-1-propylxanthine, 77.2 % of theory, mp.
= 231 - 233°C

i) from

7-benzyl-8-cyclopentyl-3-(3-(p-methylcarbonyloxyphenyl)-propyl)-1-propylxanthine:

8-cyclopentyl-3-(3-(p-methylcarbonyloxyphenyl)-propyl)-1-propylxanthine, 63.9 % of theory, mp. = 181 - 183°C

j) from

7-benzyl-8-cyclopentyl-3-(2-(N-morpholinocarbonyl)-ethyl)-1-propylxanthine:

8-cyclopentyl-3-(2-(N-morpholinocarbonyl)-ethyl)-1-propylxanthine, 50 % of theory, mp. = 169 - 171°C

k) from

7-benzyl-8-cyclopentyl-3-(3-(N-morpholino)-propyl)-1-propylxanthine:

8-cyclopentyl-3-(3-(N-morpholino)-propyl)-1-propylxanthine, 59.7 % of theory, mp. = 176 - 178°C

l) from

7-benzyl-8-cyclopentyl-3-(2-(2,4,6-trimethoxybenzylaminocarbonyl)-ethyl)-1-propylxanthine:
8-cyclopentyl-3-(2-(2,4,6-trimethoxybenzylamino-carbonyl)-ethyl)-1-propylxanthine, 47.2 % of theory, mp.
= 241 - 243°C

m) from

7-benzyl-8-cyclopentyl-3-(3-(p-(ethoxycarbonylmethyloxy)-phenyl)-propyl)-1-propylxanthine,

8-cyclopentyl-3-(3-(p-(ethoxycarbonylmethyloxy)-phenyl)-propyl)-1-propylxanthine, 77.4 % of theory, mp. = 141 - 143°C

n) from

7-benzyl-8-cyclopentyl-3-(3-acetoxypropyl)-1-propylxanthine:

8-cyclopentyl-3-(3-acetoxypropyl)-1-propylxanthine,



93.5 % of theory, mp. = 157 - 159°C

o) from

7-benzyl-8-cyclopentyl-3-(3-hydroxybutyl)-1-propylxanthine:

8-cyclopentyl-3-(3-hydroxybutyl)-1-propylxanthine,
60.0 % of theory, mp. = 198 - 199°C

p) from

7-benzyl-8-cyclopentyl-3-(3-(p-(2-hydroxyethoxy)-phenyl)-propyl)-1-propylxanthine:

8-cyclopentyl-3-(3-(p-(2-hydroxyethoxy)-phenyl)-propyl)-1-propylxanthine, 59.6 % of theory, mp. = 168 - 169°C

q) from

7-benzyl-8-cyclopentyl-3-(3-(p-(2-(methylcarbonyloxy)-ethoxy)-phenyl)-propyl)-1-propylxanthine:

8-cyclopentyl-3-(3-(p-(2-(methylcarbonyloxy)-ethoxy)-phenyl)-propyl)-1-propylxanthine, 48.1 % of theory, mp. = 139 - 140°C

r) from

7-benzyl-8-cyclopentyl-3-(3-(N-piperidinyl)-propyl)-1-propylxanthine:

8-cyclopentyl-3-(3-(N-piperidinyl)-propyl)-1-propylxanthine, 78.4 % of theory, mp. = 152 - 154°C

s) from

7-benzyl-8-cyclopentyl-3-(3-(N-pyrrolidinyl)-propyl)-1-propylxanthine:

8-cyclopentyl-3-(3-(N-pyrrolidinyl)-propyl)-1-propylxanthine, 52.6 % of theory, mp. = 162 - 163°C

t) from

7-benzyl-8-cyclopentyl-3-(3-(p-(methoxycarbonylmethoxy)-phenyl)-propyl)-1-propylxanthine:

8-cyclopentyl-3-(3-(p-(methoxycarbonylmethoxy)-phenyl)-propyl)-1-propylxanthine, 86.5 % of theory, ¹H-NMR (250 MHz, DMSO-d₆): δ (ppm) = 7.11 (d, J = 8.8 Hz, 2H), 6.79 (d, J = 8.8 Hz, 2H), 4.72 (s, 2H), 3.98 (t, J = 7.3 Hz, 2H), 3.80 (t, J = 7.3 Hz, 2H), 3.69 (s, 3H), 3.13 (m, 1H), 2.55 (m, 2H), 2.07 - 1.45 (m, 12 H), 0.85



(t, J = 7.6 Hz, 3H).

u) from

7-benzyl-8-cyclopentyl-3-(2-methoxyethyl)-1-propylxanthine:

8-cyclopentyl-3-(2-methoxyethyl)-1-propylxanthine,
81.2 % of theory, mp. = 185°C

v) from

7-benzyl-3-(2-(cyclohexyl)-ethyl)-8-cyclopentyl-1-propylxanthine:

3-(2-(cyclohexyl)-ethyl)-8-cyclopentyl-1-propylxanthine,
mp. = 188 - 189°C

w) from

7-benzyl-8-cyclopentyl-3-(2-phenylethyl)-1-propylxanthine:

8-cyclopentyl-3-(2-phenylethyl)-1-propylxanthine, 34.5 %
of theory, mp. = 215 - 216°C

x) from

7-benzyl-8-cyclopentyl-3-(3-(phenyl)-propyl)-1-propylxanthine:

8-cyclopentyl-3-(3-(phenyl)-propyl)-1-propylxanthine,
28.6 % of theory, mp. = 153°C (decomposition)

y) from

7-benzyl-3-(3-cyanopropyl)-8-cyclopentyl-1-propylxanthine:

3-(3-cyanopropyl)-8-cyclopentyl-1-propylxanthine, 69.0 %
of theory, mp. = > 300°C

z) from

7-benzyl-3-(5-cyanopentyl)-8-cyclopentyl-1-propylxanthine:

3-(5-cyanopentyl)-8-cyclopentyl-1-propylxanthine, 21.1 %
of theory, mp. = 160°C (decomposition)

a1) from

3-(3-(aminocarbonyl)-propyl)-7-benzyl-8-cyclopentyl-1-propylxanthine:

3-(3-(aminocarbonyl)-propyl)-8-cyclopentyl-1-propylxanthine, mp = 264 - 165°C



Method B:

3.3 mMol of N-benzyl compound are dissolved in 70 ml of absolute methylene chloride. 3.36 g (52.8 mMol) of ammonium formate and 1.32 g of Pearlman-catalyst are added and the suspension is refluxed for 2 hours. After cooling, the mixture is filtered over kieselguhr and the filtrate is evaporated to dryness. If necessary the residue is purified by crystallisation or chromatography.

Numerous hydrogenolyses were carried out using this method, to obtain inter alia:

a) from

7-benzyl-8-cyclopentyl-1-propyl-3-(2-(2-pyridyl)-ethyl)-xanthine:

8-cyclopentyl-1-propyl-3-(2-(2-pyridyl)-ethyl)-xanthine,
mp = 201 - 202°C

14. Hydrogenation of nitrile groups

3.3 mMol of nitrile derivative are dissolved in 40 ml of methanol and 10.5 ml of 25% aqueous ammonia solution and hydrogenated under pressure in the presence of Raney nickel, optionally with heating, until all the starting compound has reacted.

The following was obtained, for example, using this method:

a)

3-(4-aminobutyl)-8-cyclopentyl-1-propylxanthine, 40.9 %
of theory, mp. = 159 - 161°C

15. Acylation of hydroxy groups

1.3 mMol of hydroxy compound and 0.53 ml (6.5 mMol) of



pyridine are dissolved or suspended in 10 ml of absolute methylene chloride. A solution of 1.44 mMol of carboxylic acid chloride in 1 ml of absolute methylene chloride is added dropwise at ambient temperature with stirring and the reaction mixture is stirred until all the starting compound has reacted. The mixture is then extracted with distilled water and dilute hydrochloric acid, the organic phase is dried over sodium sulphate and evaporated to dryness. The residue is purified by crystallisation or by chromatography.

Using this method, the following O-acyl compounds were prepared, inter alia:

a)

8-cyclopentyl-3-(2-(methylcarbonyloxy)-ethyl)-1-propylxanthine, 47 % of theory, mp. = 149°C

b)

8-cyclopentyl-3-(2-(p-(methylcarbonyloxy)-phenyl)-ethyl)-1-propylxanthine, 47 % of theory, mp. = 232°C

c)

7-benzyl-8-cyclopentyl-3-(3-(p-(methylcarbonyloxy)-phenyl)-propyl)-1-propylxanthine, 77.5 % of theory, gradually crystallising oil

d)

7-benzyl-8-cyclopentyl-3-(3-(methylcarbonyloxy)-propyl)-1-propylxanthine, 98.6 % of theory, gradually crystallising oil

e)

7-benzyl-8-cyclopentyl-3-(3-(p-(2-(methylcarbonyloxy)-ethoxy)-phenyl)-propyl)-1-propylxanthine, 82.1 % of theory, colourless oil

16. Hydrolysis of carboxylic acid esters

0.6 mMol of ester derivative are dissolved in about 4 ml of tetrahydrofuran and mixed with a solution of 0.17 g



(4.0 mMol) of lithium hydroxide-hydrate in 10 ml of distilled water. The reaction mixture is stirred until all the starting substance has reacted, then made alkaline with dilute hydrochloric acid and the product is filtered off or the aqueous phase is extracted with organic solvent. In order to purify it it may be recrystallised or chromatographed.

Using this method, the following compounds were prepared inter alia:

a) from

8-cyclopentyl-3-(3-(p-(ethoxycarbonylmethoxy)-phenyl)-propyl)-1-propylxanthine:

3-(3-(p-(carboxymethoxy)-phenyl)-propyl)-8-cyclopentyl-1-propylxanthine, 85.2 % of theory, mp. = 190 - 192°C

b) from

8-cyclopentyl-3-(2-(methyloxycarbonyl)-ethyl)-1-propylxanthine:

3-(2-carboxyethyl)-8-cyclopentyl-1-propylxanthine, 78.5 % of theory, mp. = 265 - 267°C

17. Hydrolysis of methoxybenzylamides

1.1 mMol of methoxybenzylamide derivative are suspended or dissolved at 0°C in 50 ml of absolute methylene chloride. A solution of 5 ml of trifluoroacetic acid in 5 ml of absolute methylene chloride is added dropwise, the mixture is heated to ambient temperature and stirred until all the starting compound has reacted. The reaction mixture is washed with distilled water, the organic phase is dried over sodium sulphate and evaporated to dryness. The crude product is purified by crystallisation or by chromatography.

Using this method, the following compounds are obtained,



inter alia:

a) from

8-cyclopentyl-3-(2-(2,4,6-trimethoxybenzylamino-carbonyl)-ethyl)-1-propylxanthine:

3-(2-carbamoylethyl)-8-cyclopentyl-1-propylxanthine,
64.9 % of theory, mp. = 289 - 291°C

b) from

3-(3-(p-(2,4,6-trimethoxybenzylamino-carbonyl-methyloxy)-phenyl)-propyl)-8-cyclopentyl-1-propylxanthine:

3-(3-(p-(carbamoylmethyloxy)-phenyl)-propyl)-8-cyclopentyl-1-propylxanthine, 49.0 % of theory, mp. =
224 - 226°C

18. Preparation of oximes

2.5 mMol of aldehyde, 0.17 g (2.5 mMol) of hydroxylamine-hydrochloride and 0.13 g (1.3 mMol) of sodium carbonate are mixed into 15 ml of distilled water and stirred together at ambient temperature until all the starting compound has reacted. Methylene chloride is added to the mixture and the solid is removed by suction filtering or the aqueous phase is extracted with methylene chloride. The crude product is purified by crystallisation or by chromatography.

Using this method the following was prepared, for example:

a) from

8-cyclopentyl-3-formylmethyl-1-propylxanthine:

8-cyclopentyl-3-hydroximinoethyl-1-propylxanthine, 64 %
of theory, mp. = 247°C



19. Oxidation of alcohols into aldehydes or ketones

0.4 mMol of alcohol derivative are stirred together with 180 mg (0.84 mMol) of pyridinium chlorochromate in 5 ml of absolute methylene chloride until all the starting compound has reacted. The reaction mixture is washed with distilled water, the organic phase is dried over sodium sulphate and evaporated to dryness. The crude product is purified by crystallisation or by chromatography.

Using this method, the following was prepared, inter alia:

a) from

8-cyclopentyl-3-(3-hydroxybutyl)-1-propylxanthine:

8-cyclopentyl-3-(3-oxobutyl)-1-propylxanthine, 73.3 % of theory, mp. = 223 - 224°C

20. Preparation of thioethers

3.6 mol of alkylhalide derivative are dissolved or suspended in a solution of 0.42 g (7.5 mol) of potassium hydroxide in 60 ml of ethanol. 3.6 mMol of substituted thiol are added and the mixture is refluxed until all the starting compound has reacted. It is evaporated to dryness, the residue is mixed with 4N hydrochloric acid and extracted with methylene chloride. The combined organic phases are dried with magnesium sulphate and evaporated to dryness. The residue is purified by crystallisation or by chromatography.

Using this method, the following were prepared, inter alia:

from 8-cyclopentyl-3-(2-iodoethyl)-1-propylxanthine:

a) 8-cyclopentyl-3-(2-ethylthio)-ethyl)-1-



propylxanthine, 71.3 % of theory, mp. = 144 - 145°C

- b) 8-cyclopentyl-3-(2-(2-hydroxyethyl)-thioethyl)-1-propylxanthine, 95 % of theory, mp. = 160 - 161°C.

21. Saponification of nitriles

0.5 mMol of nitrile are suspended or dissolved at 10°C in 1 ml of 95 - 97% sulphuric acid. The mixture is stirred for 3.5 hours at ambient temperature, 5 ml of water and 5 ml of methylene chloride are added thereto, the organic phase is separated off and evaporated to dryness. The residue is purified by crystallisation or chromatography. For example, from


7-benzyl-3(3-cyano-propyl)-8-cyclopentyl-1-propylxanthine is obtained:

3-(3-(aminocarbonyl)-propyl)-7-benzyl-8-cyclopentyl-1-propylxanthine,
mp. = 180 - 181°C

22. Preparation of alkyl iodides from alcohols

3.1 mMol of 8-cyclopentyl-3-(2-hydroxyethyl)-1-propylxanthine, 3.1 mMol of tetraiodomethane and 3.1 mMol of triphenylphosphine are mixed in 15 ml of absolute toluene and refluxed for 2 hours. The mixture is diluted with toluene and the organic phase is washed with water and sodium thiosulphate solution. The crystals precipitated are filtered off, the organic phase of the filtrate is separated off, washed with water, dried and evaporated to dryness. The residue and the filtered off crystals are combined, stirred in acetonitrile for 16 hours at ambient temperature and the solid is isolated by filtration.

Yield: 1.0 g (77.5 % of theory) of 8-cyclopentyl-3-(2-iodoethyl)-1-propyl-xanthine in the form of colourless crystals, mp. = 223 - 226°C.



23. Oxidation of thioethers into sulphones

0.55 g of neutral aluminium oxide are mixed with 0.11 ml of water and shaken until a fine powder is formed. 8 ml of methylene chloride, 1.0 g (1.65 mMol) of oxone [= 2KHSO₅ * KHSO₄ * K₂HSO₄] and a solution of 0.2 g (0.55 mMol) of 8-cyclopentyl-3-(2-(2-hydroxyethyl)-thioethyl)-1-propylxanthine in 4 ml of absolute methylene chloride are added successively and the mixture is refluxed for 2 hours with stirring. After cooling, the solids are filtered off, washed thoroughly with methylene chloride and the combined filtrates are evaporated to dryness. The residue is purified by chromatography on silica gel.

0.2 g (91.3 % of theory) of 8-cyclopentyl-3-(2-(2-hydroxyethyl)-sulphonylethyl)-1-propyl-xanthine is obtained in the form of colourless crystals mp. 213 - 214°C.

24. Synthesis of 8-cyclopentyl-7-benzyl-3-p-methoxy-xanthine

50 g (0.20 mol) of 6-amino-1-p-methoxybenzyl-uracil are added with 17.5 g of NaHCO₃ (0.21 mol) of 200 ml of methanol and at 5°C 11 ml of bromine are slowly added dropwise (vigorous foaming). Then the mixture is stirred for 2 hours in an ice bath. It is suction filtered and washed twice with 150 ml of methanol.

Yield: 54.3 g of light yellow crystals (82.2 % of theory)

~~6-amino-5-bromo-1-p-methoxybenzyl-uracil~~

TLC: 95:5 CH₂Cl₂:CH₃OH

mp: 245°C (Decomp.)

121.1 g (0.37 mol) of 6-amino-5-bromo-1-p-methoxybenzyl-



uracil are mixed with 396.5 g of benzylamine (3.7 mol) and stirred for 2 hours at 80°C. The mixture is cooled, extracted with 1000 ml of ethanol, cooled and suction filtered. It is then washed with cold ethanol.

Yield: 110.0 g of white crystals (83.6 % of theory)
5-amino-5-benzyl-amino-1-p-methoxybenzyl-uracil
TLC: 90:10 CH₂Cl₂:CH₃OH
mp: 230°-231°C

110.0 g (0.31 mol) of 5-amino-5-benzyl-amino-1-p-methoxybenzyl-uracil are placed with 52.8 g of 4-dimethylamino-pyridine (0.43 mol) in 1,650 ml of DMF and at 5°C a solution of 66.0 g of cyclopentancarboxylic acid chloride (0.50 mol) and 165 ml of DMF is added dropwise. The mixture is then stirred at 5 - 25°C for 3 days. It is evaporated down in vacuo, the residue is boiled twice with 700 ml of ethanol, then cooled and suction filtered.

Yield: 113.0 g of white crystals (81.3 % of theory)
6-cyclopentyl-carbonylamino-5-benzylamino-1-p-methoxybenzyluracil
TLC: 95:5 CH₂Cl₂:CH₃OH

113.0 g (0.25 mol) of 6-cyclopentyl-carbonylamino-5-benzylamino-1-p-methoxybenzyluracil are combined with 1,300 ml of H₂O and 650 ml of ethanol, 83.3 g of Ca(OH)₂ (1.1 mol) and 330 ml of 50% NaOH are added and the resulting mixture is stirred at 100°C for 20 hours. The mixture is evaporated down in vacuo (only the ethanol is distilled off!). The aqueous residue is cooled adjusted to pH 2 with conc. HCl, with ice cooling, and suction filtered.


Yield: 93.0 g of beige crystals (86.4 % of theory)
7-benzyl-8-cyclopentyl-3-p-methoxybenzyl-xanthine



TLC: 90:10 CH_2Cl_2 : CH_3OH



mp: 172°C

Analogously to the methods described hereinbefore, the compounds of general formula I listed in the Table were prepared.



R_1 = n-propyl, R_3 = cyclopentyl, R_4 = hydrogen









Example No.	R ₂	MP. °C
1	CH ₂ CH ₂ CH ₂ CN	>300
2	CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ CN	160
3	CH ₂ CH ₂ OCH ₃	185
4	CH ₂ CH ₂ CH ₂ OCH ₃	174 - 175
5	CH ₂ CH ₂ OH	216
6	CH ₂ CH ₂ CH ₂ OH	213 - 215
7	CH ₂ CH ₂ OCOCH ₃	149
8	CH ₂ CH ₂ CH ₂ OCOCH ₃	157 - 159
9	CH ₂ CH ₂ COOH	265 - 267
10	CH ₂ CH ₂ COOCH ₃	201 - 203
11	CH ₂ CH ₂ CONH ₂	289 - 291
12	CH ₂ CH ₂ CONHCH ₃	297 - 298
13	CH ₂ -CH ₂ CONHCH ₂ - 	221 - 233
14	CH ₂ CH ₂ CO-N 	169 - 171
15	CH ₂ CH ₂ CH(OH)CH ₃	198 - 199
16	CH ₂ CH ₂ COCH ₃	223 - 224
17	CH ₂ CH=NOH	247











Example No.	R ₂	MP. °C
18	$\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{NH}_2$	159 - 161
19	$\text{CH}_2\text{CH}_2\text{CH}_2 - \text{N} \begin{array}{c} \diagup \quad \diagdown \\ \diagdown \quad \diagup \end{array} \text{O}$	176 - 178
20	$\text{CH}_2\text{CH}_2\text{CH}_2 - \text{N} \begin{array}{c} \diagup \quad \diagdown \\ \diagdown \quad \diagup \end{array}$	152 - 159
21	$\text{CH}_2\text{CH}_2 - \text{C}_6\text{H}_5$	215 - 216
22	$\text{CH}_2\text{CH}_2 - \text{C}_6\text{H}_{11}$	188 - 189
23	$\text{CH}_2\text{CH}_2\text{CH}_2 - \text{C}_6\text{H}_5$	153
24	$\text{CH}_2\text{CH}_2 - \text{C}_6\text{H}_4\text{OH}$	270 - 272
25	$\text{CH}_2\text{CH}_2\text{CH}_2 - \text{C}_6\text{H}_4\text{OH}$	239 - 241
26	$\text{CH}_2\text{CH}_2 - \text{C}_6\text{H}_4\text{OCH}_3$	208
27	$\text{CH}_2\text{CH}_2\text{CH}_2 - \text{C}_6\text{H}_4\text{OCH}_3$	153 - 154



Example No.	R ₂	MP. °C
28		232
29		181 - 183
30		190 - 192
31		141 - 143
32		224 - 226
33		139 - 140
34	CH ₂ CH ₂ CH ₂ OCH ₃	R ₁ =H 257 - 258
35		292 - 293 R ₁ =H
36	CH ₂ CH ₂ CH ₂ OCH ₃	R ₁ =H 137 - 138 R ₇ =CH ₂ Ph
37		298 - 299 R ₁ =H










- 60 -









Example No.	R ₂		MP. °C
38	CH ₂ CH ₂ OCH ₃	R ₁ =H	293 - 294
39	CH ₂ CH ₂ -  -OCH ₃	R ₁ =H	256 - 258
40	CH ₂ - 		311
41	CH ₂ - 	R ₁ =H	>350
42	CH ₂ - 		265 - 267
43	CH ₂ - 		322
44	CH ₂ - 		259 - 260
45	CH ₂ - 		168-169
46	(CH ₂)-S-Et		144 - 145
47	-(CH ₂)-S-(CH ₂) ₂ -OH		160 - 161
48	CH ₂ CH ₂ CH ₂ -  -OCH ₂ CH ₂ O		168 - 169
49			162 - 163

This Sheet Has Been Replaced












Example No.	R ₂	MP. °C
	$\text{CH}_2\text{CH}_2\text{CH}_2\text{-N}$ 	
50	$\text{CH}_2\text{CH}_2\text{-}$  $\text{-OCH}_2\text{COOEt}$	191 - 193
51	$\text{CH}_2\text{CH}_2\text{-}$ 	179 - 181
52	$\text{CH}_2\text{CH}_2\text{CH}_2\text{-}$ 	187 - 189
53	$\text{CH}_2\text{CH}_2\text{CH}_2\text{-}$ 	167 - 168
54	$\text{CH}_2\text{CH}_2\text{SO}_2\text{CH}_2\text{CH}_2\text{OCOCH}_3$	171 - 172
55	$\text{CH}_2\text{CH}_2\text{-N}$ 	162 - 163
56	$\text{CH}_2\text{CH}_2\text{NH-}$ 	141 - 142
57	$\text{CH}_2\text{CH}_2\text{-}$  $\text{-OCH}_2\text{CONH}_2$	231 - 232
58	$\text{CH}_2\text{CH}_2\text{-N}$ 	255 - 256

Example No.	R ₂	MP. °C
59		201 - 201
60	(CH ₂) ₃ CONH ₂	264 - 265
61		224-226
62		195 - 196
63		168 - 196
64		231
65		235 - 236
66		310 - 311
67		196 - 197
68		246 - 248

Example No.	R ₂	MP. °C
79	$\text{CH}_2\text{CH}_2\text{CH}_2\text{-N}\langle\text{C}_6\text{H}_{11}\rangle\text{N-H}$	253 - 254
80	$\text{CH}_2\text{CH}_2\text{CH}_2\text{-}\langle\text{C}_6\text{H}_{11}\rangle\text{N-COCH}_3$	136 - 137
81	$\text{CH}_2\text{CH}_2\text{CH}_2\text{-}\langle\text{C}_6\text{H}_{11}\rangle\text{N-SO}_2\text{CH}_3$	216 - 217
82	$\text{CH}_2\text{CH}_2\text{CH}_2\text{-}\langle\text{C}_6\text{H}_{11}\rangle\text{N-H}$	146 - 147
83	$\text{CH}_2\text{CH}_2\text{CH}_2\text{-NH}\langle\text{C}_5\text{H}_9\rangle$	218 - 220
84	$(R)\text{-CH}_2\text{CH}_2\text{CH(OH)CH}_3$	198 - 199
85	$\text{CH}_2\text{CH}_2\text{-}\langle\text{C}_6\text{H}_4\rangle\text{-SO}_2\text{NH}_2$	307 - 308
86	$\text{CH}_2\text{CH}_2\text{-}\langle\text{C}_6\text{H}_4\rangle\text{-SO}_2\text{NHCH}_3$	225 - 226
87	$\text{CH}_2\text{CH}_2\text{-}\langle\text{C}_6\text{H}_4\rangle\text{-SO}_2\text{N(CH}_3)_2$	190 - 191

Example No.	R ₂	MP. °C
69		160
70	$\text{CH}_2\text{CH}_2\text{SO}_2\text{CH}_2\text{CH}_2\text{OH}$	213 - 214
71		265 - 266
72		188
73		163 - 164
74	$\text{CH}_2\text{CH}(\text{OH})\text{CH}_2\text{OH}$	225 - 226
75		210
76		214 - 215°C
77		169 - 170
78		162 - 163

THIS SHEET HAS BEEN
REPLACED

- 65 -

Example No.	R ₂	MP. °C
88	$\text{CH}_2\text{CH}_2\text{NHCOCH}_3$	268 - 269
89	$\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2 - \text{N} \begin{array}{c} \diagup \quad \diagdown \\ \diagdown \quad \diagup \end{array} \text{N} - \text{SO}_2\text{CH}_3$	160
90	$\text{CH}_2\text{CH}_2\text{NH-CO-} \begin{array}{c} \diagup \quad \diagdown \\ \diagdown \quad \diagup \end{array} \text{N}$	254 - 255
91	$\text{CH}_2\text{CH}_2\text{NH-CO-} \begin{array}{c} \diagup \quad \diagdown \\ \diagdown \quad \diagup \end{array} \text{N-H}$	267 - 268

Me = Methyl

Et = Ethyl

Ph = Phenyl

This Sheet Has Been Replaced



- 66 -

The compounds of general formula I may be used on their own or in conjunction with other active substances according to the invention, possibly combined with other pharmacologically active substances. Suitable forms include, for example, tablets, capsules, suppositories, solutions, syrups, emulsions, aerosols or dispersible powders. Tablets may be produced, for example, by mixing the active substance or substances with known excipients, e.g. inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for obtaining delayed release, such as carboxymethylcellulose, cellulose acetate phthalate or polyvinylacetate. The tablets may also consist of several layers.

Coated tablets may be produced analogously by coating cores made in the same way as the tablets with substances conventionally used for tablet coatings, e.g. collidone or shellac, gum arabic, talc, titanium dioxide or sugar. In order to obtain delayed release or avoid incompatibilities, the core may also consist of several layers. Similarly, the tablet coating may consist of several layers to achieve delayed release, whilst the excipients mentioned for the tablets may be used.

Syrups containing the active substances or combinations of active substances according to the invention may additionally contain a sweetener such as saccharin, cyclamate, glycerol or sugar as well as a flavour enhancer, e.g. a flavouring such as vanillin or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethylcellulose, wetting agents, e.g. condensation products of fatty alcohols with ethylene oxide or preservatives such as p-hydroxybenzoates.





hydroxybenzoates.

Injectable solutions are produced in the usual way, e.g. by adding preservatives such as p-hydroxybenzoates or stabilisers such as alkali metal salts of ethylene diamine tetraacetic acid, and are then transferred into injection vials or ampoules.

Capsules containing one or more active substances or combinations of active substances may be prepared for example by mixing the active substances with inert carriers such as lactose or sorbitol and encapsulating them in gelatine capsules.

Suitable suppositories may be produced for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or derivatives thereof.

A therapeutically effective daily dose is between 1 and 800 mg, preferably 10 - 300 mg per adult.

The following Examples illustrate the present invention without restricting their scope:

Examples of pharmaceutical formulations

A)	<u>Tablets</u>	<u>per tablet</u>
	Active substance	100 mg
	Lactose	140 mg
	Corn starch	240 mg
	Polyvinylpyrrolidone	15 mg
	Magnesium stearate	<u>5 mg</u>
		500 mg

The finely ground active substance, lactose and some of the corn starch are mixed together. The mixture is

screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, moist-granulated and dried. The granules, the remaining corn starch and the magnesium stearate are screened and mixed together. The mixture is compressed to form tablets of a suitable shape and size.

B) <u>Tablets</u>	<u>per tablet</u>
Active substance	80 mg
Corn starch	190 mg
Lactose	55 mg
Microcrystalline cellulose	35 mg
Polyvinylpyrrolidone	15 mg
Sodium-carboxymethylstarch	23 mg
Magnesium stearate	<u>2 mg</u>
	400 mg

The finely ground active substance, some of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and processed with the remaining corn starch and water to form granules which are dried and screened. The sodium carboxymethyl starch and the magnesium stearate are added, mixed together and the mixture is compressed to form tablets of a suitable size.






THIS SHEET HAS BEEN
REPLACED

- 69 -

Claims

1) New compounds of general formula






wherein R_1 cannot simultaneously represent the same as R_2 , and the definitions are as follows:

R_1 denotes hydrogen, C_1 - C_6 -alkyl, or allyl, C_3 - C_6 -alkenyl, C_3 - C_6 -alkynyl;

R_2 denotes hydrogen, a C_1 - C_8 -alkyl-, C_2 - C_8 -alkenyl- or C_2 - C_8 -alkynyl- group which is substituted by -CN, $-\text{CH}_2\text{NR}_6\text{R}_7$, OH (multiple substitution also being possible), $-\text{OR}_8$, $-\text{NR}_6\text{R}_7$, $-\text{NHCOR}_8$, $-\text{NHCONR}_6\text{R}_7$, halogen, $-\text{OCOR}_8$, $-\text{OCH}_2\text{COOH}$, $-\text{OCH}_2\text{COOR}_8$, $-\text{SO}_2\text{R}_5$, $-\text{S}-\text{R}_5$, $-\text{NHCONH}$ phenyl, $-\text{OCH}_2-\text{CONR}_6\text{R}_7$, $-\text{OCH}_2\text{CH}_2\text{OH}$, $-\text{SO}_2-\text{CH}_2-\text{CH}_2-\text{O}-\text{COR}_8$, $-\text{OCH}_2-\text{CH}_2-\text{NR}_6\text{R}_7$, $-\text{SO}_2-\text{CH}_2-\text{CH}_2-\text{OH}$, $-\text{CONHSO}_2\text{R}_8$, $-\text{CH}_2\text{CONHSO}_2\text{R}_8$, $-\text{OCH}_2\text{CH}_2\text{OR}_8$, $-\text{COOH}$, $-\text{COOR}_8$, $-\text{CONR}_6\text{R}_7$, $-\text{CHO}$, $-\text{SR}_8$, $-\text{SOR}_8$, $-\text{SO}_2\text{R}_8$, $-\text{SO}_3\text{H}$, $-\text{SO}_2\text{NR}_6\text{R}_7$, $-\text{OCH}_2-\text{CH}_2\text{OCOR}_8$, $-\text{CH}=\text{NOH}$, $-\text{CH}=\text{NOR}_8$, $-\text{COR}_9$, $-\text{CH}(\text{OH})\text{R}_9$, $-\text{CH}(\text{OR}_8)_2$, $-\text{CH}=\text{CH}-\text{R}_{10}$, OCONR_6R_7 ,

This Sheet Has Been Replaced





or by 1,3-dioxolane or 1,3-dioxane which is optionally mono- or polysubstituted, preferably mono-substituted, by methyl;

R_2 denotes phenyl- C_1 - C_6 -alkylene, preferably phenyl- C_1 - C_4 -alkylene, phenyl- C_2 - C_6 -alkenylene or phenyl- C_2 - C_6 -alkynylene, in which the phenyl ring is optionally substituted, either directly or via a C_{1-4} -alkylene group, with one or more, preferably one, of the following groups,

- C_1 - C_3 -alkyl, -CN, - $CH_2NR_6R_7$, - NO_2 ,
- OH, - OR_8 , - $CH_2NH-SO_2-R_8$, - $NHCO_8R_8$,
- $NHCONR_6R_7$, halogen, - $OCOR_8$, - OCH_2COOH ,
- OCH_2COOR_8 , - CH_2OCOR_8 , - SO_2R_5 ,
- $OCH_2-CONR_6R_7$, - OCH_2CH_2OH ,
- $OCH_2-CH_2-NR_6R_7$, - $CONHSO_2R_8$,
- $OCH_2CH_2OR_8$, -COOH, - $COOR_8$, - CF_3 ,
- cyclopropyl, - $CONR_6R_7$, - CH_2OH ,
- CH_2OR_8 , -CHO, - SR_8 , - SOR_8 , - SO_2R_8 ,
- SO_3H , - $SO_2NR_6R_7$, - $OCH_2-CH_2OCOR_8$,
- $CH=NOH$, - $CH=NOR_8$, - COR_9 , - $CH(OH)R_9$,
- $CH(OR_8)_2$, - $NHCOOR_8$, - $CH_2CONHSO_2R_8$,
- $CH=CH-R_{10}$, - $OCONR_6R_7$,
- $CH_2-O-CONR_6R_7$,
- $CH_2-CH_2-O-CONR_6R_7$,








* C L M S *

- 71 -

THIS SHEET HAS BEEN
REPLACED






or by 1,3-dioxolane or 1,3-dioxane which is optionally mono- or polysubstituted, preferably monosubstituted, by methyl;

R_2 denotes C_3 - C_7 -cycloalkyl- C_1 - C_6 -alkylene-, C_3 - C_7 -cycloalkyl- C_2 - C_6 -alkenylene-, C_3 - C_7 -cycloalkyl- C_2 - C_6 -alkynylene-, in which the cycloalkyl group may optionally be substituted, either directly or via a C_{1-4} -alkylene group, by

- CN, $-\text{CH}_2\text{NR}_6\text{R}_7$, =O, -OH, $-\text{OR}_8$, $-\text{NR}_6\text{R}_7$,
- $-\text{NHCOR}_8$, $-\text{NHCONR}_6\text{R}_7$, halogen, $-\text{OCOR}_8$,
- $-\text{OCH}_2\text{COOH}$, $-\text{OCH}_2\text{COOR}_8$, $-\text{CH}_2\text{OCOR}_8$,
- $-\text{SO}_2\text{R}_5$, $-\text{OCH}_2-\text{CONR}_6\text{R}_7$,
- $-\text{OCH}_2\text{CH}_2\text{OH}$, $-\text{OCH}_2-\text{CH}_2-\text{NR}_6\text{R}_7$,
- $-\text{OCH}_2\text{CH}_2\text{OR}_8$, -COOH, $-\text{COOR}_8$,
- $-\text{CONR}_6\text{R}_7$, $-\text{CH}_2\text{OH}$, $-\text{CH}_2\text{OR}_8$, -CHO,
- $-\text{SR}_8$, $-\text{SOR}_8$, $-\text{SO}_2\text{R}_8$, $-\text{SO}_3\text{H}$,
- $-\text{SO}_2\text{NR}_6\text{R}_7$, $-\text{OCH}_2-\text{CH}_2\text{OCOR}_8$, $-\text{CH}=\text{NOH}$,
- $-\text{CH}=\text{NOR}_8$, $-\text{COR}_9$, $-\text{CH}(\text{OH})\text{R}_9$,
- $-\text{CONHSO}_2\text{R}_8$, $-\text{CH}(\text{OR}_8)_2$, $-\text{NHCOOR}_8$,
- $-\text{CH}=\text{CH}-\text{R}_{10}$, $-\text{OCONR}_6\text{R}_7$, $-\text{CH}_2-\text{O}-\text{CONR}_6\text{R}_7$,
- $-\text{CH}_2-\text{CH}_2-\text{O}-\text{CONR}_6\text{R}_7$,

This Sheet Has Been Replaced






or by 1,3-dioxolane or 1,3-dioxane which is optionally mono- or polysubstituted, preferably monosubstituted, by methyl;

R_2 denotes a group of the formula

A-C₁-C₆-alkylene-, A-C₂-C₆-alkenylene, A-C₂-C₆-alkynylene, A-CONH-C₁-C₆-alkylene-, A-CONH-C₂-C₆-alkenylene- or A-CONH-C₂-C₆-alkynylene-, A-NH-CO-C₁-C₆-alkylene, A-NH-CO-C₂-C₆-alkenylene, A-NH-CO-C₂-C₆-alkynylene, wherein A is a C- or N-linked 5- or 6-membered heterocyclic ring which contains nitrogen, oxygen or sulphur as heteroatoms and may optionally be mono- or polysubstituted, preferably monosubstituted, by C₁-C₄-alkyl, halogen, -OR₈, -CN, -NO₂, -NH₂, -CH₂NR₆R₇, -OH, =O, a ketal, -COOH, -SO₃H, -COOR₈, -CONR₆R₇, -COR₉, -SO₂-R₈, -CONR₆R₇ or



R_3 denotes C₃-C₇-cycloalkyl, preferably cyclopentyl, optionally substituted by =O, -OH, -OR₈, OCOR₈, or

R_3 denotes phenyl, which is optionally substituted by -OH, halogen, -OR₈, C₁-C₄-alkyl, preferably -CH₃,





- 73 -

$-\text{NH}_2$, $-\text{COOH}$, $-\text{SO}_3\text{H}$, $-\text{COOR}_8$, $-\text{OCH}_2\text{COOR}_8$, $-\text{CN}$, or
 $-\text{OCH}_2\text{CONR}_6\text{R}_7$, or




R_3 denotes a norbornane-, norbornene-, a C_3 - C_6 -
dicycloalkylmethyl, preferably dicyclopropylmethyl,
adamantane- or noradamantane- group;

R_3 denotes $-\text{CH}=\text{CH}$ -phenyl, wherein the phenyl ring is
mono- or polysubstituted by methoxy, hydroxy or
halogen;


R_3 denotes a [3.3.0]-bicyclooctane, preferably a
[3.3.0]-bicyclooctan-2-yl;

R_3 denotes a C-linked piperidine or furan;

R_4 denotes hydrogen, methyl or benzyl, in which the
benzyl group may be substituted by 1-3 methoxy
groups;



privaloyloxymethyl or



R_5 denotes C_1 - C_4 -alkyl, optionally substituted by OH,
 OCOR_8 , NH_2 , NR_6R_7 or NHCOR_8 , and R_5 preferably
represents $-\text{CH}_2-\text{CH}_2-\text{OH}$, $-\text{CH}_2\text{CH}_2\text{OCOR}_8$,
 $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{OH}$; $-\text{CH}_2-\text{CH}_2\text{CH}_2\text{OCOR}_8$;

R_6 denotes hydrogen, an optionally substituted C_{3-6} -





cycloalkyl group, a branched or unbranched alkyl-, alkenyl- or alkynyl group having up to 10 carbon atoms, which may optionally be substituted by hydroxy, phenyl, substituted phenyl, amino, substituted amino, C_1 to C_8 , preferably C_1 to C_4 -alkoxy, or it denotes $-(CH_2)_m-NHCOOR_8$ wherein $m = 1, 2, 3$ or 4 ;

R_7 denotes hydrogen, an optionally substituted C_{3-6} -cycloalkyl group, a branched or unbranched alkyl, alkenyl or alkynyl group having up to 10 carbon atoms, which may optionally be substituted by hydroxy, phenyl, substituted phenyl, amino, substituted amino, C_1 to C_8 -alkoxy, or it denotes $-(CH_2)_m-NHCOOR_8$ wherein $m = 1, 2, 3$ or 4 ;

or

R_6 and R_7 together with the nitrogen atom form a saturated or unsaturated 5- or 6-membered ring which may contain as heteroatoms nitrogen, oxygen or sulphur, whilst the heterocyclic ring may be substituted by a branched or unbranched C_{1-4} -alkyl group, preferably methyl, or may carry one of the following groups:

$-(CH_2)_n-NH_2$, $=O$, a ketal,
 $-(CH_2)_nNH-C_1-C_4$ -alkyl,
 $-(CH_2)_n-N(C_1-C_8\text{-alkyl})_2$,
 $-(CH_2)_n-NHCOOR_8$, ($n = 2, 3, 4$), halogen,
 $-OR_8$, $-CN$, $-NO_2$, $-NH_2$, $-CH_2NR_6R_7$,
 $-OH$, $-COOH$, $-SO_3H$, $-COOR_8$, $-CONR_6R_7$, $-SO_2-R_8$,

R_8 denotes hydrogen, C_1-C_4 -alkyl, C_2-C_4 -alkenyl, C_2-C_4 -alkynyl, a benzyl- or phenyl-group, which is optionally mono- or polysubstituted by OCH_3 ;

R_9 denotes C_1-C_4 -alkyl, C_2-C_4 -alkenyl, C_2-C_4 -alkynyl, optionally substituted phenyl, optionally




substituted benzyl, C_3 - C_6 -cycloalkyl,

R_{10} denotes $-COOR_8$, $-CH_2OR_8$, $-CONR_6R_7$, hydrogen, C_1 - C_3 -alkyl, optionally substituted phenyl, $-CH_2NR_6R_7$;

R_{11} denotes hydrogen, phenyl, substituted phenyl, $-CH_3$;

optionally in the form of the racemates, the enantiomers, the diastereomers and the mixtures thereof and optionally in the form of the pharmacologically acceptable salts thereof.

2) New xanthine derivatives of general formula



according to claim 1, wherein

R_1 denotes methyl, ethyl, n-butyl, allyl, or n-propyl;




R_2 denotes a C_2 -alkyl or an unbranched C_3 -alkyl group which is substituted by

$-CN$, $-CH_2NR_6R_7$, $-OH$, $-OR_8$, $-NR_6R_7$,
 $-NHCOR_8$, $-NHCONR_6H$, halogen, $-OCOR_8$,
 $-OCH_2COOH$, $-OCH_2COOR_8$, $-SR_5$, $-SO_2R_5$,
 $-OCH_2-CONR_6R_7$, $-OCH_2CH_2OH$,
 $OCH_2-CH_2-NR_6R_7$, $CONHSO_2R_8$,
 $-CH_2CONHSO_2R_8$,
 $-OCH_2CH_2OR_8$, $-COOH$, $-COOR_8$,
 $-CONR_6R_7$, $-CHO$, $-SR_8$, $-SO_2R_8$,
 $-SO_3H$, $-SO_2NR_6R_7$, $-OCH_2-CH_2OCOR_8$,
 $=NOH$, $=NOR_8$, $-COR_9$, $-CH(OH)R_9$,
 $-CH=CH-R_{10}$, ONR_6H





THIS SHEET HAS BEEN
REPLACED



or by 1,3-dioxolane or 1,3-dioxane optionally mono- or polysubstituted by methyl;

R_2 denotes a benzyl- or phenethyl- or phenylpropyl group which is substituted by one of the following groups

-C₁-C₃-alkyl, -CN, -CH₂NR₆R₇,
-NO₂, -OH, -OR₈, -NHCOR₈,
-NHCONR₆R₇, halogen, -OCOR₈, -OCH₂COOH,
-OCH₂COOR₈, -CH₂OCOR₈, -SO₂R₅,
-OCH₂-CONR₆R₇, -OCH₂CH₂OH,
-CH₂CONHSO₂R₈, -OCH₂-CH₂-NR₆R₇,
-CONHSO₂R₈, -OCH₂CH₂OR₈, -COOH,
-COOR₈, -CF₃,
cyclopropyl, -CONR₆R₇, -CH₂OH,
-CH₂OR₈, -CHO, -SR₈, -SOR₈, -SO₂R₈,
-SO₃H, -SO₂NR₆R₇, -OCH₂-CH₂OCOR₈,
-CH=NOH, CH=NOR₈, -COR₉, -CH(OH)R₉,
-CH(OR₈)₂, -NHCOOR₈,
-CH=CH-R₁₀, -OCONR₆R₇,
-CH₂-O-CONR₆R₇,
-CH₂-CH₂-O-CONR₆R₇,




This Sheet Has Been Replaced





THIS SHEET HAS BEEN
REPLACED

- 77 -



or by 1,3-dioxolane or 1,3-dioxane optionally mono- or polysubstituted by methyl, and if R_2 represents OR_8 , particularly OCH_3 , the phenyl group may be trisubstituted;

R_2 denotes a C_3 -, C_4 -, C_5 - or C_6 -cycloalkyl- C_2 - C_3 -alkylene group, wherein the cycloalkyl group is optionally monosubstituted by $-\text{CN}$, $-\text{CH}_2\text{NR}_6\text{R}_7$, $=\text{O}$, $-\text{OH}$, $-\text{OR}_8$, $-\text{NR}_6\text{R}_7$, $-\text{NHCOR}_8$, $-\text{NHCONR}_6\text{R}_7$, halogen, $-\text{OCOR}_8$, $-\text{OCH}_2\text{COOH}$, $-\text{OCH}_2\text{COOR}_8$, $-\text{CH}_2\text{OCOR}_8$, $-\text{SO}_2\text{R}_5$, $-\text{OCH}_2-\text{CONR}_6\text{R}_7$, $-\text{OCH}_2\text{CH}_2\text{OH}$, $-\text{OCH}_2-\text{CH}_2-\text{NR}_6\text{R}_7$, $-\text{OCH}_2\text{CH}_2\text{OR}_8$, $-\text{COOH}$, $-\text{COOR}_8$, $-\text{CONR}_6\text{R}_7$, $-\text{CH}_2\text{OH}$, $-\text{CH}_2\text{OR}_8$, $-\text{CHO}$, $-\text{SR}_8$, $-\text{SOR}_8$, $-\text{SO}_2\text{R}_8$, $-\text{SO}_3\text{H}$, $-\text{SO}_2\text{NR}_6\text{R}_7$, $-\text{OCH}_2-\text{CH}_2\text{OCOR}_8$, $-\text{CH}=\text{NOH}$, $-\text{CH}=\text{NOR}_8$, $-\text{COR}_9$, $-\text{CH}(\text{OH})\text{R}_9$, $-\text{CH}(\text{OR}_8)_2$, $-\text{NHCOOR}_8$, $-\text{CONHSO}_2\text{R}_8$, $-\text{CH}=\text{CH}-\text{R}_{10}$, $-\text{OCONR}_6\text{R}_7$, $-\text{CH}_2-\text{O}-\text{CONR}_6\text{R}_7$, $-\text{CH}_2-\text{CH}_2-\text{O}-\text{CONR}_6\text{R}_7$,

This Sheet Has Been Replaced








* C L M S *



THIS SHEET HAS BEEN
REPLACED

- 78 -



or by 1,3-dioxolane or 1,3-dioxane optionally mono- or polysubstituted, preferably monosubstituted by methyl;


R_2 denotes a group of the formula



wherein A is a C- or N-linked 5- or 6-membered heterocyclic ring which contains nitrogen, oxygen or sulphur as heteroatoms and which may optionally be mono- or polysubstituted by C_{1-4} -alkyl, =O, OH, COR_9 , SO_2-R_8 , NH_2 , COOR_8 , CONR_6R_7 , or OR_8 ;

and R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} and R_{11} are as hereinbefore defined, optionally in the form of the racemates, the enantiomers, the diastereomers and the mixtures thereof and optionally the pharmacologically acceptable salts thereof.

3) New xanthine derivatives of general formula



Ia

This Sheet Has Been Replaced






* C L M S *

- 79 -

THIS SHEET HAS BEEN
REPLACED

wherein R_2 is as hereinbefore defined and R_3 is a group selected from the groups



optionally in the form of the racemates, the enantiomers, the diastereomers and the mixtures thereof and optionally the pharmacologically acceptable salts thereof.

- 4) New xanthine derivatives according to one of claims 1, 2 or 3, wherein R_2 denotes an unbranched C_2 - C_3 -alkyl group which is substituted by $-CN$, $-OH$, $-COOH$, $-COOR_8$, particularly $-COOCH_3$ or $-COOC_2H_5$, $-OCOCH_3$, $-OCOC_2H_5$, $-CONR_6R_7$, $=NOH$, $-NR_6R_7$ or a linked 5- or 6-membered nitrogen-containing heterocyclic ring, optionally substituted as hereinbefore defined.
- 5) New xanthine derivatives according to one of claims 1 to 4 wherein R_2 denotes A - C_1 - C_3 -alkylene-, A - $CONH$ - C_1 - C_3 -alkylene, A - NH - CO - C_1 - C_3 -alkylene, wherein A is a C- or N-linked 5- or 6-membered heterocyclic ring which contains nitrogen, oxygen or sulphur as heteroatoms and may optionally be mono- or polysubstituted, preferably monosubstituted, by C_1 - C_4 -alkyl, halogen, $-OR_8$, $-CN$, $-NO_2$, $-NH_2$, $-CH_2NR_6R_7$, $-OH$, $=O$, a ketal, $-COOH$, $-SO_3H$, $-COOR_8$, $-CONR_6R_7$,

This Sheet Has Been Replaced






THIS SHEET HAS BEEN
REPLACED


- 80 -

$-\text{COR}_9$, $-\text{SO}_2-\text{R}_8$, $-\text{CONR}_6\text{R}_7$ or



- 6) New xanthine derivatives of general formula I according to one of claims 1, 2, 3, 4 or 5, wherein

R_3 is a group selected from the following



and

R_2 denotes $\text{CH}_2\text{CH}_2\text{OH}$, $\text{CH}_2\text{CH}_2\text{OCOCH}_3$, $(\text{CH}_2)_3\text{OCOCH}_3$, $(\text{CH}_2)_3\text{OCH}_3$, $\text{CH}_2\text{CH}_2\text{COCH}_3$, $\text{CH}_2\text{CH}_2\text{CH}(\text{OH})\text{CH}_3$, $\text{CH}_2\text{CH}_2\text{COOCH}_3$, $\text{CH}_2\text{CH}_2\text{CONH}_2$, $(\text{CH}_2)_3\text{CONH}_2$, $\text{CH}_2\text{CH}=\text{NOH}$, $(\text{CH}_2)_3\text{CN}$, $\text{CH}_2\text{CH}_2\text{SCH}_2\text{CH}_3$, $\text{CH}_2\text{CH}_2\text{SCH}_2\text{CH}_2\text{OH}$, $\text{CH}_2\text{CH}_2\text{SO}_2\text{CH}_2\text{CH}_2\text{OH}$, $\text{CH}_2\text{CH}_2\text{SO}_2\text{CH}_2\text{CH}_2\text{OCOCH}_3$, $\text{A}-(\text{CH}_2)_2-$ or

$\text{A}-(\text{CH}_2)_3-$, $\text{A}-\text{CH}_2-\text{CH}_2$

wherein A is a C- or N-linked 5- or 6-membered heterocyclic ring which contains nitrogen, oxygen or sulphur as heteroatoms,

optionally in the form of the racemates, the enantiomers, the diastereomers and the mixtures thereof and optionally the pharmacologically acceptable salts thereof.

This Sheet Has Been Replaced






THIS SHEET HAS BEEN
REPLACED


- 81 -

- 7) New xanthine derivatives of general formula I or Ia according to one of the preceding claims, characterised in that the group R_3 is an unsubstituted cyclopentyl group.
- 8) Process for preparing xanthines of general formula I



wherein the groups R_1 , R_2 , R_3 and R_4 are defined as in one of the preceding claims, characterised in that

- a) a compound of general formula



wherein

R'_2 corresponds to the definition of R_2 or R'_2 denotes a protecting group such as a benzyl- or methoxybenzyl group which is easily cleavable


is reacted with a compound of general formula $R_3\text{CHO}$, $R_3\text{COOH}$ or a reactive derivative thereof, whilst functional groups in R_3 must be protected if necessary, and is then cyclised to obtain the xanthine of general formula I wherein $R_4 = \text{H}$; or

- b) a compound of general formula

This Sheet Has Been Replaced



- 82 -




wherein

R_1 and R'_2 are as hereinbefore defined is reacted with a compound of general formula $R_3\text{CHO}$ - wherein R_3 is as hereinbefore defined, whilst functional groups in R_3 must be protected if necessary - and is then cyclised with *N,N*-dimethylhydrazine to form the xanthine of general formula I wherein $R_4 = \text{H}$;

or

c) a compound of general formula




wherein

R_1 , R'_2 and R_3 are as hereinbefore defined, is cyclised to form a compound of general formula I,

and subsequently a compound prepared according to a, b or c is optionally further treated using partly known processes as follows:

if $R_1 = \text{H}$, $R_4 = \text{H}$ of formula V






a protecting group is introduced into the 7-position (R_4),

then by N-alkylation $R_1 = H$ is converted into $R_1 =$ alkyl, alkenyl or alkynyl and

in order to prepare compounds of formula I wherein $R_4 = H$ the protecting group is cleaved,

if R'_2 does not yet have the desired meaning of R_2 , R'_2 is now converted into R_2 using methods known per se.


- 9) Process for preparing xanthines of general formula I



wherein

R_1 , R_2 and R_3 are defined as in one of the preceding claims, characterised in that, starting from a compound of general formula






wherein

R_1 and R_3 are as hereinbefore defined, R_4 denotes a protecting group, particularly benzyl- and R'_2 denotes the group p-methoxybenzyl, dimethoxybenzyl or trimethoxybenzyl,

R'_2 is converted into $R_2 = H$ by acid-hydrolysis, retaining the protecting group R_4 ,

then by N-alkylation with R'_2-X a compound of general formula




wherein R_4 denotes a protecting group - particularly benzyl- and R_1 and R_3 are as hereinbefore defined and $R'_2 = R_2$ or a precursor thereof,

then the protecting group R_4 is cleaved by conventional methods and, if desired, R'_2 is converted into R_2 .

10) Intermediate compounds of general formula







wherein


R₁, R₂ and R₃ are defined as in one of the preceding claims and R₄ denotes a p-methoxybenzyl, 2,4-dimethoxybenzyl or 2,4,6,-trimethoxybenzyl group.

- 11) Use of a compound of general formula I or Ia according to claims 1 to 6 as a pharmaceutical composition.
- 12) Use of a compound of general formula I or Ia according to claims 1 to 6 as a pharmaceutical composition having an adenosine-antagonistic activity.
- 13) Pharmaceutical preparations containing as active substance one or more compounds of general formula I or the physiologically acceptable acid addition salts thereof combined with conventional excipients and/or carriers.
- 14) Process for preparing pharmaceutical preparations according to claim 13, characterised in that compounds of general formula I are admixed with conventional galenic excipients and/or carriers to produce conventional pharmaceutical formulations.
- 15) New xanthine derivatives of general formula I






wherein R_3 denotes a group selected from the following



and

R_2 denotes a polar aliphatic group or a heterocyclic ring containing nitrogen, oxygen or sulphur as heteroatoms.

- 16) Use of a compound of general formula I according to claim 15 as a pharmaceutical composition having adenosine-antagonistic properties.



THIS SHEET HAS BEEN
REPLACED

- 87 -

Abstract

The present invention relates to new xanthine derivatives, processes for preparing them and their use in pharmaceutical compositions and as intermediate compounds.

This Sheet Has Been Replaced




23 AUG 1996

- 1 -

Asymmetrically substituted xanthines with
adenosine-antagonistic properties

The present invention relates to new xanthine derivatives, processes for preparing them and their use as pharmaceutical compositions and their use as intermediates.

The new compounds correspond to the general formula



wherein R_1 cannot simultaneously represent R_2 , and are defined as follows:




R_1 represents hydrogen, C_1 - C_6 -alkyl, preferably methyl, ethyl, n-butyl or allyl, most preferably n-propyl, C_3 - C_6 -alkenyl, C_3 - C_6 -alkynyl;

R_2 denotes hydrogen, a C_1 - C_8 -alkyl-, C_2 - C_8 -alkenyl- or C_2 - C_8 -alkynyl- group which is substituted by -CN, $-CH_2NR_6R_7$, OH (multiple

23 AUG 1996

- 2 -

substitution also being possible), $-OR_8$, $-NR_6R_7$,
 $-NHCOR_8$, $-NHCONR_6R_7$, halogen, $-OCOR_8$,
 $-OCH_2COOH$, $-OCH_2COOR_8$, $-SO_2R_5$, $-SR_5$, $-NHCONH$ phenyl,
 $-OCH_2-CONR_6R_7$, $-OCH_2CH_2OH$, $-SO_2-CH_2-CH_2-O-COR_8$,
 $-OCH_2-CH_2-NR_6R_7$, $-SO_2-CH_2-CH_2-OH$, $-CONHSO_2R_8$,
 $-CH_2CONHSO_2R_8$, $-OCH_2CH_2OR_8$, $-COOH$, $-COOR_8$,
 $-CONR_6R_7$, $-CHO$, $-SR_8$, $-SOR_8$, $-SO_2R_8$,
 $-SO_3H$, $-SO_2NR_6R_7$, $-OCH_2-CH_2OCOR_8$,
 $-CH=NOH$, $-CH=NOR_8$, $-COR_9$, $-CH(OH)R_9$,
 $-CH(OR_8)_2$, $-CH=CH-R_{10}$, ONR_6R_7 ,






or by 1,3-dioxolane or 1,3-dioxane which is optionally mono- or polysubstituted, preferably mono- substituted, by methyl;

R_2 denotes phenyl- C_1 - C_6 -alkylene, preferably phenyl- C_1 - C_4 -alkylene, phenyl- C_2 - C_6 -alkenylene or phenyl- C_2 - C_6 -alkynylene, in which the phenyl ring is optionally substituted, either directly or via a C_{1-4} -alkylene group, with one or more, preferably one, of the following groups,

$-C_1$ - C_3 -alkyl, $-CN$, $-CH_2NR_6R_7$, $-NO_2$,
 $-OH$, $-OR_8$, $-CH_2-NH-SO_2-R_8$, $-NHCOR_8$,
 $-NHCONR_6R_7$, halogen, $-OCOR_8$, $-OCH_2COOH$,
 $-OCH_2COOR_8$, $-CH_2OCOR_8$, $-SO_2R_5$,
 $-OCH_2-CONR_6R_7$, $-OCH_2CH_2OH$,
 $-OCH_2-CH_2-NR_6R_7$, $-CONHSO_2R_8$,
 $-OCH_2CH_2OR_8$, $-COOH$, $-COOR_8$, $-CF_3$,
cyclopropyl, $-CONR_6R_7$, $-CH_2OH$,

23 AUG 1996





-CH₂OR₈, -CHO, -SR₈, -SOR₈, -SO₂R₈,
 -SO₃H, -SO₂NR₆R₇, -OCH₂-CH₂OCOR₈,
 -CH=NOH, -CH=NOR₈, -COR₉, -CH(OH)R₉,
 -CH(OR₈)₂, -NHCOOR₈, -CH₂CONHSO₂R₈,
 -CH=CH-R₁₀, -OCONR₆R₇,
 -CH₂-O-CONR₆R₇,
 -CH₂-CH₂-O-CONR₆R₇,



or by 1,3-dioxolane or 1,3-dioxane which is optionally mono- or polysubstituted, preferably monosubstituted, by methyl;

R₂ denotes C₃-C₇-cycloalkyl-C₁-C₆-alkylene-,
 C₃-C₇-cycloalkyl-C₂-C₆-alkenylene-,
 C₃-C₇-cycloalkyl-C₂-C₆-alkynylene-, in which the
 cycloalkyl group may optionally be substituted,
 either directly or via a C₁₋₄-alkylene group, by
 -CN, -CH₂NR₆R₇, =O, -OH, -OR₈, -NR₆R₇,
 -NHCOR₈, -NHCONR₆R₇, halogen, -OCOR₈,
 -OCH₂COOH, -OCH₂COOR₈, -CH₂OCOR₈,
 -SO₂R₅, -OCH₂-CONR₆R₇,
 -OCH₂CH₂OH, -OCH₂-CH₂-NR₆R₇,
 -OCH₂CH₂OR₈, -COOH, -COOR₈,
 -CONR₆R₇, -CH₂OH, -CH₂OR₈, -CHO,
 -SR₈, -SOR₈, -SO₂R₈, -SO₃H,
 -SO₂NR₆R₇, -OCH₂-CH₂OCOR₈, -CH=NOH,
 -CH=NOR₈, -COR₉, -CH(OH)R₉,
 -CONHSO₂R₈, -CH(OR₈)₂, -NHCOOR₈,


23 AUG 1996



or by 1,3-dioxolane or 1,3-dioxane which is optionally mono- or polysubstituted, preferably monosubstituted, by methyl;

R_2 denotes a group of the formula

$\text{A}-\text{C}_1-\text{C}_6$ -alkylene-, $\text{A}-\text{CONH}-\text{C}_1-\text{C}_6$ -alkylene-, $\text{A}-\text{CONH}-\text{C}_2-\text{C}_6$ -alkenylene-, $\text{A}-\text{CONH}-\text{C}_2-\text{C}_6$ -alkynylene-, $\text{A}-\text{NH}-\text{CO}-\text{C}_1-\text{C}_6$ -alkylene-, $\text{A}-\text{NH}-\text{CO}-\text{C}_2-\text{C}_6$ -alkenylene-, $\text{A}-\text{NH}-\text{CO}-\text{C}_2-\text{C}_6$ -alkynylene-, $\text{A}-\text{C}_2-\text{C}_6$ -alkenylene- or $\text{A}-\text{C}_2-\text{C}_6$ -alkynylene-, wherein A is a C- or N-linked 5- or 6-membered heterocyclic ring which contains nitrogen, oxygen or sulphur as heteroatoms and may optionally be mono- or polysubstituted, preferably monosubstituted, by C_1-C_4 -alkyl, halogen, $-\text{OR}_8$, $-\text{CN}$, $-\text{NO}_2$, $-\text{NH}_2$, $-\text{CH}_2\text{NR}_6\text{R}_7$, $-\text{OH}$, $=\text{O}$, a ketal, $-\text{COOH}$, $-\text{SO}_3\text{H}$, $-\text{COOR}_8$, $-\text{CONR}_6\text{R}_7$, $-\text{COR}_9$, $-\text{SO}_2-\text{R}_8$, $-\text{CONR}_6\text{R}_7$ or




R_3 denotes C_3-C_7 -cycloalkyl, preferably cyclopentyl, optionally substituted by $=\text{O}$, $-\text{OH}$, $-\text{OR}_8$, OCOR_8 , or

23 AUG 1996

- 5 -

- R_3 denotes phenyl, which is optionally substituted by $-OH$, halogen, $-OR_8$, C_1-C_4 -alkyl, preferably $-CH_3-$, $-NH_2$, $-COOH$, $-SO_3H$, $-COOR_8$, $-OCH_2COOR_8$, $-CN$, or $-OCH_2CONR_6R_7$, or
- R_3 denotes a norbornane-, norbornene-, a C_3-C_6 -dicycloalkylmethyl, preferably dicyclopropylmethyl, adamantane- or noradamantane- group;
- R_3 denotes $-CH=CH$ -phenyl, wherein the phenyl ring is mono- or polysubstituted by methoxy, hydroxy or halogen;
- R_3 denotes a [3.3.0]-bicyclooctane, preferably a [3.3.0]-bicyclooctan-2-yl;
- R_3 denotes a C-linked piperidine or furan;
- R_4 denotes hydrogen, methyl or benzyl, in which the benzyl group may be substituted by 1-3 methoxy groups;
- CH_3-O-CH_2-
 CH_3-S-CH_2- ,



privaloyloxymethyl or

$-CH_2-CH=CH_2$;

- R_5 denotes C_1-C_4 -alkyl, optionally substituted by OH , $OCOR_8$, NH_2 , NR_6R_7 or $NHCOR_8$, and R_5 preferably represents $-CH_2-CH_2-OH$, $-CH_2CH_2OCOR_8$, $-CH_2-CH_2-CH_2-OH$; $-CH_2-CH_2CH_2OCOR_8$;

23 AUG 1996

- 6 -

R_6 denotes hydrogen, an optionally substituted C_{3-6} -cycloalkyl group, a branched or unbranched alkyl-, alkenyl- or alkynyl group having up to 10 carbon atoms, preferably a C_{1-4} -alkyl group, which may optionally be substituted by hydroxy, phenyl, substituted phenyl, amino, substituted amino, C_1 to C_8 , preferably C_1 to C_4 -alkoxy, or it denotes $-(CH_2)_m-NHCOOR_8$ wherein $m = 1, 2, 3$ or 4 ;

R_7 denotes hydrogen, an optionally substituted C_{3-6} -cycloalkyl group, a branched or unbranched alkyl-, alkenyl- or alkynyl group having up to 10, preferably 1 - 4, carbon atoms, which may optionally be substituted by hydroxy, phenyl, substituted phenyl, amino, substituted amino, C_1 to C_8 , preferably C_1 to C_4 -alkoxy, or it denotes $-(CH_2)_m-NHCOOR_8$ wherein $m = 1, 2, 3$ or 4 ;

or

R_6 and R_7 together with the nitrogen atom form a saturated or unsaturated 5- or 6-membered ring which may contain as heteroatoms nitrogen, oxygen or sulphur, whilst the heterocyclic ring may be substituted by a branched or unbranched C_{1-4} -alkyl group, preferably methyl, or may carry one of the following groups:

$-(CH_2)_n-NH_2$, $=O$, a ketal - preferably $-O-CH_2-CH_2-O-$,
 $-(CH_2)_n-NH-C_1-C_4$ -alkyl,
 $-(CH_2)_n-N(C_1-C_8$ -alkyl) $_2$,
 $-(CH_2)_n-NHCOOR_8$, ($n = 2, 3, 4$), halogen,
 $-OR_8$, $-CN$, $-NO_2$, $-NH_2$, $-CH_2NR_6R_7$,
 $-OH$, $-COOH$, $-SO_3H$, $-COOR_8$, $-CONR_6R_7$, $-SO_2-R_8$,

R_8 denotes hydrogen, C_1-C_4 -alkyl, C_2-C_4 -alkenyl, C_2-C_4 -alkynyl, a benzyl- or phenyl-group, which is optionally mono- or polysubstituted by OCH_3 ;

23 AUG 1996

- 7 -

- R_9 denotes C_1 - C_4 -alkyl, C_2 - C_4 -alkenyl, C_2 - C_4 -alkynyl, optionally substituted phenyl, optionally substituted benzyl, C_3 - C_6 -cycloalkyl,
- R_{10} denotes $-\text{COOR}_8$, $-\text{CH}_2\text{OR}_8$, $-\text{CONR}_6\text{R}_7$, hydrogen, C_1 - C_3 -alkyl, optionally substituted phenyl, $-\text{CH}_2\text{NR}_6\text{R}_7$;
- R_{11} denotes hydrogen, phenyl, substituted phenyl, $-\text{CH}_3$;

optionally in the form of the racemates, the enantiomers, the diastereomers and the mixtures thereof and optionally in the form of the pharmacologically acceptable salts thereof.

The compounds which are preferred as pharmaceutical compositions are the compounds of general formula I wherein R_1 does not denote hydrogen but R_4 is hydrogen, since compounds of general formula I wherein R_1 = hydrogen have a lowering A_1 -receptor-affinity; however, these compounds are of particular importance as intermediates.

Preferred compounds of general formula I are those wherein

R_1 = methyl, ethyl, n-butyl, allyl and preferably n-propyl;




R_2 denotes a C_2 -alkyl or an unbranched C_3 -alkyl group which is substituted by

$-\text{CN}$, $-\text{CH}_2\text{NR}_6\text{R}_7$, $-\text{OH}$, $-\text{OR}_8$, $-\text{NR}_6\text{R}_7$,
 $-\text{NHCOR}_8$, $-\text{NHCONR}_6\text{H}$, halogen, $-\text{OCOR}_8$,
 $-\text{OCH}_2\text{COOH}$, $-\text{OCH}_2\text{COOR}_8$, $-\text{SR}_5$, $-\text{SO}_2\text{R}_5$,
 $-\text{OCH}_2-\text{CONR}_6\text{R}_7$, $-\text{OCH}_2\text{CH}_2\text{OH}$,
 $\text{OCH}_2-\text{CH}_2-\text{NR}_6\text{R}_7$, $\text{CONHSO}_2\text{R}_8$,
 $-\text{CH}_2\text{CONHSO}_2\text{R}_8$,
 $-\text{OCH}_2\text{CH}_2\text{OR}_8$, $-\text{COOH}$, $-\text{COOR}_8$,

23 AUG 1996

- 8 -





$-\text{CONR}_6\text{R}_7$, $-\text{CHO}$, $-\text{SR}_8$, $-\text{SO}_2\text{R}_8$,
 $-\text{SO}_3\text{H}$, $-\text{SO}_2\text{NR}_6\text{R}_7$, $-\text{OCH}_2\text{-CH}_2\text{OCOR}_8$,
 $=\text{NOH}$, $=\text{NOR}_8$, $-\text{COR}_9$, $-\text{CH}(\text{OH})\text{R}_9$,
 $-\text{CH}=\text{CH-R}_{10}$, OCONR_6H



or by 1,3-dioxolane or 1,3-dioxane optionally mono- or polysubstituted, preferably monosubstituted, by methyl;





R_2 denotes a benzyl- or phenethyl- or phenylpropyl group which is substituted by one of the following groups

$-\text{C}_1\text{-C}_3\text{-alkyl}$, $-\text{CN}$, $-\text{CH}_2\text{NR}_6\text{R}_7$,
 $-\text{NO}_2$, $-\text{OH}$, $-\text{OR}_8$, $-\text{NHCOR}_8$,
 $-\text{NHCONR}_6\text{R}_7$, halogen, $-\text{OCOR}_8$, $-\text{OCH}_2\text{COOH}$,
 $-\text{OCH}_2\text{COOR}_8$, $-\text{CH}_2\text{OCOR}_8$, $-\text{SO}_2\text{R}_5$,
 $-\text{OCH}_2\text{-CONR}_6\text{R}_7$, $-\text{OCH}_2\text{CH}_2\text{OH}$,
 $-\text{CH}_2\text{CONHSO}_2\text{R}_8$, $-\text{OCH}_2\text{-CH}_2\text{-NR}_6\text{R}_7$,
 $-\text{CONHSO}_2\text{R}_8$, $-\text{OCH}_2\text{CH}_2\text{OR}_8$, $-\text{COOH}$,
 $-\text{COOR}_8$, $-\text{CF}_3$,
cyclopropyl, $-\text{CONR}_6\text{R}_7$, $-\text{CH}_2\text{OH}$,
 $-\text{CH}_2\text{OR}_8$, $-\text{CHO}$, $-\text{SR}_8$, $-\text{SOR}_8$, $-\text{SO}_2\text{R}_8$,
 $-\text{SO}_3\text{H}$, $-\text{SO}_2\text{NR}_6\text{R}_7$, $-\text{OCH}_2\text{-CH}_2\text{OCOR}_8$,
 $-\text{CH}=\text{NOH}$, $\text{CH}=\text{NOR}_8$, $-\text{COR}_9$, $-\text{CH}(\text{OH})\text{R}_9$,
 $-\text{CH}(\text{OR}_8)_2$, $-\text{NHCOOR}_8$,
 $-\text{CH}=\text{CH-R}_{10}$, $-\text{OCONR}_6\text{R}_7$,
 $-\text{CH}_2\text{-O-CONR}_6\text{R}_7$,
 $-\text{CH}_2\text{-CH}_2\text{-O-CONR}_6\text{R}_7$,





or by 1,3-dioxolane or 1,3-dioxane optionally mono- or polysubstituted, preferably monosubstituted, by methyl, and if R_2 represents OR_8 , particularly OCH_3 , the phenyl group may be trisubstituted;

R_2 denotes a C_3 -, C_4 -, C_5 - or C_6 -cycloalkyl- C_2 - C_3 -alkylene group, wherein the cycloalkyl group is optionally monosubstituted by $-\text{CN}$, $-\text{CH}_2\text{NR}_6\text{R}_7$, $=\text{O}$, $-\text{OH}$, $-\text{OR}_8$, $-\text{NR}_6\text{R}_7$, $-\text{NHCOR}_8$, $-\text{NHCONR}_6\text{R}_7$, halogen, $-\text{OCOR}_8$, $-\text{OCH}_2\text{COOH}$, $-\text{OCH}_2\text{COOR}_8$, $-\text{CH}_2\text{OCOR}_8$, $-\text{SO}_2\text{R}_5$, $-\text{OCH}_2-\text{CONR}_6\text{R}_7$, $-\text{OCH}_2\text{CH}_2\text{OH}$, $-\text{OCH}_2-\text{CH}_2-\text{NR}_6\text{R}_7$, $-\text{OCH}_2\text{CH}_2\text{OR}_8$, $-\text{COOH}$, $-\text{COOR}_8$, $-\text{CONR}_6\text{R}_7$, $-\text{CH}_2\text{OH}$, $-\text{CH}_2\text{OR}_8$, $-\text{CHO}$, $-\text{SR}_8$, $-\text{SOR}_8$, $-\text{SO}_2\text{R}_8$, $-\text{SO}_3\text{H}$, $-\text{SO}_2\text{NR}_6\text{R}_7$, $-\text{OCH}_2-\text{CH}_2\text{OCOR}_8$, $-\text{CH}=\text{NOH}$, $-\text{CH}=\text{NOR}_8$, $-\text{COR}_9$, $-\text{CH}(\text{OH})\text{R}_9$, $-\text{CH}(\text{OR}_8)_2$, $-\text{NHCCOOR}_8$, $-\text{CONHSO}_2\text{R}_8$, $-\text{CH}=\text{CH}-\text{R}_{10}$, $-\text{OCONR}_6\text{R}_7$, $-\text{CH}_2-\text{O}-\text{CONR}_6\text{R}_7$, $-\text{CH}_2-\text{CH}_2-\text{O}-\text{CONR}_6\text{R}_7$,



or by 1,3-dioxolane or 1,3-dioxane optionally mono- or polysubstituted, preferably monosubstituted by methyl;

R_2 denotes a group of the formula




wherein A is a C- or N-linked 5- or 6-membered heterocyclic ring which contains nitrogen, oxygen or sulphur as heteroatoms and which may optionally be mono- or polysubstituted by C_{1-4} -alkyl, $=\text{O}$, OH , COR_9 , SO_2-R_8 , NH_2 , COOR_8 , CONR_6R_7 , or OR_8 ;

and R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} and R_{11} are as hereinbefore defined, optionally in the form of the racemates, the enantiomers, the diastereomers and the mixtures thereof and optionally the pharmacologically acceptable salts thereof.

Particularly preferred R_3 groups are cyclopentyl, wherein

the cyclopentyl group may be substituted by =O, or mono or disubstituted by -OH, -OR₈, particularly -OCH₃, or -OCOR₈, particularly OCOCH₃, and these groups are particularly preferred in conjunction with R₁ = n-propyl and R₄ = hydrogen of general formula Ia



Ia

wherein R₂ is defined as hereinbefore.

















Compounds of general formula I or Ia wherein R₂ = an unbranched C₂₋₅-alkyl group substituted by -CN, -OH, SO₂-R₅, -O-C₁-C₄-alkyl, -COOH, -COOR₈, particularly COOCH₃ or -COOC₂H₅, -OCOCH₃, -OCOC₂H₅, -CONR₆R₇, =NOH, -NR₆R₇ or a C-linked 5- or 6-membered heterocyclic group containing nitrogen, are preferred inter alia.

Particularly preferred groups R₂ of general formulae I and Ia are:













- CH₂CH₂CH₂CN
- CH₂CH₂CH₂CH₂CH₂CN
- CH₂CH₂OCH₃
- CH₂CH₂CH₂OCH₃
- CH₂CH₂OH

23 AUG 1996

- 12 -













23 AUG 1996




optionally in the form of the racemates, the enantiomers, the diastereomers and the mixtures thereof and optionally the pharmacologically harmless salts thereof.

Compounds of general formula I or Ia which are particularly readily water-soluble are those wherein R_2 denotes





























$\text{CH}_2\text{CH}_2\text{SO}_2\text{CH}_2\text{CH}_2\text{OH}$, $\text{CH}_2\text{CH(OH)CH}_2\text{OH}$, $-\text{CH}_2-\text{CH}_2-\text{CHOH}-\text{CH}_3$
or






Although less readily water-soluble, compounds of general formula Ia wherein R_2 has the following groups are preferred on account of their pharmacological properties:




The following groups are particularly preferred:




23 AUG 1996



and









Also preferred are compounds of general formula Ia



wherein

R_3 denotes a radical from the group



23 AUG 1996

- 17 -

cyclopentyl being preferred,


and

R_2 denotes CH_2CH_2OH ,
 $CH_2CH_2OCOCH_3$,
 $(CH_2)_3OCOCH_3$,
 $(CH_2)_3OCH_3$,
 $CH_2CH_2COCH_3$,
 $CH_2CH_2CH(OH)CH_3$,
 $CH_2CH_2COOCH_3$,
 $CH_2CH_2CONH_2$,
 $(CH_2)_3CONH_2$,
 $CH_2CH=NOH$,
 $(CH_2)_3CN$,
 $CH_2CH_2SCH_2CH_3$,
 $CH_2CH_2SCH_2CH_2OH$,
 $CH_2CH_2SO_2CH_2CH_2OH$,
 $CH_2CH_2SO_2CH_2CH_2OCOCH_3$,

R_2 denotes $A-(CH_2)_2-$ or
 $A-(CH_2)_3-$





wherein A is a C- or N-linked 5- or 6-membered heterocyclic ring containing nitrogen, oxygen or sulphur as heteroatoms, especially pyridine, morpholine, thiomorpholine, piperidine, tetrazol,

the following groups R_2 being particularly preferred:



$CH_2CH_2SCH_2CH_2OH$,
 $CH_2CH_2SO_2CH_2CH_2OH$,
 CH_2CH_2OH ,
 $CH_2CH_2CH_2OCH_3$,

23 AUG 1996



The following xanthine derivatives are of particular interest:

1-propyl-3-(2-(pyridin-4-yl)ethyl)-8-cyclopentyl-7H-purine-2,6-dione

1-propyl-3-(2-(2-hydroxyethyl)-thioethyl)-8-cyclopentyl-7H-purine-2,6-dione

1-propyl-3-(2-(2-hydroxyethyl)-sulfonyl-ethyl)-8-cyclopentyl-7H-purine-2,6-dione

1-propyl-3-(2-hydroxyethyl)-8-cyclopentyl-7H-purine-2,6-dione

1-propyl-3-(3-methoxypropyl)-8-cyclopentyl-7H-purine-2,6-dione

1-propyl-3-(3-morpholin-1-yl-propyl)-8-cyclopentyl-7H-purine-2,6-dione

1-propyl-3-(3-tetrazol-5-yl-propyl)-8-cyclopentyl-7H-

23 AUG 1996

purine-2,6-dione

1-propyl-3-(3-(aminocarbonyl)propyl)-8-cyclopentyl-7H-purine-2,6-dione

1-propyl-3-(hydroxyiminoethyl)-8-cyclopentyl-7H-purine-2,6-dione

1-propyl-3-(3-pyridin-3-yl-propyl)-8-cyclopentyl-7H-purine-2,6-dione

The term "alkyl groups" (even when they are components of other groups) refers to branched and unbranched C_{1-10} , preferably C_{1-4} -alkyl groups, for example: methyl, ethyl, n-propyl, iso-propyl, butyl, iso-butyl, sec.butyl, tert.-butyl, pentyl, iso-pentyl, hexyl, heptyl and octyl.

The term "alkenyl groups" denotes branched and unbranched C_{2-10} , preferably C_{2-3} -alkenyl groups, provided that they have at least one double bond, e.g. including the alkyl groups mentioned above provided that they have at least one double bond, such as vinyl (provided that no unstable enamines or enolethers are formed), propenyl, isopropenyl, butenyl, pentenyl and hexenyl.

Examples of alkynyl groups are C_{2-10} -alkynyl groups provided that they have at least one triple bond, such as ethynyl, propargyl, butynyl, pentynyl and hexynyl.

The term C_{3-6} -cycloalkyl groups denotes, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, which may also be substituted by branched or unbranched C_{1-4} -alkyl, hydroxy and/or halogen or which may be substituted as hereinbefore defined. The word halogen generally refers to fluorine, chlorine, bromine or iodine.

23 AUG 1996

- 20 -

Examples of cyclic groups of general formula NR_6R_7 include: pyrrole, pyrroline, pyrrolidine, 2-methylpyrrolidine, 3-methylpyrrolidine, piperidine, piperazine, N-methylpiperazine, N-ethylpiperazine, N-(n-propyl)-piperazine, N-benzylpiperazine, morpholine, thiomorpholine, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine - the above-mentioned heterocycles may be substituted by C_{1-4} -alkyl, preferably methyl, or carry one of the following groups:

- $(\text{CH}_2)_n\text{-NH}_2$, a ketal,
- $(\text{CH}_2)_n\text{NH-C}_1\text{-C}_4\text{-alkyl}$,
- $(\text{CH}_2)_n\text{-N(C}_1\text{-C}_8\text{-alkyl)}_2$, =O,
- $(\text{CH}_2)_n\text{-NHCOOR}_8$, ($n = 2, 3, 4$), halogen,
- OR₈, -CN, -NO₂, -NH₂, -CH₂NR₆R₇,
- OH, -COOH, -SO₃H, -COOR₈, -CONR₆R₇,
- CONR₆R₇.

Examples of C-linked 5- or 6-membered heterocyclic rings which may contain nitrogen, oxygen or sulphur as heteroatoms, include tetrahydrofuran, 2-methyltetrahydrofuran, 2-hydroxymethylfuran, tetrahydrofuranone, γ -butyrolactone, α -pyran, γ -pyran, tetrahydropyran, pyrrole, pyrroline, pyrrolidine, piperazine, morpholine, thiomorpholine, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, triazole, tetrazole, oxazole, oxadizole, pyrazolidine, whilst the heterocycle may be substituted as specified in the definitions.

"=O" denotes an oxygen atom linked via a double bond.

Xanthine derivatives with a high adenosine-A₁-affinity promote neurotransmission in the brain and can be regarded for example as functional cholinomimetics.

Substances of this kind of great interest for the

23 AUG 1996

symptomatic treatment of degenerative disorders of the central nervous system such as senile dementia and Alzheimer's disease.

The high receptor affinity should make it possible to treat patients with low doses, so that virtually no side effects can be expected which cannot be traced back to the blockade of adenosine receptors. In addition to their use as gerontopsychopharmaceuticals and nootropics, the adenosine antagonists described could be useful in the treatment of cardiac and circulatory disorders and in the treatment of respiratory disorders, particularly bronchial asthma. Furthermore, xanthines of general formula I exhibit diuretic properties and are thus of interest in the treatment of kidney disease and, because of their diuretic properties, for treating high blood pressure.

Other possible indications are degenerative illnesses such as organic brain syndrome, Parkinson's disease, depression, traumatic CNS-damage, post stroke neurological deficit, respiratory depression (intoxication, post op) neonatal brain trauma, dyslexia and hyperactivity. Compounds of general formula I, wherein R_3 has an optionally substituted phenylvinylene group are proposed for the treatment of Parkinson's disease.

Cystic fibrosis - also known as mucoviscidosis - is a hereditary disorder caused by a genetic defect on a certain chromosome. Only homozygotic carriers of the feature succumb to the disease. The genetic defects leads to the dysfunction of exocrine glands. As a result of increased production and greater viscosity of the secretions of the mucous glands in the bronchi, severe complications may arise in the respiratory tract. Preliminary investigations have shown that A_1 -antagonists

23 AUG 1996

- 22 -

increase the efflux of chloride ions, e.g. in CF PAC cells. The cells come from a pancreas adenocarcinoma cell line which was isolated from patients suffering from cystic fibrosis (CF). The activity was successfully blocked by agonists such as 2-chloroadenosine. Interestingly, an increase in the efflux was observed only in those cells which came from patients suffering the disease or having the corresponding genetic defect.

Starting from these findings it is to be expected that, in patients suffering from cystic fibrosis (mucoviscidosis), the compounds according to the invention will regulate the disrupted electrolyte management of the cells and will alleviate the symptoms of the disease.

Adenosine antagonists can be used to treat lung diseases, particularly asthma, allergic lung diseases and chronically obstructive lung diseases. It is to be expected that the compounds according to the invention will also be suitable for the treatment of lung diseases by inhalation, because of their high potency.

Of particular interest is also a combination of compounds of general formula I according to the invention, in particular the compounds mentioned by name, with cholinomimetic active substances, for example 3-(2-propynyloxy)-1-azabicyclo[2.2.2]octane (Wal 801), for the treatment of degenerative diseases of ageing.

The receptor binding values were determined analogously to Ensinger et al. in "Cloning and functional characterisation of human A₁ adenosine receptor - Biochemical and Biophysical Communications, Vol 187, No. 2, 919-926, 1992".

23 AUG 1996

Effect on the inhibition of locomotor activity in the mouse achieved by adenosine antagonists: adenosine-antagonism:

Subcutaneous administration of an adenosine-agonist was able to induce inhibition of locomotor activity in mice in the hour following administration. The test is to determine how a test substance will influence this hypomotility.

The measurements for this test are concerned with the number of times a light beam is broken in motility chambers. The figures are recorded by computer immediately after the substance has been administered. Only the first hour after administration is evaluated, since the activity of adenosine agonist occurs during this period.

In addition to the mice which are given both the adenosine agonist and the test substance, one group is given placebo (tylose and NaCl solution), one is given the adenosine agonist and tylose solution and one group is given the maximum dose of the test substance and NaCl solution. The individual animals of all the treatment groups are tested in separate measuring chambers over the same period of time.

23 AUG 1996




Table Ia

Examples according to Table I	Ki[nMol/l] A ₁	Locom. (mg/kg)
01	7.5	3.0
04	8.0	0.6
05	46.7	0.6
06	66.8	0.6
07	2.7	
08	3.5	10.0
10	3.1	10.0
11	4.0	0.6
14	36.4	2.5
15	6.4	0.6
17	3.8	0.6
19	11.5	0.6
24	1.7	
28	29.3	
31	9.1	10.0
47	2.1	2.5
52	5.0	0.6
59	2.0	0.6
60	3.8	0.6
68	32.6	2.5
70	6.2	0.6


The compounds according to the invention can be prepared by analogous methods known per se as illustrated, for example, in synthesis plans I, II and III. The person skilled in the art is familiar enough with the synthesis of xanthines, but the following experimental section will explain it in detail once more with reference to ~~some~~ important key compounds.

23 AUG 1996



Synthesis plan I




II




III





IV




V




VI




VII



VIIa



VIII



I

23 AUG 1996

- 26 -

A characteristic feature of the synthesis illustrated in plan I is that R_2' is introduced at the diaminouracil stage (III). R_2' is a functional group, selected from the group of definitions of R_2 with the proviso that R_2' must not interfere with the synthesis of the xanthine and can be converted into the desired R_2 of general formula I before or after the cleavage of the protecting group R_4 (preferably benzyl) (formula VIII). A preferred definition of R_2' is a methoxybenzyl group, for example. R_3 is inserted by aminoacylation and subsequent cyclisation to form the xanthine. In order to be able to carry out alkylation deliberately in 1-position, it is necessary to protect the 7-position, e.g. using a benzyl group. The alkylations are carried out by reacting with R_4-Z , wherein R_4 = benzyl or methyl and Z is a readily cleavable group such as halogen, mesyl or tosyl. In case R_4 denotes a methyl group in the final compound of general formula I, the xanthine V is already irreversibly methylated at this stage.

R_1 is then inserted into the protected xanthine VI by N-alkylation. The conversion of R_4 into hydrogen can then be carried out by cleaving the protecting group in the 7-position. If R_2' has not yet assumed the desired definition R_2 of the end compound I, R_2' can now be converted into R_2 (formula VIIa) and, if this has not yet happened, the protecting group is then split off.

Examples of this are described in the general operation instructions under points 12 and 14 to 23. The compounds of general formula II and III are important intermediates and are claimed as such. It has been found, surprisingly, that a p-methoxybenzyl group or a di- or trimethoxybenzyl group in the 3-position of the xanthine of formula IX can be selectively cleaved in order to obtain the benzyl protecting group in the 7-position. This opens up a new method of obtaining xanthine derivatives of general formula I. By

23 AUG 1996


- 27 -

alkylating xanthines of general formula X with $R_2'-X$ ($X =$ halogen, OH, mesyl or tosyl), cleaving the benzyl protecting group and optionally converting R_2' into R_2 , compounds of general formula I can be obtained in a simple manner.

23 AUG 1996

The invention also relates to a simple and generally applicable method of preparation for synthesising xanthine derivatives substituted in the 1- and 3-positions, wherein R_1 and R_2 may represent any desired groups, provided that they can be inserted by an electrophilic reaction.

Synthesis plan II




23 AUG 1996

- 29 -

Compounds of general formula X (R_4 -benzyl) can easily be obtained by acid hydrolysis (e.g. with formula IX wherein R_4 = benzyl and R_2 = p-methoxybenzyl).

Synthesis plan III



The following are general operative instructions in order to prepare the compounds according to the invention.

23 AUG 1996

1. Monosubstituted ureas:

0.69 mol of amine are dissolved in a solution of 18.3 ml (0.34 mol) of conc. H_2SO_4 and 1000 ml of distilled water. The mixture is heated to $85^\circ C$, 55.8 g (0.69 mol) of KOCN are added and the resulting mixture is stirred at this temperature until the reaction is complete (30 - 90 min.). The reaction mixture is diluted with ethanol, cooled to ambient temperature and filtered. The filtrate is evaporated down and the solid residue is dried in a drying cupboard.

The following monosubstituted ureas, inter alia, were prepared in this way:

a)

p-methoxybenzylurea, 85.5 % of theory, mp. = $156 - 158^\circ C$

b)

2-(p-methoxyphenyl)-ethylurea, 91.4 % of theory, mp. = $127^\circ C$

c)

3-(p-methoxyphenyl)-propylurea, 91.8 % of theory, mp. = $170 - 173^\circ C$

d)

2-methoxyethylurea, 97.3 % of theory, mp. = $72^\circ C$

e)

3-methoxypropylurea, 92.2 % of theory, mp. = $79 - 81^\circ C$

f)

2-(p-chlorophenyl)-ethylurea, 73.2% of theory, mp. = $150 - 151^\circ C$

g)

2-(p-bromophenyl)-ethylurea, 92.3% of theory, mp. = $183 - 184^\circ C$

h)

3-(p-chlorophenyl)-propylurea, 82.4 % of theory, mp. = $146 - 150^\circ C$

23 AUG 1996

2. Substituted cyanoacetylureas:

220 ml of acetanhydride are mixed with 57.6 g (0.68 mol) of cyanoacetic acid and 0.62 Mol of monosubstituted urea [see 1.]. The mixture is heated to 75 - 80°C and stirred at this temperature until the reaction is complete (30 - 90 min.). It is then cooled, diluted with ether and suction filtered and the crystalline product is washed with ether. The following cyanoacetylureas, inter alia, were prepared in this way:

a)

N-(p-methoxybenzyl)-N'-cyanoacetylurea, 81.3 % of theory, mp. = 185°C

b)

N-(2-(p-methoxyphenyl)-ethyl)-N'-cyanoacetylurea, 69 % of theory, mp. = 142 - 151°C

c)

N-(3-(p-methoxyphenyl)-propyl)-N'-cyanoacethylurea, 83.7 % of theory, mp. = 162 - 164°C

d)

N-2-methoxyethyl-N'-cyanoacetylurea, 78.9 % of theory, mp. = 129 - 132°C

e)

N-3-methoxypropyl-N'-cyanoacetylurea, 74.4 % of theory, mp. = 138 - 140°C

f)

N-(2-(p-chlorophenyl)-ethyl)-N'-cyanoacetylurea, 59.5 % of theory, mp. = 192 - 193°C

g)

N-(2-(p-bromophenyl)-ethyl)-N'-cyanoacetylurea, 80.2 % of theory, mp. = 192 - 193°C

3. 1-Substituted 6-aminouracils:

0.5 mol of substituted cyanoacetylurea [see 2.] is placed in 1250 ml of absolute ethanol and heated to 50 -

23 AUG 1996

- 32 -

80°C. A solution of 3.8 g (0.17 mol) of sodium in 190 ml of absolute ethanol is added dropwise and the resulting suspension is stirred for 30 minutes at reflux temperature. The mixture is diluted with distilled water, cooled, optionally neutralised with HCl and the crystalline product is suction filtered.

The following 1-substituted 6-aminouracils were prepared, inter alia, using this method:

a)

6-amino-1-(p-methoxybenzyl)-uracil, 63.3 % of theory, mp. = 276 - 278°C

b)

6-amino-1-(2-(p-methoxyphenyl)-ethyl)-uracil, 69 % of theory, mp. = 233 - 236°C

c)

6-amino-1-(3-(p-methoxyphenyl)-propyl)uracil, 69.3 % of theory

d)

6-amino-1-(2-methoxyethyl)-uracil, 41.6 % of theory, mp. = 229 - 230°C

e)

6-amino-1-(3-methoxypropyl)-uracil, 68.1 % of theory, mp. = 208 - 210°C

f)

6-amino-1-(2-(p-chlorophenyl)-ethyl)-uracil, 78.1 % of theory, mp. = 282 - 283°C

g)

6-amino-1-(2-(p-bromophenyl)-ethyl)-uracil, 56.1 % of theory, mp. = 291 - 292°C

1.2.1-Substituted 6-amino-5-nitrosouracils:

0.005 mol of 1-substituted 6-aminouracil [see 3.] is suspended in 12.5 ml of distilled water; in the case of starting compounds which are particularly difficult to

23 AUG 1996

- 33 -

dissolve, ethanol is also added. The mixture is heated to 80°C and combined with a solution of 0.36 g (5.3 mMol) of sodium nitrite in 3 ml of distilled water. Then 0.7 ml of glacial acetic acid are added and the mixture is stirred at 80°C until the reaction has ended. The reaction mixture is cooled, the reddish-violet residue is suction filtered and washed with distilled water.

The following 1-substituted 6-amino-5-nitrosouracils were prepared, inter alia, using this method:

a)

6-amino-5-nitroso-1-(p-methoxybenzyl)-uracil, 90.6 % of theory, mp. = 233°C

b)

6-amino-5-nitroso-1-(2-(p-methoxyphenyl)-ethyl)-uracil, 75.8 % of theory, mp. = 227°C

c)

6-amino-5-nitroso-1-(3-(p-methoxyphenyl)-propyl)-uracil, 49.1 % of theory,

d)

6-amino-5-nitroso-1-(2-methoxyethyl)-uracil, 80 % of theory, mp. = 222°C

e)

6-amino-5-nitroso-1-(3-methoxypropyl)-uracil, 58.5 % of theory, mp. = 227 - 228°C

f)

6-amino-5-nitroso-1-(2-(p-chlorophenyl)-ethyl)-uracil, 88.5 % of theory, mp. = 235 - 236°C

g)

6-amino-5-nitroso-1-(2-(p-bromophenyl)-ethyl)-uracil, 76.6 % of theory, mp. = 248°C

23 AUG 1996

5. 1-Substituted 5,6-diaminouracils

4.5 mMol of 1-substituted 6-amino-5-nitrosouracil [see 4.] are dissolved in 50 ml of conc. ammonia; for starting compounds which are particularly difficult to dissolve, ethanol is added. At 30°C a solution of 2.35 g (13.5 mMol) of sodium dithionite in 24 ml of distilled water is added dropwise. The mixture is stirred at ambient temperature until the reaction has ended, then the crystalline product is suction filtered and washed with distilled water.

The following 1-substituted 5,6-diaminouracils, inter alia, were prepared using this method:

a)

5,6-diamino-1-(p-methoxybenzyl)-uracil, 93.2 % of theory, mp. = 252°C

b)

5,6-diamino-1-(2-(p-methoxyphenyl)-ethyl)-uracil, 88.5 % of theory, mp. = 249 - 250°C

c)

5,6-diamino-1-(3-(p-methoxyphenyl)-propyl)-uracil, 80.5 % of theory, mp. = 252 - 253°C

d)

5,6-diamino-1-(2-methoxyethyl)-uracil, 84.4 % of theory, mp. = 246°C

e)

5,6-diamino-1-(3-methoxypropyl)-uracil, 58.5 % of theory, mp. = 248°C (decomposition)

f)

1-(2-(p-chlorophenyl)-ethyl)-5,6-diaminouracil, 66.3 % of theory, mp. = 279 - 280°C

g)

1-(2-(p-bromophenyl)-ethyl)-5,6-diaminouracil, 79.7 % of theory, mp. = 273°C (decomposition)

23 AUG 1996

6. 1-Substituted 6-amino-5-acylaminouracils and
1-substituted 5-amino-6-acylaminouracils

The acylating position (5- or 6-position) is not important for the following reaction and has not been determined. In the interests of simplicity, the name of the product acylated in the 5-position is given hereinafter!

0.46 ml of 1-substituted 5,6-diaminouracil [see 5.] are suspended together with 78.2 g (0.64 mol) of 4-dimethylaminopyridine (DMAP) in 2400 ml of absolute dimethylformamide (DMF). At 0 - 5°C a solution consisting of 0.55 mol of the corresponding acid chloride in 200 ml of absolute DMF is added dropwise thereto, the mixture is stirred, whilst cooling with ice, until the reaction has ended and is then allowed to come up to ambient temperature. The reaction mixture is evaporated to dryness, the residue is triturated with distilled water. The crystalline product is suction filtered and washed with distilled water and diethylether.

The following title compounds were prepared, inter alia, using this method:

a)

6-amino-5-cyclopentylcarbonylamino-1-(p-methoxybenzyl)-uracil, 88.3 % of theory, mp. = 261 - 262°C

b)

6-amino-5-cyclopentylcarbonylamino-1-(2-(p-methoxyphenyl)-ethyl)-uracil, 80.6 % of theory, mp. = 217 - 222°C

c)

6-amino-5-cyclopentylcarbonylamino-1-(3-(p-methoxyphenyl)-propyl)-uracil, 84.8 % of theory, mp. = 126 - 128°C

d)

23 AUG 1996

6-amino-5-cyclopentylcarbonylamino-1-(2-methoxyethyl)-
uracil 84.4 % of theory, mp. = 209 - 213°C

e)

6-amino-5-cyclopentylcarbonylamino-1-(3-methoxypropyl)-
uracil, 84 % of theory,

f)

6-amino-5-cyclopentylcarbonylamino-1-(2-(p-
chlorophenyl)-ethyl)-uracil, 66.3 % of theory, mp. =
258 - 259°C

g)

6-amino-5-cyclopentylcarbonylamino-1-(2-(p-bromophenyl)-
ethyl)-uracil, 68.5 % of theory, mp. = 245 - 246°C

7. Xanthines substituted in the 3- and 8-positions

0.01 mol of 1-substituted 6-amino-5-acylaminouracil (or
1-substituted 5-amino-6-acylaminouracil) [see 6.] are
suspended in 10 ml of tetrahydrofuran and combined with
a solution of 2.38 g (0.056 mol) of lithium hydroxide-
hydrate in 70 ml of distilled water. The reaction
mixture is stirred at 70 - 80°C until the reaction has
ended, then made acidic with HCl and left to cool. The
crystalline product is suction filtered and washed with
distilled water. If necessary, it is recrystallised
from ethanol in order to purify it.

The following xanthines substituted in the 3- and 8-
positions were prepared, inter alia, by this method:

a)


8-cyclopentyl-3-(p-methoxybenzyl)-xanthine, 77.8 % of
theory, mp. = 311°C

b)

8-cyclopentyl-3-(2-(p-methoxyphenyl)-ethyl)-xanthine,
42.3 % of theory, mp. = 256 - 258°C

c)

8-cyclopentyl-3-(3-(p-methoxyphenyl)-propyl)-xanthine,



90.5 % of theory, mp. = 292 - 293°C

d)

8-cyclopentyl-3-(2-methoxyethyl)-xanthine, 68.3 % of theory, mp. = 293 - 294°C

e)

8-cyclopentyl-3-(3-methoxypropyl)-xanthine, 90.9 % of theory, mp. = 240 - 247°C

f)

8-cyclopentyl-3-(2-(p-chlorophenyl)-ethyl)-xanthine, 81.3 % of theory, mp. = 298 - 299°C

g)

8-cyclopentyl-3-(2-(p-bromophenyl)-ethyl)-xanthine, 60.1 % of theory, mp. = 306 - 307°C

8. 7-Benzylxanthines substituted in 3- and 8-positions

0.02 Mol of xanthine substituted in the 3- and 8-positions [see 7.] and 3.0 g (0.022 mol) of potassium carbonate are suspended in 140 ml of absolute DMF. The mixture is stirred for one hour at ambient temperature and then 2.62 ml (0.022 mol) of benzylbromide are added dropwise. The mixture continues to be stirred at ambient temperature. If the reaction stops before all the starting compounds have been reacted, up to 35 mol % of potassium carbonate and benzylbromide may be added. After the reaction has ended the mixture is evaporated to dryness, the residue is taken up in methylene chloride and extracted with water. The organic phase is dried with sodium sulphate and evaporated to dryness. The residue is purified by crystallisation or by chromatography.

23 AUG 1996

- 38 -

Using this method, the following 7-benzylxanthines substituted in the 3- and 8-positions, inter alia, were prepared:

a)

7-benzyl-8-cyclopentyl-3-(p-methoxybenzyl)-xanthine,
66.2 % of theory, mp. = 165°C

b)

7-benzyl-8-cyclopentyl-3-(2-(p-methoxyphenyl)-ethyl)-
xanthine, 77 % of theory, mp. = 152°C

c)

7-benzyl-8-cyclopentyl-3-(3-(p-methoxyphenyl)-propyl)-
xanthine, 64 % of theory, mp. = 146 - 148°C

d)

7-benzyl-8-cyclopentyl-3-(2-methoxyethyl)-xanthine,
69.1 % of theory, mp. = 140°C

e)

7-benzyl-8-cyclopentyl-3-(3-methoxypropyl)-xanthine,
77.7 % of theory, mp. = 130 - 132°C

f)

7-benzyl-8-cyclopentyl-3-(2-(p-chlorophenyl)-ethyl)-
xanthine, 39.8 % of theory, mp. = 179 - 180°C

9. 7-Benzylxanthine substituted in the 1-, 3- and 8-positions

6.5 mMol of 7-benzylxanthine substituted in the 3- and 8-positions [see 8.], 1.0 g (7.15 mMol) of potassium carbonate and 7.15 mMol of alkyl-, alkenyl- or alkynylhalide are stirred in 56 ml of absolute DMF until the starting substance has reacted completely (if necessary, some more potassium carbonate and alkylhalide may be added). The reaction mixture is neutralised, evaporated down, the residue is taken up in methylene chloride and extracted with distilled water. The organic phase is dried with sodium sulphate and

23 AUG 1996

- 39 -

evaporated to dryness and the residue is purified, if necessary, by crystallisation or by chromatography.

Using this method, the following 7-benzylxanthines substituted in the 1-, 3- and 8-positions were prepared, inter alia:

a)

7-benzyl-8-cyclopentyl-3-(p-methoxybenzyl)-1-propylxanthine, 99 % of theory, mp. = 110 - 111°C

b)

7-benzyl-8-cyclopentyl-3-(2-(p-methoxyphenyl)-ethyl)-1-propylxanthine, 77 % of theory, mp. = 151°C

c)

7-benzyl-8-cyclopentyl-3-(3-(p-methoxyphenyl)-propyl)-1-propylxanthine, 95.3 % of theory, mp. = 99 - 101°C

d)

7-benzyl-8-cyclopentyl-3-(2-methoxyethyl)-1-propylxanthine, 97.7 % of theory, mp. = 80 - 81°C

e)

7-benzyl-8-cyclopentyl-3-(3-methoxypropyl)-1-propylxanthine, 61.8 % of theory, mp. = 76 - 80°C

f)

7-benzyl-8-cyclopentyl-3-(2-(p-chlorophenyl)-ethyl)-1-propyl-xanthine, 67.9 % of theory, colourless oil

g)

1-allyl-7-benzyl-8-cyclopentyl-3-(3-methoxypropyl)-xanthine, 86.5 %, colourless oil

Numerous other xanthine derivatives described by the general formula were prepared from the xanthines thus obtained by varying the substituents in the 3-position. Only those methods which are familiar to those skilled in the art were used.

23 AUG 1996

- 40 -

10. 7-Benzylxanthines substituted in the 1- and 8-positions

6.3 mMol of 7-benzyl-3-p-methoxybenzylxanthine substituted in the 1- and 8-positions [see 9.] were mixed with 30 ml of trifluoroacetic acid and stirred for 4 days at 60°C under a protective gas atmosphere. The mixture was diluted with distilled water, extracted with ethyl acetate, and the combined organic phases were dried with sodium sulphate and evaporated to dryness. The residue was purified by crystallisation or by chromatography.

Using this method, the following title compound was prepared, inter alia:

a) from

7-benzyl-8-cyclopentyl-3-(2-p-methoxybenzyl)-1-propylxanthine:

7-benzyl-8-cyclopentyl-1-propylxanthine, 90 % of theory,
mp. = 214°C

11. Introduction of substituents into the 3-position of 7-benzylxanthines substituted in the 1- and 8-positions

Method A:

0.5 mMol of 7-benzylxanthine substituted in the 1- and 8-positions [see 10.], 75 mg (0.55 mMol) of potassium carbonate and 0.55 mMol (optionally substituted, as described under R₂) of alkyl-, alkenyl- or alkynyl halide are stirred in 3.5 ml of absolute DMF until the reaction has ended, optionally with heating. The mixture is neutralised, evaporated to dryness and the residue is distributed between methylene chloride and distilled water. The organic phase is dried over sodium sulphate and evaporated down and the residue is purified, if necessary, by crystallisation or by chromatography.

23 AUG 1996

Using this method, the following title compound was prepared, inter alia:

a) from

7-benzyl-8-cyclopentyl-1-propylxanthine:

7-benzyl-8-cyclopentyl-3-(Z-(p-methoxycarbonylphenyl)-ethyl)-1-propylxanthine, 67 % of theory, viscous oil

Method B:

To a solution of 0.56 g (2.1 mMol) of triphenylphosphine in 3.5 ml of absolute tetrahydrofuran (THF) are added, successively, 0.37 g (2.1 mMol) of diethylazodicarboxylate (DEAD) and 1.4 mMol of 7-benzylxanthine substituted in the 1- and 8-positions [see 10] and the mixture is cooled to 5°C. At this temperature, 1.4 mMol of (optionally substituted, as described in R₂) alkyl-, alkenyl- or alkynylalcohol are added dropwise and the mixture is stirred at ambient temperature until all the starting substance has reacted. The mixture is evaporated to dryness and the residue is purified by crystallisation or by chromatography.

Using this method, the following title compounds were prepared, inter alia:

from 7-benzyl-8-cyclopentyl-1-propylxanthine:

a)

7-benzyl-8-cyclopentyl-1-propyl-3-(2-(2-pyridyl)-ethyl)-xanthine, 87 % of theory, colourless oil

b)

7-benzyl-8-cyclopentyl-1-propyl-3-(3-(3-pyridyl)-propyl)-xanthine

c)

7-benzyl-3-(2-(p-cyanophenyl)-ethyl)-8-cyclopentyl-1-

23 AUG 1996

propyl-xanthine, 29.7 % of theory, colourless oil

Using the methods 11. A) and 11. B), many of the substituents R_2 described in the general formula were introduced directly or in the form of suitable precursors which were converted into the desired group R_2 by conventional methods.

12. Hydrolysis of methylethers

Method A:

0.5 mMol of methylether-derivative are dissolved in 5 ml of absolute acetonitrile. 300 mg (40 mMol) of sodium iodide are added followed by 0.39 ml (3.0 mMol) of chlorotrimethylsilane and the suspension is stirred at ambient temperature or at reflux temperature until the reaction has ended. The mixture is cooled to ambient temperature, mixed with distilled water and extracted with methylene chloride. The combined organic phases are washed with sodiumthiosulphate solution, dried over sodium sulphate and evaporated to dryness. The product is purified by crystallisation or chromatography, if required. Using this method the following title compounds were prepared, inter alia:

a)

7-benzyl-8-cyclopentyl-3-(3-hydroxypropyl)-1-propylxanthine, 78.4 % of theory, yellowish oil

b)

7-benzyl-8-cyclopentyl-3-(2-hydroxyethyl)-1-propylxanthine, 90 % of theory, mp. = 208 - 209°C

Method B:

4.8 mMol of methylether-derivative are dissolved in 60 ml of absolute methylene chloride. At $-20 \pm 5^\circ\text{C}$ a solution of 0.65 ml (6.5 mMol) of boron tribromide in 7 ml of absolute methylene chloride is added dropwise

23 AUG 1996

and the resulting mixture is stirred at ambient temperature until the reaction has ended. The reaction mixture is washed with distilled water, the organic phase is dried over sodium sulphate and evaporated to dryness. The residue is purified by crystallisation or by chromatography.

Using this method, the following title compounds were prepared, inter alia:

- a)
8-cyclopentyl-3-(2-hydroxyethyl)-1-propylxanthine,
80.7 % of theory, mp. = 216°C
- b)
8-cyclopentyl-3-(2-(p-hydroxyphenyl)-ethyl)-1-propylxanthine, 83.5 % of theory, mp. = 270 - 272°C
- c)
7-benzyl-8-cyclopentyl-3-(3-(p-hydroxyphenyl)-propyl)-1-propylxanthine, 97.3 % of theory, mp. = 130 - 132°C
- d)
7-benzyl-8-cyclopentyl-3-(3-hydroxypropyl)-1-propylxanthine, 83.6 % of theory, mp. = 116 - 117°C

13. Hydrogenolysis of N-benzyl substituents

Method A:

0.01 mol of N-benzyl compound are hydrogenated together with 0.5 g of palladium on activated charcoal or Pearlman catalyst in methanol, tetrahydrofuran or in glacial acetic acid under pressure and optionally with heating until all the starting compound has reacted.

The catalyst is filtered off, the filtrate is evaporated to dryness and the residue is purified by crystallisation or chromatography.

Using this method, numerous hydrogenolyses are carried out, to obtain, inter alia:

23 AUG 1996

a) from

7-benzyl-8-cyclopentyl-3-(2-(p-methoxyphenyl)-ethyl)-1-propylxanthine:

8-cyclopentyl-3-(2-(p-methoxyphenyl)-ethyl)-1-propylxanthine, 70.6 % of theory, mp. = 208°C

b) from

1-allyl-7-benzyl-8-cyclopentyl-3-(3-methoxypropyl)-xanthine:

8-cyclopentyl-3-(3-methoxypropyl)-1-propylxanthine, 71.4 % of theory, mp. = 174 - 175°C

c) from

7-benzyl-8-cyclopentyl-3-(3-(hydroxypropyl)-1-propylxanthine:

8-cyclopentyl-3-(3-(hydroxypropyl)-1-propylxanthine, 26.6 % of theory, mp. = 213 - 215°C

d) from

7-benzyl-8-cyclopentyl-3-(3-(p-methoxyphenyl)-propyl)-1-propylxanthine:

8-cyclopentyl-3-(3-(p-methoxyphenyl)-propyl)-1-propylxanthine, 80.6 % of theory, mp. = 153 - 154°C

e) with palladium on activated charcoal in methanol/HCl from

7-benzyl-3-(2-carboxyethyl)-8-cyclopentyl-1-propylxanthine:

8-cyclopentyl-3-(2-methoxycarbonylethyl)-1-propylxanthine, 16.3 % of theory, mp. = 201 - 203°C

f) from

7-benzyl-8-cyclopentyl-3-(3-p-hydroxyphenyl)-propyl)-1-propylxanthine:

8-cyclopentyl-3-(3-(p-hydroxyphenyl)-propyl)-1-propylxanthine, 26.8 % of theory, mp. = 239 - 241°C

g) from

7-benzyl-8-cyclopentyl-3-(2-(methylaminocarbonyl)-ethyl)-1-propylxanthine:

8-cyclopentyl-3-(2-(methylaminocarbonyl)-ethyl)-1-propylxanthine, 67.7 % of theory, mp. = 297 - 298°C

h) from

23 AUG 1996

- 45 -

7-benzyl-8-cyclopentyl-3-(2-(3,4,5-trimethoxybenzylaminocarbonyl)-ethyl)-1-propylxanthine:
8-cyclopentyl-3-(2-(3,4,5-trimethoxybenzylamino-carbonyl)-ethyl)-1-propylxanthine, 77.2 % of theory, mp.
= 231 - 233°C

i) from

7-benzyl-8-cyclopentyl-3-(3-(p-methylcarbonyloxyphenyl)-propyl)-1-propylxanthine:

8-cyclopentyl-3-(3-(p-methylcarbonyloxyphenyl)-propyl)-1-propylxanthine, 63.9 % of theory, mp. = 181 - 183°C

j) from

7-benzyl-8-cyclopentyl-3-(2-(N-morpholinocarbonyl)-ethyl)-1-propylxanthine:

8-cyclopentyl-3-(2-(N-morpholinocarbonyl)-ethyl)-1-propylxanthine, 50 % of theory, mp. = 169 - 171°C

k) from

7-benzyl-8-cyclopentyl-3-(3-(N-morpholino)-propyl)-1-propylxanthine:

8-cyclopentyl-3-(3-(N-morpholino)-propyl)-1-propylxanthine, 59.7 % of theory, mp. = 176 - 178°C

l) from

7-benzyl-8-cyclopentyl-3-(2-(2,4,6-trimethoxybenzylaminocarbonyl)-ethyl)-1-propylxanthine:

8-cyclopentyl-3-(2-(2,4,6-trimethoxybenzylamino-carbonyl)-ethyl)-1-propylxanthine, 47.2 % of theory, mp.
= 241 - 243°C

m) from

7-benzyl-8-cyclopentyl-3-(3-(p-(ethoxycarbonylmethyloxy)-phenyl)-propyl)-1-propylxanthine,


8-cyclopentyl-3-(3-(p-(ethoxycarbonylmethyloxy)-phenyl)-propyl)-1-propylxanthine, 77.4 % of theory, mp. = 141 -

143°C

n) from

7-benzyl-8-cyclopentyl-3-(3-acetoxypentyl)-1-propylxanthine:

8-cyclopentyl-3-(3-acetoxypentyl)-1-propylxanthine,



93.5 % of theory, mp. = 157 - 159°C

o) from

7-benzyl-8-cyclopentyl-3-(3-hydroxybutyl)-1-propylxanthine:

8-cyclopentyl-3-(3-hydroxybutyl)-1-propylxanthine,
60.0 % of theory, mp. = 198 - 199°C

p) from

7-benzyl-8-cyclopentyl-3-(3-(p-(2-hydroxyethoxy)-phenyl)-propyl)-1-propylxanthine:

8-cyclopentyl-3-(3-(p-(2-hydroxyethoxy)-phenyl)-propyl)-1-propylxanthine, 59.6 % of theory, mp. = 168 - 169°C

g) from

7-benzyl-8-cyclopentyl-3-(3-(p-(2-(methylcarbonyloxy)-ethoxy)-phenyl)-propyl)-1-propylxanthine:

8-cyclopentyl-3-(3-(p-(2-(methylcarbonyloxy)-ethoxy)-phenyl)-propyl)-1-propylxanthine, 48.1 % of theory, mp. = 139 - 140°C

r) from

7-benzyl-8-cyclopentyl-3-(3-(N-piperidinyl)-propyl)-1-propylxanthine:

8-cyclopentyl-3-(3-(N-piperidinyl)-propyl)-1-propylxanthine, 78.4 % of theory, mp. = 152 - 154°C

s) from

7-benzyl-8-cyclopentyl-3-(3-(N-pyrrolidinyl)-propyl)-1-propylxanthine:

8-cyclopentyl-3-(3-(N-pyrrolidinyl)-propyl)-1-propylxanthine, 52.6 % of theory, mp. = 162 - 163°C

t) from

7-benzyl-8-cyclopentyl-3-(3-(p-(methoxycarbonylmethyloxy)-phenyl)-propyl)-1-propylxanthine:

8-cyclopentyl-3-(3-(p-(methoxycarbonylmethyloxy)-phenyl)-propyl)-1-propylxanthine, 86.5 % of theory, ¹H-NMR (250 MHz, DMSO-d₆): δ (ppm) = 7.11 (d, J = 8.8 Hz, 2H), 6.79 (d, J = 8.8 Hz, 2H), 4.72 (s, 2H), 3.98 (t, J = 7.3 Hz, 2H), 3.80 (t, J = 7.3 Hz, 2H), 3.69 (s, 3H), 3.13 (m, 1H), 2.55 (m, 2H), 2.07 - 1.45 (m, 12 H), 0.85

23 AUG 1996

(t, J = 7.6 Hz, 3H).

u) from

7-benzyl-8-cyclopentyl-3-(2-methoxyethyl)-1-propylxanthine:

8-cyclopentyl-3-(2-methoxyethyl)-1-propylxanthine,
81.2 % of theory, mp. = 185°C

v) from

7-benzyl-3-(2-(cyclohexyl)-ethyl)-8-cyclopentyl-1-propylxanthine:

3-(2-(cyclohexyl)-ethyl)-8-cyclopentyl-1-propylxanthine,
mp. = 188 - 189°C

w) from

7-benzyl-8-cyclopentyl-3-(2-phenylethyl)-1-propylxanthine:

8-cyclopentyl-3-(2-phenylethyl)-1-propylxanthine, 34.5 %
of theory, mp. = 215 - 216°C

x) from

7-benzyl-8-cyclopentyl-3-(3-(phenyl)-propyl)-1-propylxanthine:

8-cyclopentyl-3-(3-(phenyl)-propyl)-1-propylxanthine,
28.6 % of theory, mp. = 153°C (decomposition)

y) from

7-benzyl-3-(3-cyanopropyl)-8-cyclopentyl-1-propylxanthine:

3-(3-cyanopropyl)-8-cyclopentyl-1-propylxanthine, 69.0 %
of theory, mp. = > 300°C

z) from

7-benzyl-3-(5-cyanopentyl)-8-cyclopentyl-1-propylxanthine:

3-(5-cyanopentyl)-8-cyclopentyl-1-propylxanthine, 21.1 %
of theory, mp. = 160°C (decomposition)

al) from

3-(3-(aminocarbonyl)-propyl)-7-benzyl-8-cyclopentyl-1-propylxanthine:

3-(3-(aminocarbonyl)-propyl)-8-cyclopentyl-1-propylxanthine, mp = 264 - 165°C

REPLACEMENT SHEET

23 AUG 1996

Method B:

3.3 mMol of N-benzyl compound are dissolved in 70 ml of absolute methylene chloride. 3.36 g (52.8 mMol) of ammonium formate and 1.32 g of Pearlman-catalyst are added and the suspension is refluxed for 2 hours. After cooling, the mixture is filtered over kieselguhr and the filtrate is evaporated to dryness. If necessary the residue is purified by crystallisation or chromatography.

Numerous hydrogenolyses were carried out using this method, to obtain inter alia:

a) from

7-benzyl-8-cyclopentyl-1-propyl-3-(2-(2-pyridyl)-ethyl)-xanthine:

8-cyclopentyl-1-propyl-3-(2-(2-pyridyl)-ethyl)-xanthine,
mp = 201 - 202°C

14. Hydrogenation of nitrile groups

3.3 mMol of nitrile derivative are dissolved in 40 ml of methanol and 10.5 ml of 25% aqueous ammonia solution and hydrogenated under pressure in the presence of Raney nickel, optionally with heating, until all the starting compound has reacted.

The following was obtained, for example, using this method:

a)

3-(4-aminobutyl)-8-cyclopentyl-1-propylxanthine, 40.9 %
of theory, mp. = 159 - 161°C

15. Acylation of hydroxy groups

1.3 mMol of hydroxy compound and 0.53 ml (6.5 mMol) of

23 AUG 1996

- 49 -

pyridine are dissolved or suspended in 10 ml of absolute methylene chloride. A solution of 1.44 mMol of carboxylic acid chloride in 1 ml of absolute methylene chloride is added dropwise at ambient temperature with stirring and the reaction mixture is stirred until all the starting compound has reacted. The mixture is then extracted with distilled water and dilute hydrochloric acid, the organic phase is dried over sodium sulphate and evaporated to dryness. The residue is purified by crystallisation or by chromatography.

Using this method, the following O-acyl compounds were prepared, inter alia:

a)

8-cyclopentyl-3-(2-(methylcarbonyloxy)-ethyl)-1-propylxanthine, 47 % of theory, mp. = 149°C

b)

8-cyclopentyl-3-(2-(p-(methylcarbonyloxy)-phenyl)-ethyl)-1-propylxanthine, 47 % of theory, mp. = 232°C

c)

7-benzyl-8-cyclopentyl-3-(3-(p-(methylcarbonyloxy)-phenyl)-propyl)-1-propylxanthine, 77.5 % of theory, gradually crystallising oil

d)

7-benzyl-8-cyclopentyl-3-(3-(methylcarbonyloxy)-propyl)-1-propylxanthine, 98.6 % of theory, gradually crystallising oil

e)

7-benzyl-8-cyclopentyl-3-(3-(p-(2-(methylcarbonyloxy)-ethoxy)-phenyl)-propyl)-1-propylxanthine, 82.1 % of theory, colourless oil

16. Hydrolysis of carboxylic acid esters

0.6 mMol of ester derivative are dissolved in about 4 ml of tetrahydrofuran and mixed with a solution of 0.17 g

23 AUG 1996

(4.0 mMol) of lithium hydroxide-hydrate in 10 ml of distilled water. The reaction mixture is stirred until all the starting substance has reacted, then made alkaline with dilute hydrochloric acid and the product is filtered off or the aqueous phase is extracted with organic solvent. In order to purify it it may be recrystallised or chromatographed.

Using this method, the following compounds were prepared inter alia:

a) from

8-cyclopentyl-3-(3-(p-(ethoxycarbonylmethyloxy)-phenyl)-propyl)-1-propylxanthine:

3-(3-(p-(carboxymethyloxy)-phenyl)-propyl)-8-cyclopentyl-1-propylxanthine, 85.2 % of theory, mp. = 190 - 192°C

b) from

8-cyclopentyl-3-(2-(methyloxycarbonyl)-ethyl)-1-propylxanthine:

3-(2-carboxyethyl)-8-cyclopentyl-1-propylxanthine, 78.5 % of theory, mp. = 265 - 267°C

17. Hydrolysis of methoxybenzylamides

1.1 mMol of methoxybenzylamide derivative are suspended or dissolved at 0°C in 50 ml of absolute methylene chloride. A solution of 5 ml of trifluoroacetic acid in 5 ml of absolute methylene chloride is added dropwise, the mixture is heated to ambient temperature and stirred until all the starting compound has reacted. The reaction mixture is washed with distilled water, the organic phase is dried over sodium sulphate and evaporated to dryness. The crude product is purified by crystallisation or by chromatography.

Using this method, the following compounds are obtained,

23 AUG 1996

inter alia:

a) from

8-cyclopentyl-3-(2-(2,4,6-trimethoxybenzylamino-carbonyl)-ethyl)-1-propylxanthine:

3-(2-carbamoylethyl)-8-cyclopentyl-1-propylxanthine,
64.9 % of theory, mp. = 289 - 291°C

b) from

3-(3-(p-(2,4,6-trimethoxybenzylamino-carbonyl-methyloxy)-phenyl)-propyl)-8-cyclopentyl-1-propylxanthine:

3-(3-(p-(carbamoylmethyloxy)-phenyl)-propyl)-8-cyclopentyl-1-propylxanthine, 49.0 % of theory, mp. = 224 - 226°C

18. Preparation of oximes

2.5 mMol of aldehyde, 0.17 g (2.5 mMol) of hydroxylamine-hydrochloride and 0.13 g (1.3 mMol) of sodium carbonate are mixed into 15 ml of distilled water and stirred together at ambient temperature until all the starting compound has reacted. Methylene chloride is added to the mixture and the solid is removed by suction filtering or the aqueous phase is extracted with methylene chloride. The crude product is purified by crystallisation or by chromatography.

Using this method the following was prepared, for example:

a) from

8-cyclopentyl-3-formylmethyl-1-propylxanthine:

8-cyclopentyl-3-hydroximinoethyl-1-propylxanthine, 64 % of theory, mp. = 247°C

23 AUG 1996

19. Oxidation of alcohols into aldehydes or ketones

0.4 mMol of alcohol derivative are stirred together with 180 mg (0.84 mMol) of pyridinium chlorochromate in 5 ml of absolute methylene chloride until all the starting compound has reacted. The reaction mixture is washed with distilled water, the organic phase is dried over sodium sulphate and evaporated to dryness. The crude product is purified by crystallisation or by chromatography.

Using this method, the following was prepared, inter alia:

a) from

8-cyclopentyl-3-(3-hydroxybutyl)-1-propylxanthine:

8-cyclopentyl-3-(3-oxobutyl)-1-propylxanthine, 73.3 % of theory, mp. = 223 - 224°C

20. Preparation of thioethers

3.6 mol of alkylhalide derivative are dissolved or suspended in a solution of 0.42 g (7.5 mol) of potassium hydroxide in 60 ml of ethanol. 3.6 mMol of substituted thiol are added and the mixture is refluxed until all the starting compound has reacted. It is evaporated to dryness, the residue is mixed with 4N hydrochloric acid and extracted with methylene chloride. The combined organic phases are dried with magnesium sulphate and evaporated to dryness. The residue is purified by crystallisation or by chromatography.

Using this method, the following were prepared, inter alia:

from 8-cyclopentyl-3-(2-iodoethyl)-1-propylxanthine:

a) 8-cyclopentyl-3-(2-ethylthio)-ethyl)-1-

23 AUG 1996

- 53 -

propylxanthine, 71.3 % of theory, mp. = 144 - 145°C

- b) 8-cyclopentyl-3-(2-(2-hydroxyethyl)-thioethyl)-1-propylxanthine, 95 % of theory, mp. = 160 - 161°C.

21. Saponification of nitriles

0.5 mMol of nitrile are suspended or dissolved at 10°C in 1 ml of 95 - 97% sulphuric acid. The mixture is stirred for 3.5 hours at ambient temperature, 5 ml of water and 5 ml of methylene chloride are added thereto, the organic phase is separated off and evaporated to dryness. The residue is purified by crystallisation or chromatography. For example, from

7-benzyl-3(3-cyano-propyl)-8-cyclopentyl-1-propylxanthine is obtained:

3-(3-(aminocarbonyl)-propyl)-7-benzyl-8-cyclopentyl-1-propylxanthine,
mp. = 180 - 181°C

22. Preparation of alkyl iodides from alcohols

3.1 mMol of 8-cyclopentyl-3-(2-hydroxyethyl)-1-propylxanthine, 3.1 mMol of tetraiodomethane and 3.1 mMol of triphenylphosphine are mixed in 15 ml of absolute toluene and refluxed for 2 hours. The mixture is diluted with toluene and the organic phase is washed with water and sodium thiosulphate solution. The crystals precipitated are filtered off, the organic phase of the filtrate is separated off, washed with water, dried and evaporated to dryness. The residue and the filtered off crystals are combined, stirred in acetonitrile for 16 hours at ambient temperature and the solid is isolated by filtration.

Yield: 1.0 g (77.5 % of theory) of 8-cyclopentyl-3-(2-iodoethyl)-1-propyl-xanthine in the form of colourless crystals, mp. = 223 - 226°C.

23 AUG 1996

23. Oxidation of thioethers into sulphones

0.55 g of neutral aluminium oxide are mixed with 0.11 ml of water and shaken until a fine powder is formed. 8 ml of methylene chloride, 1.0 g (1.65 mMol) of oxone [$= 2\text{KHSO}_5 \cdot \text{KHSO}_4 \cdot \text{K}_2\text{HSO}_4$] and a solution of 0.2 g (0.55 mMol) of 8-cyclopentyl-3-(2-(2-hydroxyethyl)-thioethyl)-1-propylxanthine in 4 ml of absolute methylene chloride are added successively and the mixture is refluxed for 2 hours with stirring. After cooling, the solids are filtered off, washed thoroughly with methylene chloride and the combined filtrates are evaporated to dryness. The residue is purified by chromatography on silica gel.

0.2 g (91.3 % of theory) of 8-cyclopentyl-3-(2-(2-hydroxyethyl)-sulphonylethyl)-1-propyl-xanthine is obtained in the form of colourless crystals mp. 213 - 214°C.

24. Synthesis of 8-cyclopentyl-7-benzyl-3-p-methoxy-xanthine

50 g (0.20 mol) of 6-amino-1-p-methoxybenzyl-uracil are added with 17.5 g of NaHCO_3 (0.21 mol) of 200 ml of methanol and at 5°C 11 ml of bromine are slowly added dropwise (vigorous foaming). Then the mixture is stirred for 2 hours in an ice bath. It is suction filtered and washed twice with 150 ml of methanol.

Yield: 54.3 g of light yellow crystals (82.2 % of theory)

~~6-amino~~-5-bromo-1-p-methoxybenzyl-uracil

TLC: 95:5 CH_2Cl_2 : CH_3OH

mp: 245°C (Decomp.)

121.1 g (0.37 mol) of 6-amino-5-bromo-1-p-methoxybenzyl-

23 AUG 1996

- 55 -

uracil are mixed with 396.5 g of benzylamine (3.7 mol) and stirred for 2 hours at 80°C. The mixture is cooled, extracted with 1000 ml of ethanol, cooled and suction filtered. It is then washed with cold ethanol.

Yield: 110.0 g of white crystals (83.6 % of theory)
5-amino-5-benzyl-amino-1-p-methoxybenzyl-uracil
TLC: 90:10 CH₂Cl₂:CH₃OH
mp: 230°-231°C

110.0 g (0.31 mol) of 5-amino-5-benzyl-amino-1-p-methoxybenzyl-uracil are placed with 52.8 g of 4-dimethylamino-pyridine (0.43 mol) in 1,650 ml of DMF and at 5°C a solution of 66.0 g of cyclopentancarboxylic acid chloride (0.50 mol) and 165 ml of DMF is added dropwise. The mixture is then stirred at 5 - 25°C for 3 days. It is evaporated down in vacuo, the residue is boiled twice with 700 ml of ethanol, then cooled and suction filtered.

Yield: 113.0 g of white crystals (81.3 % of theory)
6-cyclopentyl-carbonylamino-5-benzylamino-1-p-methoxybenzyluracil
TLC: 95:5 CH₂Cl₂:CH₃OH

113.0 g (0.25 mol) of 6-cyclopentyl-carbonylamino-5-benzylamino-1-p-methoxybenzyluracil are combined with 1,300 ml of H₂O and 650 ml of ethanol, 83.3 g of Ca(OH)₂ (1.1 mol) and 330 ml of 50% NaOH are added and the resulting mixture is stirred at 100°C for 20 hours. The mixture is evaporated down in vacuo (only the ethanol is distilled off!). The aqueous residue is cooled adjusted to pH 2 with conc. HCl, with ice cooling, and suction filtered.

Yield: 93.0 g of beige crystals (86.4 % of theory)
7-benzyl-8-cyclopentyl-3-p-methoxybenzyl-xanthine


23 AUG 1996

- 56 -

TLC: 90:10 CH_2Cl_2 : CH_3OH

mp: 172°C

Analogously to the methods described hereinbefore, the compounds of general formula I listed in the Table were prepared.





R_1 = n-propyl, R_3 = cyclopentyl, R_4 = hydrogen

23 AUG 1996

- 57 -

Example
No. R_2

MP. °C

1	$\text{CH}_2\text{CH}_2\text{CH}_2\text{CN}$	>300
2	$\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CN}$	160
3	$\text{CH}_2\text{CH}_2\text{OCH}_3$	185
4	$\text{CH}_2\text{CH}_2\text{CH}_2\text{OCH}_3$	174 - 175
5	$\text{CH}_2\text{CH}_2\text{OH}$	216
6	$\text{CH}_2\text{CH}_2\text{CH}_2\text{OH}$	213 - 215
7	$\text{CH}_2\text{CH}_2\text{OCOCH}_3$	149
8	$\text{CH}_2\text{CH}_2\text{CH}_2\text{OCOCH}_3$	157 - 159
9	$\text{CH}_2\text{CH}_2\text{COOH}$	265 - 267
10	$\text{CH}_2\text{CH}_2\text{COOCH}_3$	201 - 203
11	$\text{CH}_2\text{CH}_2\text{CONH}_2$	289 - 291
12	$\text{CH}_2\text{CH}_2\text{CONHCH}_3$	297 - 298
13	$\text{CH}_2-\text{CH}_2\text{CONHCH}_2$ 	221 - 233
14	$\text{CH}_2\text{CH}_2\text{CO}-\text{N}$ 	169 - 171
15	$\text{CH}_2\text{CH}_2\text{CH}(\text{OH})\text{CH}_3$	198 - 199
16	$\text{CH}_2\text{CH}_2\text{COCH}_3$	223 - 224
17	$\text{CH}_2\text{CH}=\text{NOH}$	247

23 AUG 1996

- 58 -

Example
No. R_2

MP. °C




Example No.	R_2	MP. °C
18	$\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{NH}_2$	159 - 161
19	$\text{CH}_2\text{CH}_2\text{CH}_2 - \text{N} \begin{array}{c} \diagup \quad \diagdown \\ \diagdown \quad \diagup \end{array} \text{O}$	176 - 178
20	$\text{CH}_2\text{CH}_2\text{CH}_2 - \text{N} \begin{array}{c} \diagup \quad \diagdown \\ \diagdown \quad \diagup \end{array}$	152 - 159
21	$\text{CH}_2\text{CH}_2 - \text{C}_6\text{H}_5$	215 - 216
22	$\text{CH}_2\text{CH}_2 - \text{C}_6\text{H}_{11}$	188 - 189
23	$\text{CH}_2\text{CH}_2\text{CH}_2 - \text{C}_6\text{H}_5$	153
24	$\text{CH}_2\text{CH}_2 - \text{C}_6\text{H}_4\text{OH}$	270 - 272
25	$\text{CH}_2\text{CH}_2\text{CH}_2 - \text{C}_6\text{H}_4\text{OH}$	239 - 241
26	$\text{CH}_2\text{CH}_2 - \text{C}_6\text{H}_4\text{OCH}_3$	208
27	$\text{CH}_2\text{CH}_2\text{CH}_2 - \text{C}_6\text{H}_4\text{OCH}_3$	153 - 154

23 AUG 1996

- 59 -

Example
No.R₂

MP. °C









28	CH_2CH_2 -  - OCOCH_3	232
29	$\text{CH}_2\text{CH}_2\text{CH}_2$ -  - OCOCH_3	181 - 183
30	$\text{CH}_2\text{CH}_2\text{CH}_2$ -  - OCH_2COOH	190 - 192
31	$\text{CH}_2\text{CH}_2\text{CH}_2$ -  - OCH_2COOEt	141 - 143
32	$\text{CH}_2\text{CH}_2\text{CH}_2$ -  - $\text{OCH}_2\text{CONH}_2$	224 - 226
33	$\text{CH}_2\text{CH}_2\text{CH}_2$ -  - $\text{OCH}_2\text{CH}_2\text{OAc}$	139 - 140
34	$\text{CH}_2\text{CH}_2\text{CH}_2\text{OCH}_3$	R ₁ =H 257 - 258
35	$\text{CH}_2\text{CH}_2\text{CH}_2$ -  - OCH_3	292 - 293 R ₁ =H
36	$\text{CH}_2\text{CH}_2\text{CH}_2\text{OCH}_3$	R ₁ =H 137 - 138 R ₇ =CH ₂ Ph
37	CH_2CH_2 -  -Cl	298 - 299 R ₁ =H

23 AUG 1996

- 60 -

Example
No. R_2


MP. °C

Example No.	R_2	R_1	MP. °C
38	$\text{CH}_2\text{CH}_2\text{OCH}_3$	$R_1=\text{H}$	293 - 294
39	CH_2CH_2 -  - OCH_3	$R_1=\text{H}$	256 - 258
40	CH_2 -  - OCH_3	$R_1=\text{H}$	311
41	CH_2 - 	$R_1=\text{H}$	>350
42	CH_2 - 		265 - 267
43	CH_2 - 		322
44	CH_2 - 		259 - 260
45	CH_2 - 		168-169
46	$(\text{CH}_2)_2-\text{S}-\text{Et}$		144 - 145
47	$-(\text{CH}_2)_2-\text{S}-(\text{CH}_2)_2-\text{OH}$		160 - 161
48	$\text{CH}_2\text{CH}_2\text{CH}_2$ -  - $\text{OCH}_2\text{CH}_2\text{O}$		168 - 169
49			162 - 163

 $R_1=\text{H}$


293 - 294

39

 $R_1=\text{H}$


256 - 258

40

 $R_1=\text{H}$

311

41

 $R_1=\text{H}$


>350

42




265 - 267

43




322

44




259 - 260

45




168-169

46




144 - 145

47



160 - 161

48



168 - 169

49

162 - 163

23 AUG 1996


- 61 -

Example

 R_2


MP. °C

No.




50

191 - 193




51

179 - 181




52

187 - 189




53

167 - 168




54

171 - 172




55

162 - 163




56

141 - 142




57

231 - 232



58

255 - 256




23 AUG 1996

- 62 -

Example
No. R_2


MP. °C

59




201 - 201

60




264 - 265

61




224-226

62




195 - 196

63



168 - 196

64



231

65




235 - 236

66




310 - 311

67



196 - 197

68



246 - 248

23 AUG 1996

- 63 -

Example
No. R_2

MP. °C


69	$\text{CH}_2\text{CH}_2\text{---}\langle\text{benzene ring}\rangle\text{---OCH}_2\text{---CON(CH}_3\text{)}_2$	160
70	$\text{CH}_2\text{CH}_2\text{SO}_2\text{CH}_2\text{CH}_2\text{OH}$	213 - 214
71	$\text{CH}_2\text{CH}_2\text{---}\langle\text{benzene ring}\rangle\text{---CONH}_2$	265 - 266
72	$\text{CH}_2\text{CH}_2\text{---N}\langle\text{pyrrolidine ring}\rangle\text{C(=O)---}$	188
73	$\text{CH}_2\text{CH}_2\text{CH}_2\text{---N}\langle\text{piperidine ring}\rangle\text{---OH}$	163 - 164
74	$\text{CH}_2\text{CH(OH)CH}_2\text{OH}$	225 - 226
75	$\text{CH}_2\text{CH}_2\text{---}\langle\text{benzene ring}\rangle\text{---CH}_2\text{NHSO}_2\text{Me}$	210
76	$\text{CH}_2\text{CH}_2\text{---}\langle\text{benzene ring}\rangle\text{---C(=O)N}\langle\text{morpholine ring}\rangle$	214 - 215°C
77	$\text{CH}_2\text{CH}_2\text{CH}_2\text{---N}\langle\text{piperazine ring}\rangle\text{N---COCH}_3$	169 - 170
78	$\text{CH}_2\text{CH}_2\text{CH}_2\text{---N}\langle\text{piperazine ring}\rangle\text{N---CH}_3$	162 - 163

REPLACEMENT SHEET
23 AUG 1996
MP. °C

Example
No.

R₂

79	<chem>CCCCN1CCNCC1</chem>	253 - 254
80	<chem>CCCCN1CCCCC1C(=O)C</chem>	136 - 137
81	<chem>CCCCN1CCCCC1S(=O)(=O)C</chem>	216 - 217
82	<chem>CCCCN1CCCCC1</chem>	146 - 147
83	<chem>CCCCN1CCCC1</chem>	218 - 220
84	<chem>(R)CC(C)C(O)CC</chem>	198 - 199
85	<chem>CCc1ccc(S(=O)(=O)N)cc1</chem>	307 - 308
86	<chem>CCc1ccc(S(=O)(=O)NC)cc1</chem>	225 - 226
87	<chem>CCc1ccc(S(=O)(=O)N(C)C)cc1</chem>	190 - 191



Example
No.

R₂

MP: °C

88 CH2CH2NHCOCH3 268 - 269

89 CH2CH2OCH2CH2N1CCN(S(=O)(=O)C)CC1 160

90 CH2CH2NHCOc1cccnc1 254 - 255

91 CH2CH2NHCON1CCCCC1 267 - 268

Me = Methyl

Et = Ethyl

Ph = Phenyl

23 AUG 1996

The compounds of general formula I may be used on their own or in conjunction with other active substances according to the invention, possibly combined with other pharmacologically active substances. Suitable forms include, for example, tablets, capsules, suppositories, solutions, syrups, emulsions, aerosols or dispersible powders. Tablets may be produced, for example, by mixing the active substance or substances with known excipients, e.g. inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for obtaining delayed release, such as carboxymethylcellulose, cellulose acetate phthalate or polyvinylacetate. The tablets may also consist of several layers.

Coated tablets may be produced analogously by coating cores made in the same way as the tablets with substances conventionally used for tablet coatings, e.g. collidone or shellac, gum arabic, talc, titanium dioxide or sugar. In order to obtain delayed release or avoid incompatibilities, the core may also consist of several layers. Similarly, the tablet coating may consist of several layers to achieve delayed release, whilst the excipients mentioned for the tablets may be used.

Syrups containing the active substances or combinations of active substances according to the invention may additionally contain a sweetener such as saccharin, cyclamate, glycerol or sugar as well as a flavour enhancer, e.g. a flavouring such as vanillin or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethylcellulose, wetting agents, e.g. condensation products of fatty alcohols with ethylene oxide or preservatives such as p-hydroxybenzoates.

23 AUG 1996

- 67 -

hydroxybenzoates.

Injectable solutions are produced in the usual way, e.g. by adding preservatives such as p-hydroxybenzoates or stabilisers such as alkali metal salts of ethylene diamine tetraacetic acid, and are then transferred into injection vials or ampoules.

Capsules containing one or more active substances or combinations of active substances may be prepared for example by mixing the active substances with inert carriers such as lactose or sorbitol and encapsulating them in gelatine capsules.

Suitable suppositories may be produced for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or derivatives thereof.

A therapeutically effective daily dose is between 1 and 800 mg, preferably 10 - 300 mg per adult.

The following Examples illustrate the present invention without restricting their scope:

Examples of pharmaceutical formulations

A)	<u>Tablets</u>	<u>per tablet</u>
	Active substance	100 mg
	Lactose	140 mg
	Corn starch	240 mg
	Polyvinylpyrrolidone	15 mg
	Magnesium stearate	5 mg
		500 mg

The finely ground active substance, lactose and some of the corn starch are mixed together. The mixture is

23 AUG 1996

- 68 -

screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, moist-granulated and dried. The granules, the remaining corn starch and the magnesium stearate are screened and mixed together. The mixture is compressed to form tablets of a suitable shape and size.

B) <u>Tablets</u>	<u>per tablet</u>
Active substance	80 mg
Corn starch	190 mg
Lactose	55 mg
Microcrystalline cellulose	35 mg
Polyvinylpyrrolidone	15 mg
Sodium-carboxymethylstarch	23 mg
Magnesium stearate	<u>2 mg</u>
	400 mg

The finely ground active substance, some of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and processed with the remaining corn starch and water to form granules which are dried and screened. The sodium carboxymethyl starch and the magnesium stearate are added, mixed together and the mixture is compressed to form tablets of a suitable size.



- 69 -


Claims

THIS SHEET HAS BEEN
REPLACED

REPLACEMENT SHEET

23 AUG 1996

1) New compounds of general formula



wherein R_1 cannot simultaneously represent the same as R_2 , and the definitions are as follows:

R_1 denotes hydrogen, C_1 - C_6 -alkyl, or allyl, C_3 - C_6 -alkenyl, C_3 - C_6 -alkynyl;

R_2 denotes hydrogen, a C_1 - C_8 -alkyl-, C_2 - C_8 -alkenyl- or C_2 - C_8 -alkynyl- group which is substituted by -CN, $-CH_2NR_6R_7$, OH (multiple substitution also being possible), $-OR_8$, $-NR_6R_7$, $-NHCOR_8$, $-NHCONR_6R_7$, halogen, $-OCOR_8$, $-OCH_2COOH$, $-OCH_2COOR_8$, $-SO_2R_5$, $-S-R_5$, $-NHCONH$ phenyl, $-OCH_2-CONR_6R_7$, $-OCH_2CH_2OH$, $-SO_2-CH_2-CH_2-O-COR_8$, $-OCH_2-CH_2-NR_6R_7$, $-SO_2-CH_2-CH_2-OH$, $-CONHSO_2R_8$, $-CH_2CONHSO_2R_8$, $-OCH_2CH_2OR_8$, $-COOH$, $-COOR_8$, $-CONR_6R_7$, $-CHO$, $-SR_8$, $-SOR_8$, $-SO_2R_8$, $-SO_3H$, $-SO_2NR_6R_7$, $-OCH_2-CH_2OCOR_8$, $-CH=NOH$, $-CH=NOR_8$, $-COR_9$, $-CH(OH)R_9$, $-CH(OR_8)_2$, $-CH=CH-R_{10}$, ONR_6R_7 ,

This Sheet Has Been Replaced








THIS SHEET HAS BEEN
REPLACED

REPLACEMENT SHEET

23 AUG 1996

- 70 -



or by 1,3-dioxolane or 1,3-dioxane which is optionally mono- or polysubstituted, preferably mono- substituted, by methyl;

R_2 denotes phenyl- C_1 - C_6 -alkylene, preferably phenyl- C_1 - C_4 -alkylene, phenyl- C_2 - C_6 -alkenylene or phenyl- C_2 - C_6 -alkynylene, in which the phenyl ring is optionally substituted, either directly or via a C_{1-4} -alkylene group, with one or more, preferably one, of the following groups,

- C_1 - C_3 -alkyl, -CN, - $\text{CH}_2\text{NR}_6\text{R}_7$, - NO_2 ,
- OH, - OR_8 , - $\text{CH}_2\text{-NH-SO}_2\text{-R}_8$, - NHCOR_8 ,
- $\text{NHCONR}_6\text{R}_7$, halogen, - OCOR_8 , - OCH_2COOH ,
- $\text{OCH}_2\text{COOR}_8$, - CH_2OCOR_8 , - SO_2R_5 ,
- $\text{OCH}_2\text{-CONR}_6\text{R}_7$, - $\text{OCH}_2\text{CH}_2\text{OH}$,
- $\text{OCH}_2\text{-CH}_2\text{-NR}_6\text{R}_7$, - $\text{CONHSO}_2\text{R}_8$,
- $\text{OCH}_2\text{CH}_2\text{OR}_8$, -COOH, - COOR_8 , - CF_3 ,
- cyclopropyl, - CONR_6R_7 , - CH_2OH ,
- CH_2OR_8 , -CHO, - SR_8 , - SOR_8 , - SO_2R_8 ,
- SO_3H , - $\text{SO}_2\text{NR}_6\text{R}_7$, - $\text{OCH}_2\text{-CH}_2\text{OCOR}_8$,
- CH=NOH , - CH=NOR_8 , - COR_9 , - CH(OH)R_9 ,
- $\text{CH(OR}_8)_2$, - NHCOOR_8 , - $\text{CH}_2\text{CONHSO}_2\text{R}_8$,
- CH=CH-R_{10} , - OCONR_6R_7 ,
- $\text{CH}_2\text{-O-CONR}_6\text{R}_7$,
- $\text{CH}_2\text{-CH}_2\text{-O-CONR}_6\text{R}_7$,

This Sheet Has Been Replaced








THIS SHEET HAS BEEN
REPLACED

REPLACEMENT SHEET

23 AUG 1996

- 71 -



or by 1,3-dioxolane or 1,3-dioxane which is optionally mono- or polysubstituted, preferably monosubstituted, by methyl;

R_2 denotes C_3 - C_7 -cycloalkyl- C_1 - C_6 -alkylene-,
 C_3 - C_7 -cycloalkyl- C_2 - C_6 -alkenylene-,
 C_3 - C_7 -cycloalkyl- C_2 - C_6 -alkynylene-, in which the
cycloalkyl group may optionally be substituted,
either directly or via a C_{1-4} -alkylene group, by
-CN, $-\text{CH}_2\text{NR}_6\text{R}_7$, =O, -OH, $-\text{OR}_8$, $-\text{NR}_6\text{R}_7$,
 $-\text{NHCOR}_8$, $-\text{NHCONR}_6\text{R}_7$, halogen, $-\text{OCOR}_8$,
 $-\text{OCH}_2\text{COOH}$, $-\text{OCH}_2\text{COOR}_8$, $-\text{CH}_2\text{OCOR}_8$,
 $-\text{SO}_2\text{R}_5$, $-\text{OCH}_2-\text{CONR}_6\text{R}_7$,
 $-\text{OCH}_2\text{CH}_2\text{OH}$, $-\text{OCH}_2-\text{CH}_2-\text{NR}_6\text{R}_7$,
 $-\text{OCH}_2\text{CH}_2\text{OR}_8$, -COOH, $-\text{COOR}_8$,
 $-\text{CONR}_6\text{R}_7$, $-\text{CH}_2\text{OH}$, $-\text{CH}_2\text{OR}_8$, -CHO,
-SR₈, -SOR₈, -SO₂R₈, -SO₃H,
 $-\text{SO}_2\text{NR}_6\text{R}_7$, $-\text{OCH}_2-\text{CH}_2\text{OCOR}_8$, -CH=NOH,
-CH=NOR₈, -COR₉, -CH(OH)R₉,
 $-\text{CONHSO}_2\text{R}_8$, $-\text{CH}(\text{OR}_8)_2$, $-\text{NHCOOR}_8$,
 $-\text{CH}=\text{CH}-\text{R}_{10}$, $-\text{OCONR}_6\text{R}_7$, $-\text{CH}_2-\text{O}-\text{CONR}_6\text{R}_7$,
 $-\text{CH}_2-\text{CH}_2-\text{O}-\text{CONR}_6\text{R}_7$,

This Sheet Has Been Replaced








THIS SHEET HAS BEEN
REPLACED

REPLACEMENT SHEET

23 AUG 1996


- 72 -



or by 1,3-dioxolane or 1,3-dioxane which is optionally mono- or polysubstituted, preferably monosubstituted, by methyl;

R_2 denotes a group of the formula

A-C₁-C₆-alkylene-, A-C₂-C₆-alkenylene, A-C₂-C₆-alkynylene, A-CONH-C₁-C₆-alkylene-, A-CONH-C₂-C₆-alkenylene- or A-CONH-C₂-C₆-alkynylene-, A-NH-CO-C₁-C₆-alkylene, A-NH-CO-C₂-C₆-alkenylene, A-NH-CO-C₂-C₆-alkynylene, wherein A is a C- or N-linked 5- or 6-membered heterocyclic ring which contains nitrogen, oxygen or sulphur as heteroatoms and may optionally be mono- or polysubstituted, preferably monosubstituted, by C₁-C₄-alkyl, halogen, -OR₈, -CN, -NO₂, -NH₂, -CH₂NR₆R₇, -OH, =O, a ketal, -COOH, -SO₃H, -COOR₈, -CONR₆R₇, -COR₉, -SO₂-R₈, -CONR₆R₇ or



R_3 denotes C₃-C₇-cycloalkyl, preferably cyclopentyl, optionally substituted by =O, -OH, -OR₈, OCOR₈, or

R_3 denotes phenyl, which is optionally substituted by -OH, halogen, -OR₈, C₁-C₄-alkyl, preferably -CH₃,

This Sheet Has Been Replaced





THIS SHEET HAS BEEN
REPLACED

REPLACEMENT SHEET

23 AUG 1996

- 73 -

$-\text{NH}_2$, $-\text{COOH}$, $-\text{SO}_3\text{H}$, $-\text{COOR}_8$, $-\text{OCH}_2\text{COOR}_8$, $-\text{CN}$, or
 $-\text{OCH}_2\text{CONR}_6\text{R}_7$, or




R_3 denotes a norbornane-, norbornene-, a C_3 - C_6 -
dicycloalkylmethyl, preferably dicyclopropylmethyl,
adamantane- or noradamantane- group;

R_3 denotes $-\text{CH}=\text{CH}$ -phenyl, wherein the phenyl ring is
mono- or polysubstituted by methoxy, hydroxy or
halogen;


R_3 denotes a [3.3.0]-bicyclooctane, preferably a
[3.3.0]-bicyclooctan-2-yl;

R_3 denotes a C-linked piperidine or furan;

R_4 denotes hydrogen, methyl or benzyl, in which the
benzyl group may be substituted by 1-3 methoxy
groups;



privaloyloxymethyl or



R_5 denotes C_1 - C_4 -alkyl, optionally substituted by OH,
 OCOR_8 , NH_2 , NR_6R_7 or NHCOR_8 , and R_5 preferably
represents $-\text{CH}_2-\text{CH}_2-\text{OH}$, $-\text{CH}_2\text{CH}_2\text{OCOR}_8$,
 $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{OH}$; $-\text{CH}_2-\text{CH}_2\text{CH}_2\text{OCOR}_8$;

R_6 denotes hydrogen, an optionally substituted C_3 - C_6 -

This Sheet Has Been Replaced





THIS SHEET HAS BEEN
REPLACED

REPLACEMENT SHEET

23 AUG 1996

- 74 -

cycloalkyl group; a branched or unbranched alkyl-, alkenyl- or alkynyl group having up to 10 carbon atoms, which may optionally be substituted by hydroxy, phenyl, substituted phenyl, amino, substituted amino, C_1 to C_8 , preferably C_1 to C_4 -alkoxy, or it denotes $-(CH_2)_m-NHCOOR_8$ wherein $m = 1, 2, 3$ or 4 ;

R_7 denotes hydrogen, an optionally substituted C_{3-6} -cycloalkyl group, a branched or unbranched alkyl, alkenyl or alkynyl group having up to 10 carbon atoms, which may optionally be substituted by hydroxy, phenyl, substituted phenyl, amino, substituted amino, C_1 to C_8 -alkoxy, or it denotes $-(CH_2)_m-NHCOOR_8$ wherein $m = 1, 2, 3$ or 4 ;
or

R_6 and R_7 together with the nitrogen atom form a saturated or unsaturated 5- or 6-membered ring which may contain as heteroatoms nitrogen, oxygen or sulphur, whilst the heterocyclic ring may be substituted by a branched or unbranched C_{1-4} -alkyl group, preferably methyl, or may carry one of the following groups:

$-(CH_2)_n-NH_2$, $=O$, a ketal,
 $-(CH_2)_nNH-C_1-C_4$ -alkyl,
 $-(CH_2)_n-N(C_1-C_8\text{-alkyl})_2$,
 $-(CH_2)_n-NHCOOR_8$, ($n = 2, 3, 4$), halogen,
 $-OR_8$, $-CN$, $-NO_2$, $-NH_2$, $-CH_2NR_6R_7$,
 $-OH$, $-COOH$, $-SO_3H$, $-COOR_8$, $-CONR_6R_7$, $-SO_2-R_8$,

R_8 denotes hydrogen, C_1-C_4 -alkyl, C_2-C_4 -alkenyl, C_2-C_4 -alkynyl, a benzyl- or phenyl-group, which is optionally mono- or polysubstituted by OCH_3 ;

R_9 denotes C_1-C_4 -alkyl, C_2-C_4 -alkenyl, C_2-C_4 -alkynyl, optionally substituted phenyl, optionally

This Sheet Has Been Replaced





THIS SHEET HAS BEEN
REPLACED

REPLACEMENT SHEET

23 AUG 1996

- 75 -


substituted benzyl, C_3 - C_6 -cycloalkyl,

R_{10} denotes $-COOR_8$, $-CH_2OR_8$, $-CONR_6R_7$, hydrogen, C_1 - C_3 -alkyl, optionally substituted phenyl, $-CH_2NR_6R_7$;

R_{11} denotes hydrogen, phenyl, substituted phenyl, $-CH_3$;

optionally in the form of the racemates, the enantiomers, the diastereomers and the mixtures thereof and optionally in the form of the pharmacologically acceptable salts thereof.

2) New xanthine derivatives of general formula



according to claim 1, wherein

R_1 denotes methyl, ethyl, n-butyl, allyl, or n-propyl;

R_2 denotes a C_2 -alkyl or an unbranched C_3 -alkyl group which is substituted by

$-CN$, $-CH_2NR_6R_7$, $-OH$, $-OR_8$, $-NR_6R_7$,
 $-NHCOR_8$, $-NHCONR_6H$, halogen, $-OCOR_8$,
 $-OCH_2COOH$, $-OCH_2COOR_8$, $-SR_5$, $-SO_2R_5$,
 $-OCH_2-CONR_6R_7$, $-OCH_2CH_2OH$,
 $OCH_2-CH_2-NR_6R_7$, $CONHSO_2R_8$,
 $-CH_2CONHSO_2R_8$,
 $-OCH_2CH_2OR_8$, $-COOH$, $-COOR_8$,
 $-CONR_6R_7$, $-CHO$, $-SR_8$, $-SO_2R_8$,
 $-SO_3H$, $-SO_2NR_6R_7$, $-OCH_2-CH_2OCOR_8$,
 $=NOH$, $=NOR_8$, $-COR_9$, $-CH(OH)R_9$,
 $-CH=CH-R_{10}$, $OCONR_6H$

This Sheet Has Been Replaced








- 76 -

REPLACEMENT SHEET

23 AUG 1996

THIS SHEET HAS BEEN
REPLACED



or by 1,3-dioxolane or 1,3-dioxane optionally mono- or polysubstituted by methyl;

R_2 denotes a benzyl- or phenethyl- or phenylpropyl group which is substituted by one of the following groups

-C₁-C₃-alkyl, -CN, -CH₂NR₆R₇,
-NO₂, -OH, -OR₈, -NHCOR₈,
-NHCONR₆R₇, halogen, -OCOR₈, -OCH₂COOH,
-OCH₂COOR₈, -CH₂OCOR₈, -SO₂R₅,
-OCH₂-CONR₆R₇, -OCH₂CH₂OH,
-CH₂CONHSO₂R₈, -OCH₂-CH₂-NR₆R₇,
-CONHSO₂R₈, -OCH₂CH₂OR₈, -COOH,
-COOR₈, -CF₃,
cyclopropyl, -CONR₆R₇, -CH₂OH,
-CH₂OR₈, -CHO, -SR₈, -SOR₈, -SO₂R₈,
-SO₃H, -SO₂NR₆R₇, -OCH₂-CH₂OCOR₈,
-CH=NOH, CH=NOR₈, -COR₉, -CH(OH)R₉,
-CH(OR₈)₂, -NHCOOR₈,
-CH=CH-R₁₀, -OCONR₆R₇,
-CH₂-O-CONR₆R₇,
-CH₂-CH₂-O-CONR₆R₇,

This Sheet Has Been Replaced








- 77

THIS SHEET HAS BEEN
REPLACED

REPLACEMENT SHEET

23 AUG 1996



or by 1,3-dioxolane or 1,3-dioxane optionally mono- or polysubstituted by methyl, and if R_2 represents OR_8 , particularly OCH_3 , the phenyl group may be trisubstituted;

R_2 denotes a C_3 -, C_4 -, C_5 - or C_6 -cycloalkyl- C_2 - C_3 -alkylene group, wherein the cycloalkyl group is optionally monosubstituted by $-\text{CN}$, $-\text{CH}_2\text{NR}_6\text{R}_7$, $=\text{O}$, $-\text{OH}$, $-\text{OR}_8$, $-\text{NR}_6\text{R}_7$, $-\text{NHCOR}_8$, $-\text{NHCONR}_6\text{R}_7$, halogen, $-\text{OCOR}_8$, $-\text{OCH}_2\text{COOH}$, $-\text{OCH}_2\text{COOR}_8$, $-\text{CH}_2\text{OCOR}_8$, $-\text{SO}_2\text{R}_5$, $-\text{OCH}_2-\text{CONR}_6\text{R}_7$, $-\text{OCH}_2\text{CH}_2\text{OH}$, $-\text{OCH}_2-\text{CH}_2-\text{NR}_6\text{R}_7$, $-\text{OCH}_2\text{CH}_2\text{OR}_8$, $-\text{COOH}$, $-\text{COOR}_8$, $-\text{CONR}_6\text{R}_7$, $-\text{CH}_2\text{OH}$, $-\text{CH}_2\text{OR}_8$, $-\text{CHO}$, $-\text{SR}_8$, $-\text{SOR}_8$, $-\text{SO}_2\text{R}_8$, $-\text{SO}_3\text{H}$, $-\text{SO}_2\text{NR}_6\text{R}_7$, $-\text{OCH}_2-\text{CH}_2\text{OCOR}_8$, $-\text{CH}=\text{NOH}$, $-\text{CH}=\text{NOR}_8$, $-\text{COR}_9$, $-\text{CH}(\text{OH})\text{R}_9$, $-\text{CH}(\text{OR}_8)_2$, $-\text{NHCOOR}_8$, $-\text{CONHSO}_2\text{R}_8$, $-\text{CH}=\text{CH}-\text{R}_{10}$, $-\text{OCONR}_6\text{R}_7$, $-\text{CH}_2-\text{O}-\text{CONR}_6\text{R}_7$, $-\text{CH}_2-\text{CH}_2-\text{O}-\text{CONR}_6\text{R}_7$.

This Sheet Has Been Replaced








* C L M S *

- 78 -

REPLACEMENT SHEET




23 AUG 1996



THIS SHEET HAS BEEN REPLACED

or by 1,3-dioxolane or 1,3-dioxane optionally mono- or polysubstituted, preferably monosubstituted by methyl;


R_2 denotes a group of the formula



wherein A is a C- or N-linked 5- or 6-membered heterocyclic ring which contains nitrogen, oxygen or sulphur as heteroatoms and which may optionally be mono- or polysubstituted by C_{1-4} -alkyl, =O, OH, COR_9 , SO_2-R_8 , NH_2 , COOR_8 , CONR_6R_7 , or OR_8 ;

and R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} and R_{11} are as hereinbefore defined, optionally in the form of the racemates, the enantiomers, the diastereomers and the mixtures thereof and optionally the pharmacologically acceptable salts thereof.

3) New xanthine derivatives of general formula



Ia

This Sheet Has Been Replaced






- 79 -

REPLACEMENT SHEET

23 AUG 1996

wherein R_2 is as hereinbefore defined and R_3 is a group selected from the groups

THIS SHEET HAS BEEN REPLACED



optionally in the form of the racemates, the enantiomers, the diastereomers and the mixtures thereof and optionally the pharmacologically acceptable salts thereof.

- 4) New xanthine derivatives according to one of claims 1, 2 or 3, wherein R_2 denotes an unbranched C_2 - C_3 -alkyl group which is substituted by $-CN$, $-OH$, $-COOH$, $-COOR_8$, particularly $-COOCH_3$ or $-COOC_2H_5$, $-OCOCH_3$, $-OCOC_2H_5$, $-CONR_6R_7$, $=NOH$, $-NR_6R_7$ or a linked 5- or 6-membered nitrogen-containing heterocyclic ring, optionally substituted as hereinbefore defined.
- 5) New xanthine derivatives according to one of claims 1 to 4 wherein R_2 denotes A - C_1 - C_3 -alkylene-, A - $CONH$ - C_1 - C_3 -alkylene, A - NH - CO - C_1 - C_3 -alkylene, wherein A is a C- or N-linked 5- or 6-membered heterocyclic ring which contains nitrogen, oxygen or sulphur as heteroatoms and may optionally be mono- or polysubstituted, preferably monosubstituted, by C_1 - C_4 -alkyl, halogen, $-OR_8$, $-CN$, $-NO_2$, $-NH_2$, $-CH_2NR_6R_7$, $-OH$, $=O$, a ketal, $-COOH$, $-SO_3H$, $-COOR_8$, $-CONR_6R_7$,

This Sheet Has Been Replaced






- 80 -

$-\text{COR}_9$, $-\text{SO}_2-\text{R}_8$, $-\text{CONR}_6\text{R}_7$ or

REPLACEMENT SHEET







23 AUG 1996

THIS SHEET HAS BEEN
REPLACED



- 6) New xanthine derivatives of general formula I according to one of claims 1, 2, 3, 4 or 5, wherein

R_3 is a group selected from the following



and

R_2 denotes $\text{CH}_2\text{CH}_2\text{OH}$, $\text{CH}_2\text{CH}_2\text{OCOCH}_3$, $(\text{CH}_2)_3\text{OCOCH}_3$, $(\text{CH}_2)_3\text{OCH}_3$, $\text{CH}_2\text{CH}_2\text{COCH}_3$, $\text{CH}_2\text{CH}_2\text{CH}(\text{OH})\text{CH}_3$, $\text{CH}_2\text{CH}_2\text{COOCH}_3$, $\text{CH}_2\text{CH}_2\text{CONH}_2$, $(\text{CH}_2)_3\text{CONH}_2$, $\text{CH}_2\text{CH}=\text{NOH}$, $(\text{CH}_2)_3\text{CN}$, $\text{CH}_2\text{CH}_2\text{SCH}_2\text{CH}_3$, $\text{CH}_2\text{CH}_2\text{SCH}_2\text{CH}_2\text{OH}$, $\text{CH}_2\text{CH}_2\text{SO}_2\text{CH}_2\text{CH}_2\text{OH}$, $\text{CH}_2\text{CH}_2\text{SO}_2\text{CH}_2\text{CH}_2\text{OCOCH}_3$, $\text{A}-(\text{CH}_2)_2-$

or

$\text{A}-(\text{CH}_2)_3-$, $\text{A}-\text{CH}_2-\text{CH}_2$

wherein A is a C- or N-linked 5- or 6-membered heterocyclic ring which contains nitrogen, oxygen or sulphur as heteroatoms,

optionally in the form of the racemates, the enantiomers, the diastereomers and the mixtures thereof and optionally the pharmacologically acceptable salts thereof.

This Sheet Has Been Replaced






23 AUG 1996

THIS SHEET HAS BEEN
REPLACED


- 7) New xanthine derivatives of general formula I or Ia according to one of the preceding claims, characterised in that the group R_3 is an unsubstituted cyclopentyl group.

- 8) Process for preparing xanthines of general formula I



wherein the groups R_1 , R_2 , R_3 and R_4 are defined as in one of the preceding claims, characterised in that

- a) a compound of general formula



wherein

R'_2 corresponds to the definition of R_2 or R'_2 denotes a protecting group such as a benzyl- or methoxybenzyl group which is easily cleavable

is reacted with a compound of general formula $R_3\text{CHO}$, $R_3\text{COOH}$ or a reactive derivative thereof, whilst functional groups in R_3 must be protected if necessary, and is then cyclised to obtain the xanthine of general formula I wherein $R_4 = \text{H}$; or


- b) a compound of general formula

This Sheet Has Been Replaced





- 82 -



REPLACEMENT SHEET

23 AUG 1996


THIS SHEET HAS BEEN
REPLACED

wherein

R_1 and R'_2 are as hereinbefore defined is reacted with a compound of general formula $R_3\text{CHO}$ - wherein R_3 is as hereinbefore defined, whilst functional groups in R_3 must be protected if necessary - and is then cyclised with *N,N*-dimethylhydrazine to form the xanthine of general formula I wherein $R_4 = \text{H}$;

or

c) a compound of general formula



wherein

R_1 , R'_2 and R_3 are as hereinbefore defined, is cyclised to form a compound of general formula I,

and subsequently a compound prepared according to a, b or c is optionally further treated using partly known processes as follows:

if $R_1 = \text{H}$, $R_4 = \text{H}$ of formula V

This Sheet Has Been Replaced






- 83 -

REPLACEMENT SHEET

23 AUG 1996

THIS SHEET HAS BEEN
REPLACED




a protecting group is introduced into the 7-position (R_4),

then by N-alkylation $R_1 = H$ is converted into $R_1 =$ alkyl, alkenyl or alkynyl and

in order to prepare compounds of formula I wherein $R_4 = H$ the protecting group is cleaved,

if R'_2 does not yet have the desired meaning of R_2 , R'_2 is now converted into R_2 using methods known per se.

- 9) Process for preparing xanthines of general formula I



wherein

R_1 , R_2 and R_3 are defined as in one of the preceding claims, characterised in that, starting from a compound of general formula


This Sheet Has Been Replaced





REPLACEMENT SHEET

23 AUG 1996




THIS SHEET HAS BEEN
REPLACED

wherein

R_1 and R_3 are as hereinbefore defined, R_4 denotes a protecting group, particularly benzyl- and R'_2 denotes the group p-methoxybenzyl, dimethoxybenzyl or trimethoxybenzyl,

R'_2 is converted into $R_2 = H$ by acid-hydrolysis, retaining the protecting group R_4 ,

then by N-alkylation with R'_2-X a compound of general formula



wherein R_4 denotes a protecting group - particularly benzyl- and R_1 and R_3 are as hereinbefore defined and $R'_2 = R_2$ or a precursor thereof,

then the protecting group R_4 is cleaved by conventional methods and, if desired, R'_2 is converted into R_2 .

10) Intermediate compounds of general formula

This Sheet Has Been Replaced






REPLACEMENT SHEET

23 AUG 1996

THIS SHEET HAS BEEN
REPLACED



wherein

R_1 , R_2 and R_3 are defined as in one of the preceding claims and R_4 denotes a p-methoxybenzyl, 2,4-dimethoxybenzyl or 2,4,6,-trimethoxybenzyl group.

- 11) Use of a compound of general formula I or Ia according to claims 1 to 6 as a pharmaceutical composition.
- 12) Use of a compound of general formula I or Ia according to claims 1 to 6 as a pharmaceutical composition having an adenosine-antagonistic activity.
- 13) Pharmaceutical preparations containing as active substance one or more compounds of general formula I or the physiologically acceptable acid addition salts thereof combined with conventional excipients and/or carriers.
- 14) Process for preparing pharmaceutical preparations according to claim 13, characterised in that compounds of general formula I are admixed with conventional galenic excipients and/or carriers to produce conventional pharmaceutical formulations.
- 15) New xanthine derivatives of general formula I

This Sheet Has Been Replaced






- 86 -


REPLACEMENT SHEET

23 AUG 1996



THIS SHEET HAS BEEN
REPLACED

wherein R_3 denotes a group selected from the following




and

R_2 denotes a polar aliphatic group or a heterocyclic ring containing nitrogen, oxygen or sulphur as heteroatoms.

- 16) Use of a compound of general formula I according to claim 15 as a pharmaceutical composition having adenosine-antagonistic properties.

This Sheet Has Been Replaced



23 AUG 1996


**ASYMMETRICALLY SUBSTITUTED XANTHINES WITH ADENOSINE-
ANTAGONISTIC PROPERTIES**

Abstract


The present invention relates to new xanthine derivatives, processes for preparing them and their use in pharmaceutical compositions and as intermediate compounds.



Claims






1) Compounds of general formula



wherein R_1 cannot simultaneously represent the same as R_2 , and the definitions are as follows:

R_1 denotes hydrogen, C_1 - C_6 -alkyl, or allyl, C_3 - C_6 -alkenyl, C_3 - C_6 -alkynyl;

R_2 denotes a C_1 - C_8 -alkyl-, C_2 - C_8 -alkenyl- or C_2 - C_8 -alkynyl- group which is substituted by -CN, $-\text{CH}_2\text{NR}_6\text{R}_7$, OH (multiple substitution also being possible), $-\text{OR}_8$, $-\text{NR}_6\text{R}_7$, $-\text{NHCOR}_8$, $-\text{NHCONR}_6\text{R}_7$, halogen, $-\text{OCOR}_8$, $-\text{OCH}_2\text{COOH}$, $-\text{OCH}_2\text{COOR}_8$, $-\text{SO}_2\text{R}_5$, $-\text{S}-\text{R}_5$, $-\text{NHCONH-phenyl}$, $-\text{OCH}_2-\text{CONR}_6\text{R}_7$, $-\text{OCH}_2\text{CH}_2\text{OH}$, $-\text{SO}_2-\text{CH}_2-\text{CH}_2-\text{O}-\text{COR}_8$, $-\text{OCH}_2-\text{CH}_2-\text{NR}_6\text{R}_7$, $-\text{SO}_2-\text{CH}_2-\text{CH}_2-\text{OH}$, $-\text{CONHSO}_2\text{R}_8$, $-\text{CH}_2\text{CONHSO}_2\text{R}_8$, $-\text{OCH}_2\text{CH}_2\text{OR}_8$, $-\text{COOH}$, $-\text{COOR}_8$, $-\text{CONR}_6\text{R}_7$, $-\text{CHO}$, $-\text{SR}_8$, $-\text{SOR}_8$, $-\text{SO}_2\text{R}_8$, $-\text{SO}_3\text{H}$, $-\text{SO}_2\text{NR}_6\text{R}_7$, $-\text{OCH}_2-\text{CH}_2\text{OCOR}_8$, $-\text{CH}=\text{NOH}$, $-\text{CH}=\text{NOR}_8$, $-\text{COR}_9$, $-\text{CH}(\text{OH})\text{R}_9$, $-\text{CH}(\text{OR}_8)_2$, $-\text{CH}=\text{CH}-\text{R}_{10}$, OCONR_6R_7 ,








16 MAR 1999

or by 1,3-dioxolane or 1,3-dioxane which is optionally mono- or polysubstituted, preferably mono-substituted, by methyl;

R₂ denotes phenyl-ethyl or phenyl-propyl,

R₂ denotes phenyl-C₁-C₆-alkylene, preferably phenyl-C₁-C₄-alkylene, phenyl-C₂-C₆-alkenylene or phenyl-C₂-C₆-alkynylene, in which the phenyl ring is substituted, either directly or via a C₁₋₄-alkylene group, with one or more, preferably one, of the following groups, -C₁-C₃-alkyl, -CN, -CH₂NR₆R₇, -NO₂, -OH, -OR₈, -CH₂-NH-SO₂-R₈, -NHCOR₈, -NHCONR₆R₇, halogen, -OCOR₈, -OCH₂COOH, -OCH₂COOR₈, -CH₂OCOR₈, -SO₂R₅, -OCH₂-CONR₆R₇, -OCH₂CH₂OH, -OCH₂-CH₂-NR₆R₇, -CONHSO₂R₈, -OCH₂CH₂OR₈, -COOH, -COOR₈, -CF₃, cyclopropyl, -CONR₆R₇, -CH₂OH, -CH₂OR₈, -CHO, -SR₈, -SOR₈, -SO₂R₈, -SO₃H, -SO₂NR₆R₇, -OCH₂-CH₂OCOR₈, -CH=NOH, -CH=NOR₈, -COR₉, -CH(OH)R₉, -CH(OR₈)₂, -NHCOOR₈, -CH₂CONHSO₂R₈, -CH=CH-R₁₀, -OCONR₆R₇, -CH₂-O-CONR₆R₇, -CH₂-CH₂-O-CONR₆R₇,








16 MAR 1999

or by 1,3-dioxolane or 1,3-dioxane which is optionally mono- or polysubstituted by methyl;

R_2 denotes C_3 - C_7 -cycloalkyl- C_1 - C_6 -alkylene-,
 C_3 - C_7 -cycloalkyl- C_2 - C_6 -alkenylene-,
 C_3 - C_7 -cycloalkyl- C_2 - C_6 -alkynylene-, in which the
cycloalkyl group may optionally be substituted,
either directly or via a C_{1-4} -alkylene group, by
 $-CN$, $-CH_2NR_6R_7$, $=O$, $-OH$, $-OR_8$, $-NR_6R_7$,
 $-NHCOR_8$, $-NHCONR_6R_7$, halogen, $-OCOR_8$,
 $-OCH_2COOH$, $-OCH_2COOR_8$, $-CH_2OCOR_8$,
 $-SO_2R_5$, $-OCH_2-CONR_6R_7$,
 $-OCH_2CH_2OH$, $-OCH_2-CH_2-NR_6R_7$,
 $-OCH_2CH_2OR_8$, $-COOH$, $-COOR_8$,
 $-CONR_6R_7$, $-CH_2OH$, $-CH_2OR_8$, $-CHO$,
 $-SR_8$, $-SOR_8$, $-SO_2R_8$, $-SO_3H$,
 $-SO_2NR_6R_7$, $-OCH_2-CH_2OCOR_8$, $-CH=NOH$,
 $-CH=NOR_8$, $-COR_9$, $-CH(OH)R_9$,
 $-CONHSO_2R_8$, $-CH(OR_8)_2$, $-NHCOOR_8$,
 $-CH=CH-R_{10}$, $-OCONR_6R_7$, $-CH_2-O-CONR_6R_7$,
 $-CH_2-CH_2-O-CONR_6R_7$,



or by 1,3-dioxolane or 1,3-dioxane which is optionally mono- or polysubstituted by methyl;


R_2 denotes a group of formula

A - C_1 - C_6 -alkylene-, A - C_2 - C_6 -alkenylene, A - C_2 - C_6 -
alkynylene, A - $CONH$ - C_1 - C_6 -alkylene-, A - $CONH$ - C_2 - C_6 -



16 MAR 1999

alkenylene- or A-CONH-C₂-C₆-alkynylene-, A-NH-CO-C₁-C₆-alkylene, A-NH-CO-C₂-C₆-alkenylene, A-NH-CO-C₂-C₆-alkynylene, wherein A is a C- or N-linked 5- or 6-membered heterocyclic ring which contains nitrogen, oxygen or sulphur as heteroatoms and may optionally be mono- or polysubstituted by C₁-C₄-alkyl, halogen, -OR₈, -CN, -NO₂, -NH₂, -CH₂NR₆R₇, -OH, =O, a ketal, -COOH, -SO₃H, -COOR₈, -CONR₆R₇, -COR₉, -SO₂-R₈, -CONR₆R₇ or






- R₃ denotes C₃-C₇-cycloalkyl, preferably cyclopentyl, optionally substituted by =O, -OH, -OR₈, OCOR₈, or
- R₃ denotes phenyl, which is optionally substituted by -OH, halogen, -OR₈, C₁-C₄-alkyl, preferably -CH₃, -NH₂, -COOH, -SO₃H, -COOR₈, -OCH₂COOR₈, -CN, or -OCH₂CONR₆R₇, or
- R₃ denotes a norbornane-, norbornene-, a C₃-C₆-dicycloalkylmethyl, adamantane- or noradamantane-group;
- R₃ denotes -CH=CH-phenyl, wherein the phenyl ring is mono- or polysubstituted by methoxy, hydroxy or halogen;
- R₃ denotes a [3.3.0]-bicyclooctane, a [3.3.0]-bicyclooctan-2-yl;
- R₃ denotes a C-linked piperidine or furan;



16 MAR 1999

- R₄ denotes hydrogen, methyl or benzyl, in which the benzyl group may be substituted by 1-3 methoxy groups;



privaloyloxymethyl or
-CH₂-CH=CH₂;

- R₅ denotes C₁-C₄-alkyl, optionally substituted by OH, OCOR₈, NH₂, NR₆R₇, or NHCOR₈, and R₅ preferably represents -CH₂-CH₂-OH, -CH₂CH₂OCOR₈, -CH₂-CH₂-CH₂-OH; -CH₂-CH₂CH₂OCOR₈;
- R₆ denotes hydrogen, an optionally substituted C₃₋₆-cycloalkyl group, a branched or unbranched alkyl-, alkenyl- or alkynyl group having up to 10 carbon atoms, which may optionally be substituted by hydroxy, phenyl, substituted phenyl, amino, substituted amino, C₁ to C₈-, preferably C₁ to C₄-, alkoxy, or it denotes -(CH₂)_m-NHCOOR₈ wherein m = 1, 2, 3 or 4;
- R₇ denotes hydrogen, an optionally substituted C₃₋₆-cycloalkyl group, a branched or unbranched alkyl-, alkenyl or alkynyl group having up to 10 carbon atoms, which may optionally be substituted by hydroxy, phenyl, substituted phenyl, amino, substituted amino, C₁ to C₈-alkoxy, or it denotes -(CH₂)_m-NHCOOR₈ wherein m = 1, 2, 3 or 4;
or



REPLACEMENT SHEET

16 MAR 1999

- 74 -

R_6 and R_7 together with the nitrogen atom form a saturated or unsaturated 5- or 6-membered ring which may contain as heteroatoms nitrogen, oxygen or sulphur, whilst the heterocyclic ring may be substituted by a branched or unbranched C_{1-4} -alkyl group or may carry one of the following groups:

- $(CH_2)_n-NH_2$, $=O$, a ketal,
- $(CH_2)_nNH-C_1-C_4$ -alkyl,
- $(CH_2)_n-N(C_1-C_8$ -alkyl) $_2$,
- $(CH_2)_n-NHCOOR_8$, ($n = 2, 3, 4$), halogen,
- OR_8 , $-CN$, $-NO_2$, $-NH_2$, $-CH_2NR_6R_7$,
- $-OH$, $-COOH$, $-SO_3H$, $-COOR_8$, $-CONR_6R_7$, $-SO_2-R_8$,

R_8 denotes hydrogen, C_1-C_4 -alkyl, C_2-C_4 -alkenyl, C_2-C_4 -alkynyl, a benzyl- or phenyl-group, which is optionally mono- or polysubstituted by OCH_3 ;


R_9 denotes C_1-C_4 -alkyl, C_2-C_4 -alkenyl, C_2-C_4 -alkynyl, optionally substituted phenyl, optionally substituted benzyl, C_3-C_6 -cycloalkyl,

R_{10} denotes $-COOR_8$, $-CH_2OR_8$, $-CONR_6R_7$, hydrogen, C_1-C_3 -alkyl, optionally substituted phenyl, $-CH_2NR_6R_7$;

R_{11} denotes hydrogen, phenyl, substituted phenyl, $-CH_3$;

optionally in the form of racemates, enantiomers, diastereomers and mixtures thereof and optionally in the form of pharmacologically acceptable salts thereof.

2) Xanthine derivatives of general formula








16 MAR 1999

according to claim 1, wherein

R₁ denotes methyl, ethyl, n-butyl, allyl, ~~or n-propyl;~~

R₂ denotes a C₂-alkyl or an unbranched C₃-alkyl group which is substituted by

-CN, -CH₂NR₆R₇, -OH, -OR₈, -NR₆R₇,
-NHCOR₈, -NHCONR₆H, halogen, -OCOR₈,
-OCH₂COOH, -OCH₂COOR₈, -SR₅, -SO₂R₅,
-OCH₂-CONR₆R₇, -OCH₂CH₂OH,
OCH₂-CH₂-NR₆R₇, CONHSO₂R₈,
-CH₂CONHSO₂R₈,
-OCH₂CH₂OR₈, -COOH, -COOR₈,
-CONR₆R₇, -CHO, -SR₈, -SO₂R₈,
-SO₃H, -SO₂NR₆R₇, -OCH₂-CH₂OCOR₈,
=NOH, =NOR₈, -COR₉, -CH(OH)R₉,
-CH=CH-R₁₀, OCONR₆H



or by 1,3-dioxolane or 1,3-dioxane optionally mono- or polysubstituted by methyl;

R₂ denotes a benzyl- or phenethyl- or phenylpropyl group which is substituted by one of the following groups

-C₁-C₃-alkyl, -CN, -CH₂NR₆R₇,
-NO₂, -OH, -OR₈, -NHCOR₈,
-NHCONR₆R₇, halogen, -OCOR₈, -OCH₂COOH,
-OCH₂COOR₈, -CH₂OCOR₈, -SO₂R₅,
-OCH₂-CONR₆R₇, -OCH₂CH₂OH,
-CH₂CONHSO₂R₈, -OCH₂-CH₂-NR₆R₇,






- 76 -

REPLACEMENT SHEET

16 MAR 1999

-CONHSO₂R₈, -OCH₂CH₂OR₈, -COOH,
-COOR₈, -CF₃,
cyclopropyl, -CONR₆R₇, -CH₂OH,
-CH₂OR₈, -CHO, -SR₈, -SOR₈, -SO₂R₈,
-SO₃H, -SO₂NR₆R₇, -OCH₂-CH₂OCOR₈,
-CH=NOH, CH=NOR₈, -COR₉, -CH(OH)R₉,
-CH(OR₈)₂, -NHCOOR₈,
-CH=CH-R₁₀, -OCONR₆R₇,
-CH₂-O-CONR₆R₇,
-CH₂-CH₂-O-CONR₆R₇,









or by 1,3-dioxolane or 1,3-dioxane optionally mono- or polysubstituted by methyl, and if R₂ represents OR₈, particularly OCH₃, the phenyl group may be trisubstituted;

R₂ denotes a C₃-, C₄-, C₅- or C₆-cycloalkyl-C₂-C₃-alkylene group, wherein the cycloalkyl group is optionally monosubstituted by -CN, -CH₂NR₆R₇, =O, -OH, -OR₈, -NR₆R₇, -NHCOR₈, -NHCONR₆R₇, halogen, -OCOR₈, -OCH₂COOH, -OCH₂COOR₈, -CH₂OCOR₈, -SO₂R₅, -OCH₂-CONR₆R₇, -OCH₂CH₂OH, -OCH₂-CH₂-NR₆R₇, -OCH₂CH₂OR₈, -COOH, -COOR₈, -CONR₆R₇, -CH₂OH, -CH₂OR₈, -CHO, -SR₈, -SOR₈, -SO₂R₈, -SO₃H, -SO₂NR₆R₇, -OCH₂-CH₂OCOR₈, -CH=NOH, -CH=NOR₈, -COR₉, -CH(OH)R₉, -CH(OR₈)₂, -NHCOOR₈, -CONHSO₂R₈, -CH=CH-R₁₀, -OCONR₆R₇,




- 77 -



or

by 1,3-dioxolane or 1,3-dioxane optionally mono- or polysubstituted by methyl;


R_2 denotes a group of the formula




wherein A is a C-linked 5- or 6-membered heterocyclic ring which contains nitrogen, oxygen or sulphur as heteroatoms and which may optionally be mono- or polysubstituted by C_{1-4} -alkyl, =O, OH, COR_9 , SO_2-R_8 , NH_2 , COOR_8 , CONR_6R_7 , or OR_8 ;


and R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} and R_{11} are as hereinbefore defined, optionally in the form of racemates, enantiomers, diastereomers and mixtures thereof and optionally pharmacologically acceptable salts thereof.

3) Xanthine derivatives of general formula







wherein R_2 is as hereinbefore defined and R_3 is a group selected from the groups




optionally in the form of racemates, enantiomers, diastereomers and mixtures thereof and optionally pharmacologically acceptable salts thereof.

- 4) Xanthine derivatives according to any one of claims 1, 2 or 3, wherein R_2 denotes an unbranched C_2 - C_3 -alkyl group which is substituted by $-CN$, $-OH$, $-COOH$, $-COOR_8$, particularly $-COOCH_3$ or $-COOC_2H_5$, $-OCOCH_3$, $-OCOC_2H_5$, $-CONR_6R_7$, $=NOH$, $-NR_6R_7$ or a C-linked 5- or 6-membered nitrogen-containing heterocyclic ring, optionally substituted as hereinbefore defined.
- 5) Xanthine derivatives according to any one of claims 1 to 4 wherein R_2 denotes A- C_1 - C_3 -alkylene-, A-CONH- C_1 - C_3 -alkylene, A-NH-CO- C_1 - C_3 -alkylene, wherein A is a C- or N-linked 5- or 6-membered heterocyclic ring which contains nitrogen, oxygen or sulphur as heteroatoms and may optionally be mono- or polysubstituted, preferably monosubstituted, by C_1 - C_4 -alkyl, halogen, $-OR_8$, $-CN$, $-NO_2$, $-NH_2$, $-CH_2NR_6R_7$, $-OH$, $=O$, a ketal, $-COOH$, $-SO_3H$, $-COOR_8$, $-CONR_6R_7$, $-COR_9$, $-SO_2-R_8$, $-CONR_6R_7$ or



- 6) Xanthine derivatives of general formula I according to any one of claims 1, 2, 3, 4 or 5, wherein R_3 is a group selected from the following



and

R_2 denotes $\text{CH}_2\text{CH}_2\text{OH}$, $\text{CH}_2\text{CH}_2\text{OCOCH}_3$, $(\text{CH}_2)_3\text{OCOCH}_3$, $(\text{CH}_2)_3\text{OCH}_3$, $\text{CH}_2\text{CH}_2\text{COCH}_3$, $\text{CH}_2\text{CH}_2\text{CH}(\text{OH})\text{CH}_3$, $\text{CH}_2\text{CH}_2\text{COOCH}_3$, $\text{CH}_2\text{CH}_2\text{CONH}_2$, $(\text{CH}_2)_3\text{CONH}_2$, $\text{CH}_2\text{CH}=\text{NOH}$, $(\text{CH}_2)_3\text{CN}$, $\text{CH}_2\text{CH}_2\text{SCH}_2\text{CH}_3$, $\text{CH}_2\text{CH}_2\text{SCH}_2\text{CH}_2\text{OH}$, $\text{CH}_2\text{CH}_2\text{SO}_2\text{CH}_2\text{CH}_2\text{OH}$, $\text{CH}_2\text{CH}_2\text{SO}_2\text{CH}_2\text{CH}_2\text{OCOCH}_3$, $\text{A}-(\text{CH}_2)_2-$

or

$\text{A}-(\text{CH}_2)_3-$, $\text{A}-\text{CH}_2-\text{CH}_2$

wherein A is a C- or N-linked 5- or 6-membered heterocyclic ring which contains nitrogen, oxygen or sulphur as heteroatoms,

optionally in the form of racemates, enantiomers, diastereomers and mixtures thereof and optionally pharmacologically acceptable salts thereof.


- 7) Xanthine derivatives of general formula I or Ia according to any one of the preceding claims, characterised in that the group R_3 is an



16 MAR 1999


unsubstituted cyclopentyl group.

- 8) Compounds as claimed in any one of the preceding claims as herein specifically disclosed in any one of the Examples.
- 9) Process for preparing xanthines of general formula I



wherein the groups R_1 , R_2 , R_3 and R_4 are defined as in any one of the preceding claims, characterised in that

- a) a compound of general formula



wherein


R_1 is as hereinbefore defined and

R'_2 corresponds to the definition of R_2 or R'_2 denotes a protecting group such as a benzyl- or methoxybenzyl group which is readily cleavable

is reacted with a compound of general formula $R_3\text{CHO}$, $R_3\text{COOH}$ or a reactive derivative thereof, whilst functional groups in R_3 must be protected if necessary, and is then cyclised to obtain the xanthine of general formula I wherein $R_4 = \text{H}$; or

16 MAR 1999

b) a compound of general formula




wherein

R_1 and R'_2 are as hereinbefore defined, is reacted with a compound of general formula $R_3\text{CHO}$ - wherein R_3 is as hereinbefore defined, whilst functional groups in R_3 must be protected if necessary - and is then cyclised with N,N -dimethylhydrazine to form the xanthine of general formula I wherein $R_4 = \text{H}$;

or

c) a compound of general formula



wherein

R_1 , R'_2 and R_3 are as hereinbefore defined, is cyclised to form a compound of general formula I,


and subsequently a compound prepared according to a, b or c is optionally further treated using partly known processes as follows:

if $R_1 = \text{H}$, $R_4 = \text{H}$ of formula V





16 MAR 1999




a protecting group is introduced into the 7-position (R_4),

then by N-alkylation $R_1 = H$ is converted into $R_1 =$ alkyl, alkenyl or alkynyl and

in order to prepare compounds of formula I wherein $R_4 = H$ the protecting group is cleaved,



if R'_2 does not yet have the desired meaning of R_2 , R'_2 is now converted into R_2 using methods known per se.

- 10) Process for preparing xanthines of general formula I



wherein

R_1 , R_2 and R_3 are defined as in any one of the preceding claims, characterised in that, starting from a compound of general formula




wherein

R_1 and R_3 are as hereinbefore defined, R_4 denotes a protecting group, particularly benzyl- and R'_2 denotes the group p-methoxybenzyl, dimethoxybenzyl or trimethoxybenzyl,

R'_2 is converted into $R_2 = H$ by acid-hydrolysis, retaining the protecting group R_4 ,



then by N-alkylation with R'_2-X a compound of general formula



wherein R_4 denotes a protecting group - particularly benzyl- and R_1 and R_3 are as hereinbefore defined and $R'_2 = R_2$ or a precursor thereof,

then the protecting group R_4 is cleaved by conventional methods and, if desired, R'_2 is converted into R_2 .


- 11) A process as claimed in claim 9 or claim 10 substantially as hereinbefore described in any one of the Examples.
- 12) Intermediate compounds of general formula




wherein

R_1 , R_2 and R_3 are defined as in any one of the preceding claims and R_4 denotes a p-methoxybenzyl, 2,4-dimethoxybenzyl or 2,4,6,-trimethoxybenzyl group.

13) Xanthine derivatives of general formula I



wherein R_3 denotes a group selected from the following



and

R_2 denotes a polar aliphatic group or a heterocyclic



- 85 -

REPLACEMENT SHEET

16 MAR 1999

ring containing nitrogen, oxygen or sulphur as heteroatoms.

- 14) Pharmaceutical compositions containing as active substance one or more compounds as claimed in any one of claims 1 to 8 and 13 or the physiologically acceptable acid addition salts thereof combined with conventional excipients and/or carriers.
- 15) A pharmaceutical composition as claimed in claim 14 substantially as hereinbefore described in any one of the pharmaceutical examples.
- 16) Process for preparing pharmaceutical compositions according to any one of claims 14 and 15, characterised in that compounds as claimed in any one of claims 1 to 8 and 13 are admixed with conventional galenic excipients and/or carriers to produce conventional pharmaceutical formulations.
- 17) Use of a compound as claimed in any one of claims 1 to 8 and 13 in the manufacture of a medicament for use in the treatment of diseases in which adenosine-antagonistic therapy is required.